,id,ticker,title,category,content,date,provider,url,article_id
14780,236295,SRPT,Sarepta s Vyondys 53 Receives FDA Approval For DMD  Stock Up,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   announced that the FDA granted accelerated approval to Vyondys 53  golodirsen  for the treatment of patients with Duchenne muscular dystrophy   DMD   who are exon 53 amenable  Vyondys 53 is Sarepta s second approved exon skipping RNA therapy for DMD  The company will launch the drug immediately The company has to conduct a post marketing confirmatory study to convert the accelerated approval to a continued approval for Vyondys 53  We note that Sarepta is already conducting a similar study   ESSENCE  The study is currently enrolling patients and is expected to conclude by 2024 Please note that the new drug application   NDA   seeking approval for Vyondys 53 had received a complete response letter   CRL   from the FDA in   The FDA cited two concerns   the risk of infections related to intravenous infusion ports and renal toxicity seen in pre clinical models   in the CRL Shares of Sarepta surged 29 6  in after hours trading on Dec 12  following the approval to Vyondys 53  Investors cheered the news as the company resolved the issues mentioned in the CRL in just four months  The company s shares have decreased 8  so far this year  against the  s increase of 6 3   The approval to Vyondys 53 is likely to boost total revenues for Sarepta  The company s already approved DMD drug  Exondys 51  treats patients who are exon 51 amenable  Exondys 51 has generated sales of  280 7 million in the first nine months of 2019  up almost 30  year over year  The company stated that Vyondys 53 will increase eligible DMD patient population by 8  in the United States  Both the drugs combined will offer treatment options for approximately 20  of U S  DMD patients The company is developing another exon skipping RNA therapy  casimersen  for DMD patients who are exon 45 amenable  It stated in its third quarter earnings release that it will submit a NDA for the candidate following clarity on golodirsen NDA  Thus  we expect the company to file the same with the FDA soon Sarepta is also developing next generation PPMO platform candidate  SRP 5051  in DMD patients amenable to exon 51 skipping and gene therapies targeting DMD and other muscular dystrophies as well as central nervous system disorders Meanwhile  there are several other companies developing gene therapies for treating DMD including Solid Biosciences   NASDAQ SLDB    Audentes Therapeutics   NASDAQ BOLD   and Pfizer   NYSE PFE    Successful development of gene therapies for DMD will increase competition in the field Sarepta Therapeutics  Inc  Price
    Zacks RankSarepta currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-12-12,Zacks Investment Research,https://www.investing.com/analysis/sareptas-vyondys-53-receives-fda-approval-for-dmd-stock-up-200492404,200492404
14781,236296,SRPT,Sarepta Signs Gene Therapy Agreement With Roche For  1 15B,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   announced that it has entered into a licensing agreement with Roche   OTC RHHBY   related to its lead gene therapy candidate  SRP 9001  for treating Duchenne muscular dystrophy   DMD    Per the agreement  Sarepta will Roche grant exclusive rights to launch and commercialize SRP 9001 in ex U S  markets in exchange of an upfront payment of  1 15 billion  The upfront payment includes  750 million in cash and  400 million investment in Sarepta s stock for  158 59 per share  The deal is expected to close in the first quarter of 2020 Per the deal  Sarepta will also be eligible to receive  1 7 billion in regulatory and sales milestones  along with royalties on potential future sales of the candidate  Please note that Sarepta is currently developing SRP 9001  an AAV mediated micro dystrophin gene therapy candidate  in a phase I II study for treating DMD  Sarepta will remain responsible for clinical development and manufacturing of SRP 9001  However  global clinical development cost for the candidate will be shared by both the companies The deal is likely to help both the companies  While Roche will gain Sarepta s expertise in the field of DMD  especially development of gene therapy  Sarepta will benefit from Roche s global reach  commercial presence and regulatory expertise to accelerate approval and commercialization process for SRP 9001 Moreover  the upfront payment will significantly boost Sarepta s cash resources  which  in turn  will help it to continue its other research activities in the field of gene therapies  Shares of Sarepta were up more than 12  in pre market trading on Dec 23  Sarepta s stock has outperformed the  so far this year  The company s shares are up 15 6  compared with the industry s increase of 9 2  in that period The  of Vyondys 53 by the FDA for treating DMD patients who are exon 53 amenable earlier this month was also an encouraging news for Sarepta s investors  The drug s approvalis likely to increase eligible DMD patient population for the company s commercial portfolio of DMD drugs by 8  in the United States  The company s older DMD drug  Exondys 51  treats patients who are exon 51 amenable and has generated sales of  280 7 million in the first nine months of 2019  up almost 30  year over year  Successful development of SRP 9001 as a potential treatment for DMD will further boost the company s prospects  Meanwhile  there are several other companies developing gene therapies for treating DMD including Solid Biosciences   NASDAQ SLDB    Audentes Therapeutics   NASDAQ BOLD   and Pfizer  NYSE PFE  Sarepta Therapeutics  Inc  Price
    Zacks RankSarepta currently carries a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2019-12-22,Zacks Investment Research,https://www.investing.com/analysis/sarepta-signs-gene-therapy-agreement-with-roche-for-115b-200494428,200494428
14782,236297,SRPT, Company News For Dec 24  2019,opinion,Shares of Aurora Cannabis Inc    TSX ACB   dropped 10 7  after it announced that Chief Corporate Officer Cam Battley has left the companyShares of Apache Corporation   NYSE APA   jumped 17 3  after the company announced  an agreement to acquire a 50  working interest of French company Total SA  PA TOTF  in Block 58 of the offshore Guyana Suriname basinShares of Intra Cellular Therapies  Inc    NASDAQ ITCI   soared 193 5  after the company announced that it has received FDA approval for CAPLYTA  the treatment of schizophrenia in adultsShares of Sarepta Therapeutics  Inc    NASDAQ SRPT   rose 7 5  after the company announced it has entered into a partnership with Roche  which will provide Sarepta an exclusive right to launch and commercialize SRP 9001 outside the United States,2019-12-23,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-dec-24-2019-200494635,200494635
14885,236400,SRPT,4 Solid Gene Therapy Buyout Bets Post Audentes Astellas Deal,opinion,The ongoing M A wave in the pharma biotech sector gains further momentum from the significant rally in the share price movement of gene therapy company Audentes Therapeutics  Inc    NASDAQ BOLD   earlier in the week  The stock s impressive upsurge followed the Japanese company Astellas Pharma Inc s announcement to acquire Audentes for a cash consideration of  60 per share or a total deal value of approximately  3 billion   The offer price represents a premium of 110  to Audentes  closing share price of  28 61 on Dec 2  2019 It is interesting to note that attractive modest valuations on account of a disappointing run in 2018 rekindled interest in the ever volatile biotech sector from the start of this year  Evidently  the spotlight is back on mergers   acquisitions  A slowdown in mature products due to increasing competition and the rise of biosimilars forced most pharma behemoths to target lucrative buyouts in the biotech space to bolster their pipelines   While oncology and immuno oncology are the key areas of focus  companies targeting non alcoholic steatohepatitis  NASH   rare diseases and candidates based on gene therapy also promise great potential  thereby making the respective areas profitable for investments  Bristol Myers Squibb Company   NYSE BMY    one of the largest pharma giants  acquired leading biotech company Celgene  NASDAQ CELG  for a whopping  74 billion in what could be a major acquisition of recent times  Thereafter  a slew of deals was struck with most companies eyeing smaller entities with impressive pipelines  the latest being the Swiss pharma leader Novartis  which reached an agreement to acquire U S  based biopharmaceutical company  The Medicines Company  for  9 7 billion Earlier in the year  Roche   OTC RHHBY   announced that it will acquire gene therapy company Spark Therapeutics Inc  However  the buyout has been getting delayed  dampening hopes of investors Nevertheless  the recent acquisition announcement by Astellas brings the gene therapy space into prominence once again What is Gene Therapy Gene therapy enables to mitigate the adverse effects of a malfunctioning disease causing gene  The therapy intends to add a functional gene to a person s system  replacing the malfunctioning one to cure diseases  The gene is delivered to a cell though a carrier known as vector   The therapy has a different approach from the traditional drug treatments as the underlying cause can be treated with it Gene therapy is set to become one of the most vital spaces with high prospects in the volatile biotech sector  The promising therapy is being evaluated for varied diseases  such as hemophilia  Duchenne muscular dystrophy  DMD   Parkinson s disease  cancer among others Gene Therapy Companies in FocusGiven the potential of the therapy to treat complex diseases  the companies developing candidates using gene therapy are in focus  Let us consider a few players with promising drugs candidates in their portfolios pipelines as they appear attractive targets of acquisition uniQure N V    NASDAQ QURE   is one of the most promising players in this space with a focused pipeline of innovative gene therapies for hemophilia B and Huntington s disease  Etranacogene dezaparvovec is its lead gene therapy candidate and includes an AAV5 vector incorporating the Factor IX Padua variant  The company is currently conducting a pivotal study in patients with severe and moderately severe hemophilia B  The candidate is granted a Breakthrough Therapy Designation by the FDA  In early September 2019  the company completed patient enrollment in its HOPE B pivotal study of etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B  uniQure  expects to provide top line Factor IX  FIX  activity data on all patients before the end of 2020 and submit a Biologics License Application  BLA  for the marketing authorization of etranacogene dezaparvovec in 2021 With a market cap of  2 85 billion  this company is the front runner for a likely buyout  uniQure currently carries a Zacks Rank  2  Buy   You can see  Commercial stage biopharmaceutical company Sarepta Therapeutics  Inc    NASDAQ SRPT   is focused on developing unique RNA targeted therapeutics  gene therapy and other genetic therapeutic modalities for the treatment of rare diseases  Its first commercial product Exondys 51 is indicated to address DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping  Sarepta is also developing gene therapies for treating Limb girdle muscular dystrophy  LGMD  and central nervous system disorders including Mucopolysaccharidosis type IIIA  MPS IIIA  and Pompe Disease With a market cap of  8 3 billion  Sarepta has been on the radar for quite some time now BioMarin Pharmaceutical Inc    NASDAQ BMRN   develops and commercializes innovative therapies for serious and life threatening rare and ultra rare genetic diseases  With a market cap of  14 6 billion  the company boasts an excellent portfolio of seven commercialized products and an impressive pipeline  It recently submitted a Marketing Authorization Application  MAA  to the European Medicines Agency  EMA  for its investigational gene therapy  valoctocogene roxaparvovec  for adults with severe hemophilia A   BioMarin is on track to submit a BLA to the FDA by this year end  The FDA granted valoctocogene roxaparvovec a Breakthrough Therapy designation   Valoctocogene roxaparvovec received an Orphan Drug tag from the FDA and the EMA Sangamo Therapeutics  Inc    NASDAQ SGMO   continues to advance its SB 525 hemophilia A gene therapy program  It is conducting a phase I II Alta study  an open label  ascending dose clinical study to evaluate investigational SB 525 gene therapy for severe hemophilia A in collaboration with Pfizer  NYSE PFE  IncThe FDA conferred a regenerative medicine advanced therapy or RMAT status on SB 525 gene therapy to treat severe hemophilia  This includes all the benefits of the fast track and breakthrough therapy designation programs including early interactions with the FDA  Sangamo is also evaluating its wholly owned investigational ST 920 gene therapy for Fabry disease  an inherited metabolic disease  The FDA also granted Orphan Drug Designation to ST 920 for the treatment of Fabry disease  The company has a market cap of  1 36 billion More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/4-solid-gene-therapy-buyout-bets-post-audentesastellas-deal-200490281,200490281
14886,236401,SRPT,The Zacks Analyst Blog Highlights  UniQure  Sarepta Therapeutics  BioMarin Pharmaceutical And Sangamo Therapeutics,opinion,For Immediate ReleaseChicago  IL   December 6  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  uniQure N V    NASDAQ QURE    Sarepta Therapeutics  Inc    NASDAQ SRPT    BioMarin Pharmaceutical Inc    NASDAQ BMRN   and Sangamo Therapeutics  Inc    NASDAQ SGMO   Here are highlights from Thursday s Analyst Blog  4 Solid Gene Therapy Buyout BetsThe ongoing M A wave in the pharma biotech sector gains further momentum from the significant rally in the share price movement of gene therapy company Audentes Therapeutics  Inc  earlier in the week  The stock s impressive upsurge followed the Japanese company Astellas Pharma Inc s announcement to acquire Audentes for a cash consideration of  60 per share or a total deal value of approximately  3 billion   The offer price represents a premium of 110  to Audentes  closing share price of  28 61 on Dec 2  2019 It is interesting to note that attractive modest valuations on account of a disappointing run in 2018 rekindled interest in the ever volatile biotech sector from the start of this year  Evidently  the spotlight is back on mergers   acquisitions  A slowdown in mature products due to increasing competition and the rise of biosimilars forced most pharma behemoths to target lucrative buyouts in the biotech space to bolster their pipelines   While oncology and immuno oncology are the key areas of focus  companies targeting non alcoholic steatohepatitis  NASH   rare diseases and candidates based on gene therapy also promise great potential  thereby making the respective areas profitable for investments  Bristol Myers Squibb Company  NYSE BMY   one of the largest pharma giants  acquired leading biotech company Celgene  NASDAQ CELG  for a whopping  74 billion in what could be a major acquisition of recent times  Thereafter  a slew of deals was struck with most companies eyeing smaller entities with impressive pipelines  the latest being the Swiss pharma leader Novartis  which reached an agreement to acquire U S  based biopharmaceutical company  The Medicines Company  for  9 7 billion Earlier in the year  Roche announced that it will acquire gene therapy company Spark Therapeutics Inc  However  the buyout has been getting delayed  dampening hopes of investors Nevertheless  the recent acquisition announcement by Astellas brings the gene therapy space into prominence once again What is Gene Therapy Gene therapy enables to mitigate the adverse effects of a malfunctioning disease causing gene  The therapy intends to add a functional gene to a person s system  replacing the malfunctioning one to cure diseases  The gene is delivered to a cell though a carrier known as vector   The therapy has a different approach from the traditional drug treatments as the underlying cause can be treated with it Gene therapy is set to become one of the most vital spaces with high prospects in the volatile biotech sector  The promising therapy is being evaluated for varied diseases  such as hemophilia  Duchenne muscular dystrophy  DMD   Parkinson s disease  cancer among others Gene Therapy Companies in FocusGiven the potential of the therapy to treat complex diseases  the companies developing candidates using gene therapy are in focus  Let us consider a few players with promising drugs candidates in their portfolios pipelines as they appear attractive targets of acquisition uniQure N V  is one of the most promising players in this space with a focused pipeline of innovative gene therapies for hemophilia B and Huntington s disease  Etranacogene dezaparvovec is its lead gene therapy candidate and includes an AAV5 vector incorporating the Factor IX Padua variant  The company is currently conducting a pivotal study in patients with severe and moderately severe hemophilia B  The candidate is granted a Breakthrough Therapy Designation by the FDA  In early September 2019  the company completed patient enrollment in its HOPE B pivotal study of etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B  uniQure  expects to provide top line Factor IX  FIX  activity data on all patients before the end of 2020 and submit a Biologics License Application  BLA  for the marketing authorization of etranacogene dezaparvovec in 2021 With a market cap of  2 85 billion  this company is the front runner for a likely buyout  uniQure currently carries a Zacks Rank  2  Buy   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Commercial stage biopharmaceutical company Sarepta Therapeutics  Inc  is focused on developing unique RNA targeted therapeutics  gene therapy and other genetic therapeutic modalities for the treatment of rare diseases  Its first commercial product Exondys 51 is indicated to address DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping  Sarepta is also developing gene therapies for treating Limb girdle muscular dystrophy  LGMD  and central nervous system disorders including Mucopolysaccharidosis type IIIA  MPS IIIA  and Pompe Disease With a market cap of  8 3 billion  Sarepta has been on the radar for quite some time now BioMarin Pharmaceutical Inc  develops and commercializes innovative therapies for serious and life threatening rare and ultra rare genetic diseases  With a market cap of  14 6 billion  the company boasts an excellent portfolio of seven commercialized products and an impressive pipeline  It recently submitted a Marketing Authorization Application  MAA  to the European Medicines Agency  EMA  for its investigational gene therapy  valoctocogene roxaparvovec  for adults with severe hemophilia A   BioMarin is on track to submit a BLA to the FDA by this year end  The FDA granted valoctocogene roxaparvovec a Breakthrough Therapy designation   Valoctocogene roxaparvovec received an Orphan Drug tag from the FDA and the EMA Sangamo Therapeutics  Inc  continues to advance its SB 525 hemophilia A gene therapy program  It is conducting a phase I II Alta study  an open label  ascending dose clinical study to evaluate investigational SB 525 gene therapy for severe hemophilia A in collaboration with Pfizer  NYSE PFE  IncThe FDA conferred a regenerative medicine advanced therapy or RMAT status on SB 525 gene therapy to treat severe hemophilia  This includes all the benefits of the fast track and breakthrough therapy designation programs including early interactions with the FDA  Sangamo is also evaluating its wholly owned investigational ST 920 gene therapy for Fabry disease  an inherited metabolic disease  The FDA also granted Orphan Drug Designation to ST 920 for the treatment of Fabry disease  The company has a market cap of  1 36 billion More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 Click here for the 6 trades   Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-uniqure-sarepta-therapeutics-biomarin-pharmaceutical-and-sangamo-therapeutics-200490675,200490675
14890,236405,SRPT,Sarepta  SRPT  Looks Good  Stock Adds 7 5  In Session,opinion,Sarepta Therapeutics  Inc    NASDAQ SRPT   was a big mover last session  as the company saw its shares rise more than 7  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  100 47 to  135 35 in the past one month time frame The upmove came after the company announced that it has signed a gene therapy agreement with Roche for  1 15 billion The company has seen three negative estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Sarepta currently has a Zacks Rank  3  Hold  while its  is negative   Sarepta Therapeutics  Inc  Price   Investors interested in the Medical   Biomedical and Genetics industry may consider Anika Therapeutics  Inc    NASDAQ ANIK    which has a Zacks Rank  1  Strong Buy   You can seeIs SRPT going up  Or down  Predict to see what others think Up or DownThe Hottest Tech Mega Trend of All Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-12-23,Zacks Investment Research,https://www.investing.com/analysis/sarepta-srpt-looks-good-stock-adds-75-in-session-200494622,200494622
14891,236406,SRPT,Biotech Leading In Q4  Best ETFs   Stocks,opinion,The biotech space of the broader healthcare sector outperformed others in the final quarter of 2019  thanks to increased mergers   acquisitions  positive regulatory backdrop and solid trial results  Better than expected corporate earnings added to this strength  M A WaveThe latest to jump on the M A bandwagon is Sarepta Therapeutics   NASDAQ SRPT    which entered into a licensing agreement with Roche   OTC RHHBY   for its lead gene therapy candidate  SRP 9001  to treat Duchenne muscular dystrophy  DMD  outside the United States for  1 15 billion  Meanwhile  Merck   Co    NYSE MRK   and Sanofi   NASDAQ SNY   agreed to buy smaller cancer drug makers ArQule  and Synthorx   NASDAQ THOR    respectively  read    Lat month  Swiss drugmaker Novartis   NYSE NVS   agreed to merge with The Medicines Company in a  9 7 billion deal Regulatory   Trial ResultIn the latest rounds of news  Sarepta Therapeutics rallied after the Food and Drug Administration approved Vyondys 53 for muscular dystrophy treatment  Solid Biosciences  spiked following the study of two patients who received doses of its experimental DMD treatment  which showed that the therapy  has the potential  to benefit them Aurinia Pharmaceuticals  surged after the company announced positive results from a trial involving its lupus related drug  CRISPR Therapeutics  and Vertex Pharmaceuticals   NASDAQ VRTX   announced encouraging preliminary safety and efficacy data from the first two patients treated with investigational CRISPR Cas9 gene editing therapy CTX001 for severe hemoglobinopathies  The FDA recently approved Global Blood Therapeutics s   NASDAQ GBT   drug for treating sickle cell disease Further  the sector is clearly benefiting from impressive trends including approvals for new drugs  an accelerated pace of innovation  promising drug launches  growing importance of biosimilars  cost cutting efforts  an aging population  expanding insurance coverage  a rising middleclass  continuous demand for new drugs and ever increasing spending on healthcare  read    Against this backdrop  we highlight five biotech ETFs and stocks that are leading the market in Q4 Virtus LifeSci Biotech Clinical Trials ETF   ASX BBC     Up 64 3 This fund has a novel approach to biotechnology investing with exposure to companies that are in the clinical trial stage  This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index  BBC has amassed  37 7 million in its asset base and charges 79 bps in fees per year from investors  It trades in a light average daily volume of around 9 000 shares and holds 96 securities in its basket  The product carries a Zacks ETF Rank  3  Hold  with a High risk outlook  read    ALPS Medical Breakthroughs ETF   SI SBIO     Up 36 9 This fund provides exposure to companies with one or more drugs in Phase II or Phase III FDA clinical trials by tracking S Network Medical Breakthroughs Index  It holds 78 securities in its basket  The product charges 50 basis points in fees per year from investors and trades in a moderate average daily volume of about 34 000 shares  It has AUM of  226 3 million in its asset base and has a Zacks ETF Rank  3 with a High risk outlook The Cancer Immunotherapy ETF    Up 29 8 This ETF offers exposure to a basket of companies that develop therapies to treat cancer by harnessing the body s own immune system  Holding 26 stocks in its basket  it has AUM of  42 million and trades in average daily volume of 11 000 shares  The product charges 79 bps in annual fees and has a Zacks ETF Rank  3 with a High risk outlook Global X Genomics   Biotechnology ETF    Up 29 5 This is a new entrant in the space  having accumulated  20 million since its inception on Apr 5  It seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science  such as companies involved in gene editing  genomic sequencing  genetic medicine therapy  computational genomics and biotechnology  The product follows the Solactive Genomics Index  charging 68 bps in annual fees  It holds 40 stocks in its basket and trades in average daily volume of 5 000 shares  read    SPDR S P Biotech  NYSE XBI  ETF    Up 28 1 With AUM of  4 9 billion  XBI provides equal weight exposure of around 2  across 126 biotechnology stocks by tracking the S P Biotechnology Select Industry Index  It has 0 35  in expense ratio and trades in average daily volume of 4 6 million shares  The fund has a Zacks ETF Rank  2  Buy  with a High risk outlook Constellation Pharmaceuticals Inc     Up 606 2 This bio pharmaceutical company discovers and develops molecule therapeutics for the treatment of cancer  inflammatory and immunologic disorders  The stock has a Zacks Rank  3 and a VGM Score of F  It has a market cap of  1 8 billion  read    Axsome Therapeutics Inc    NASDAQ AXSM     Up 387 8 This biopharmaceutical company focuses on developing novel therapies for the management of pain and other central nervous system disorders  With a market cap of  3 47 billion  the stock has a Zacks Rank  3 and a VGM Score of F Karuna Therapeutics Inc     Up 375 4 This clinical stage biopharmaceutical company is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs  The stock has a Zacks Rank  2  Buy  and a VGM Score of D  It has a market cap of  1 91 billion  You can see  Kodiak Sciences Inc     Up 359 7 This clinical stage biopharmaceutical company specializes in novel therapeutics to treat chronic and retinal diseases  With a market cap of  2 48 billion  it has a Zacks Rank  2 and a VGM Score of C Clearside Biomedical Inc    NASDAQ CLSD     Up 327 8 This biopharmaceutical company is engaged in developing first in class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space TM  microinjector  It has a Zacks Rank  3 and a VGM Score of F  The stock has a market cap of  103 29 million Want key ETF info delivered straight to your inbox  Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-12-24,Zacks Investment Research,https://www.investing.com/analysis/biotech-leading-in-q4-best-etfs--stocks-200494773,200494773
14892,236407,SRPT,Applied Genetic Stock Up On Favorable Eye Therapy Study Data,opinion,"Applied Genetic Technologies Corporation   NASDAQ AGTC   announced positive interim six month data from the phase I II study evaluating its adeno associated virus   AAV   based gene therapy candidate in patients with X linked retinitis pigmentosa   XLRP    Based on this promising data  the company is planning to initiate a pivotal study by the end of 2020  Data from the pivotal study will support regulatory submissions seeking approval for the gene therapy candidate The XLRP disorder is a rare  inherited eye disease causing progressive vision loss in boys and young men inclusive of night blindness in early childhood and progressive constriction of the visual field Shares of Applied Genetic skyrocketed more than 120  on Jan 9 following data read out  The stock has surged 194 3  in the past year against the  s decrease of 3 4  The phase I II study is evaluating peripheral or central dosing of the AAV based gene therapy candidate in XLRP patients  Interim data from the study showed that patients treated centrally demonstrated durable improvement in visual function after six months of dosing  Among the centrally treated patients  78  saw a five letter or more improvement Management stated that such progress is never reported in any other XLRP study  Data also showed that patients who achieved improvement in either visual sensitivity or Best Corrected Visual Acuity   BCVA   also experienced greater clarity and reduced night blindness Earlier interim data from the study reported in September showed that the candidate boasts a favorable safety profile  Moreover  results demonstrated that peripherally treated patients had stable visual function through six months Applied Genetic stated that sustained improvement in visual sensitivity noticed in centrally treated patients is compelling  The company will enroll additional patients for the XLRP study in the first quarter of 2020  Data from this extra patient population is expected to generate most robust set of updates that might help the company design the pivotal study Apart from XLRP  the company is evaluating the candidate in patients with achromatopsia  an eye disorder leading to partial or total color blindness  The company will report interim six month data from the escalation cohort of this study later this month  Positive data read out can drive stocks further We note that gene therapies are increasingly becoming the latest treatment options with several big and small pharma biotech companies developing gene therapy based treatments for several diseases A popular name in the gene therapy space is Sarepta Therapeutics   NASDAQ SRPT    which is developing several gene therapy candidates for muscular dystrophies  Other promising gene therapy  include REGENXBIO Inc    NASDAQ RGNX    Solid Biosciences   NASDAQ SLDB    Editas Medicine and uniQure Applied Genetic Technologies Corporation Price
    Zacks RankApplied Genetic currently carries a Zacks Rank  3  Hold   You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2020-01-09,Zacks Investment Research,https://www.investing.com/analysis/applied-genetic-stock-up-on-favorable-eye-therapy-study-data-200497966,200497966
14899,236414,SRPT,Are Options Traders Betting On A Big Move In Sarepta  SRPT  Stock ,opinion,Investors in Sarepta Therapeutics  Inc    NASDAQ SRPT   need to pay close attention to the stock based on moves in the options market lately  That is because the Jun 19  2020  45 00 Put had some of the highest implied volatility of all equity options today What is Implied Volatility Implied volatility shows how much movement the market is expecting in the future  Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other  It could also mean there is an event coming up soon that may cause a big rally or a huge sell off  However  implied volatility is only one piece of the puzzle when putting together an options trading strategy What do the Analysts Think Clearly  options traders are pricing in a big move for Sarepta shares  but what is the fundamental picture for the company  Currently  Sarepta is a Zacks Rank  2  Buy  in the Medical   Biomedical and Genetics industry that ranks in the Top 37  of our Zacks Industry Rank  Over the last 60 days  two analysts have increased their earnings estimates for the current quarter  while three have dropped their estimates  The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of  1 81 per share to a loss of  1 89 in that period Given the way analysts feel about Sarepta right now  this huge implied volatility could mean there s a trade developing  Oftentimes  options traders look for options with high levels of implied volatility to sell premium  This is a strategy many seasoned traders use because it captures decay  At expiration  the hope for these traders is that the underlying stock does not move as much as originally expected Looking to Trade Options Check out the simple yet high powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple digit winners  In addition to impressive profit potential  these trades can actually reduce your risk ,2020-01-19,Zacks Investment Research,https://www.investing.com/analysis/are-options-traders-betting-on-a-big-move-in-sarepta-srpt-stock-200500016,200500016
124951,346466,SRPT,Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug,news,"By Tamara Mathias
 Reuters    Shares of  Sarepta  Therapeutics Inc  O SRPT  soared 36  on Friday after U S  regulators shocked Wall Street by approving the company s treatment for a muscle wasting disorder less than four months after rejecting the drug over safety concerns 
The Food and Drug Administration in August declined to approve the Duchenne Muscular Dystrophy  DMD  treatment  Vyondys 53  citing a risk of infection and kidney toxicity 
Sarepta in a statement said it had appealed the FDA rejection through a formal dispute resolution request 
Sarepta said it addressed the kidney toxicity issue in the drug s label  which recommends monthly monitoring of patients 
In making its decision  the FDA said late on Thursday it  considered the potential risks associated with the drug  the life threatening and debilitating nature of the disease and the lack of available therapy  
Data from trials showed Vyondys 53 was  reasonably likely  to predict clinical benefit in patients with DMD although such benefit  including improved motor function  had not been established  the FDA said 
The approval is contingent on results of a post approval trial expected to conclude by 2024  the FDA said 
HC Wainwright analyst Debjit Chattopadhyay found the FDA reversal to be confounding 
If the drug  was not approvable four months ago  it cannot suddenly become approvable without significant new data  and potentially reflects some contrived decision making within the agency   Chattopadhyay said 
Jefferies analyst Michael Yee said the change of heart could have implications for Biogen Inc s  O BIIB  Alzheimer s drug  aducanumab 
Biogen scrapped development of aducanumab in March  but seven months later surprised investors by saying it would pursue approval after analyzing additional data that showed it had some benefit  Wall Street has forecast annual aducanumab sales of nearly  4 billion by 2024 
The surprise approval was not the first for Sarepta 
In 2016  the FDA approved the company s first DMD treatment  Exondys 51  bowing to intense pressure from patient advocates even as an outside panel of experts and the agency s own reviewers questioned the drug s effectiveness 
Sarepta must still submit additional data on the efficacy of Exondys to the FDA  The company s chief executive in November said it expects to provide additional updates to regulators by the end of next year 
Citi Group analyst Joel Beatty said it was now more likely Sarepta will be able to win approval for Duchenne treatment casimersen and gene therapies it is developing 
Company shares  which were cut by half after the August rejection  jumped to  136 on Friday from a Thursday close of  100 46 ",2019-12-13,Reuters,https://www.investing.com/news/stock-market-news/sarepta-shares-surge-after-surprise-approval-of-duchenne-muscular-dystrophy-drug-2041215,2041215
124952,346467,SRPT,Roche enters  1 15 billion licensing deal for Sarepta gene therapy,news,"ZURICH  Reuters    Roche  S ROG  entered into a  1 15 billion licensing agreement with  Sarepta  Therapeutics  O SRPT  to obtain the right to launch and commercialize Sarepta s investigational gene therapy for Duchenne muscular dystrophy  DMD  outside the United States  Roche will make an upfront payment of  750 million in cash and  400 million worth in equity at closing for Sarepta s investigational micro dystrophin gene therapy SRP 9001 that is currently in clinical development  the Swiss drugmaker said in a statement on Monday  In addition  Sarepta is eligible to receive up to  1 7 billion in regulatory and sales milestones  plus royalties on net sales  Roche said  adding the agreement was expected to close in the first quarter of 2020  Sarepta will continue to be responsible for the clinical development and manufacturing of SRP 9001 while sharing global clinical development costs equally with Roche  DMD is a rare degenerative neuromuscular disorder  affecting about one in 3 500 5 000 male births worldwide and causing severe progressive muscle loss and premature death  Roche said  
Earlier this month  Sarepta gained U S  approval for another DMD drug  Vyondys 53 ",2019-12-23,Reuters,https://www.investing.com/news/stock-market-news/roche-enters-115-billion-licensing-deal-for-sarepta-gene-therapy-2046925,2046925
124953,346468,SRPT,China s Coronavirus Could Prompt Buying Frenzy in These Biotech Stocks,news,"China is facing an outbreak of the coronavirus  which may have spread to a few other countries in East Asia  Although less than 300 infections have been reported  there are concerns about this becoming the next epidemic  As a result  experimental vaccine stocks are skyrocketing This harkens back to a few years ago when the Ebola virus poised a threat to the international community and biotech companies were quick to pursue a treatment and vaccine  At that time  practically any company that said it was developing anything related to Ebola saw a boost from the news  As more news poured in  these companies kept running  Sarepta Therapeutics Inc   NASDAQ  SRPT  saw some its biggest gains then As for the coronavirus  there have been 275 confirmed infections and at least six deaths stemming from an outbreak in Wuhan City  according to Chinese authorities  Infections have been reported in Japan  South Korea and Thailand as well div connatix margin bottom  1 5em   div connatix img  margin  unset  Coronaviruses are a large family of viruses that cause illness ranging from the common cold to pneumonia  It primarily affects the respiratory system  In the past  coronaviruses have manifested as severe acute respiratory syndrome  SARS  and  most recently  Middle East respiratory syndrome  MERS  Currently  three U S  airports  JFK  LAX and San Francisco  are screening passengers arriving from the Wuhan Province  according to the Centers for Disease Control and Prevention  CDC  Here are a few biotech companies with exposure to experimental vaccines whose shares are seeing the biggest boost from this news Novavax Inc   NASDAQ  NVAX  shares closed Tuesday up 71  to  9 82  in a 52 week range of  3 54 to  48 80  The consensus price target is  13 75 NanoViricides Inc   NYSE  NNVC  shares closed up 153  at  8 50  The 52 week range is  1 27 to  13 60 Aethlon Medical Inc   NASDAQ  AEMD  shares clpsed up 12   at  2 31in a 52 week range of  0 76 to  21 75  The consensus price target is  3 00 Inovio Pharmaceuticals Inc   NASDAQ  INO  shares closed up 8  to  3 56  The 52 week range is  1 92 to  5 11  and the consensus price target is  9 43 Oncolytics Biotech Inc   NASDAQ  ONCY  shares closed up 14 5  to  3 55  in a 52 week range of  0 35 to  6 02  
By Chris Lange",2020-01-21,247wallst,https://invst.ly/pky5l,2064127
124954,346469,SRPT,Sarepta shares fall 4  after FDA documents show safety concerns about drug,news,By Carl O Donnell  Reuters    Shares of  Sarepta  Therapeutics Inc  O SRPT  were down around 4  Wednesday after the U S  Food and Drug Administration revealed documents detailing concerns it had about the safety and efficacy of one of the company s recently approved Duchenne muscular dystrophy  DMD  drugs   The drug  Vyondys 53  also known as golodirsen  was originally rejected by the FDA last year before the agency reversed that decision in December and approved it   It was the second controversial drug approval for Sarepta  The company saw its first drug  Exondys 51  which also treats DMD  approved in 2016 despite concerns raised by experts about its effectiveness   The newly released documents outlined concerns ranging from kidney toxicity  to infections  to low levels of effectiveness as reasons for the FDA s original rejection of the drug  The FDA cited some of these concerns at the time of its original rejection of Vyondys 53 but the documents provide further detail   The documents added that Vyondys 53 comes with greater risk of kidney toxicity than Exondys 51 and that the risks of infection  which exist for both drugs  were not as well understood at the time Exondys was approved  Therefore  while Exondys was approved based on assumptions that it had  essentially no risk   Vyondys 53 has a less favorable risk profile    I have reached the conclusion that this small benefit  which has not yet been verified  does not outweigh its risks   Ellis Unger  a director at the Center for Drug Evaluation and Research  wrote in his letter   Sarepta successfully appealed the FDA s decision in 2019  The company said it addressed the kidney toxicity issue in the drug s label  which recommends monthly monitoring of patients  The FDA said in a statement to Reuters that its eventual approval of Vyondys 53 demonstrates its flexibility in approving new drugs for serious diseases that have no satisfactory treatments available  It added that it stands by its eventual decision to approve the drug   Both of Sarepta s drug approvals are contingent on it conducting additional post marketing studies to show their efficacy and submitting them to the FDA   This story corrects typographical errors in paragraphs 5 and 8 ,2020-01-22,Reuters,https://www.investing.com/news/stock-market-news/sarepta-shares-fall-4-after-fda-documents-show-safety-concern-about-drug-2065419,2065419
124955,346470,SRPT,FDA documents show safety concerns about Sarepta s DMD drug,news,"Sarepta Therapeutics  NASDAQ SRPT  fell 3 8  in today s trade after the Food and Drug Administration detailed its concerns about the safety and efficacy of the company s recently approved Vyondys 53  golodirsen  drug for Duchenne muscular dystrophy 
The drug originally was rejected by the FDA last year before the agency reversed the decision in December and approved it 
The newly released FDA documents outlined concerns ranging from kidney toxicity to infections to low levels of effectiveness as reasons for the agency s original rejection  some of the concerns were cited at the time of the original rejection but the documents offer more details ",2020-01-22,Seeking Alpha,https://invst.ly/plkgh,2065519
124956,346471,SRPT,FDA Documents Show Safety Concerns Over a Sarepta Drug,news,"The Food and Drug Administration released a set of documents on Wednesday that questioned the safety of a newly approved drug from Sarepta Therapeutics  NASDAQ SRPT   The drug  Vyondys 53  golodirsen   is a treatment for Duchenne muscular dystrophy  DMD   a rare condition that causes muscle weakness and muscle loss  
Although the FDA initially rejected the drug candidate last year  the agency ended up reversing its decision in December after Sarepta successfully appealed the decision  Despite this approval  it seems that the FDA is still quite reticent about the drug and potential complications  including kidney toxicity and infections 

While many of these concerns were cited when Vyondys 53 was initially rejected last year  these new documents go into much more detail surrounding the reasoning of the agency 
What does this mean 
Although Sarepta managed to successfully contest the FDA s earlier rejection  the approval of Vyondys 53 remains contingent on the company performing post marketing studies to verify the safety of the drug  The company has also addressed the possible kidney toxicity issue by recommending monthly monitoring for patients  
This isn t the first time that Sarepta has had to deal with a controversial drug approval  Back in 2016  an earlier DMD drug that the drugmaker was developing  Exondys 51  ended up receiving approval despite some skepticism from the FDA regarding its effectiveness  Many of the issues mentioned in the recently released documents  including kidney toxicity and possible infections  were also issues that Exondys 51 faced before receiving approval ",2020-01-22,The Motley Fool,https://invst.ly/plm86,2065602
124957,346472,SRPT,Coronavirus Infections Climb Hand in Hand With These Biotech Stocks,news,"China is facing an outbreak of the coronavirus  and more countries around the world are seeing cases pop up  Global infections of nearly 8 000 people have been reported  but only about 70 of these have been reported outside of mainland China  However  there are concerns that China is underreporting these numbers and asymptomatic transmission is a troubling issue  As a result  experimental vaccine stocks have become market darlings  and even more biotechs are jumping at the prospect This harkens back to a few years ago when the Ebola virus poised a threat to the international community and biotech companies were quick to pursue a treatment and vaccine  At that time  practically any company that said it was developing anything related to Ebola saw a boost from the news  As more news poured in  these companies kept running  Sarepta Therapeutics Inc   NASDAQ  SRPT  saw some its biggest gains then As for the coronavirus  there have been roughly 7 900 confirmed infections and at least 170 deaths stemming from an outbreak in Wuhan City  Infections have been reported in East Asia  with Japan and Thailand leading the count  A couple European countries have reported infections  and there have been cases in the United States and Canada as well div connatix margin bottom  1 5em   div connatix img  margin  unset  Some quick background  Coronaviruses are a large family of viruses that cause illness ranging from the common cold to pneumonia  It primarily affects the respiratory system  In the past  coronaviruses have manifested as severe acute respiratory syndrome  SARS  and  most recently  Middle East respiratory syndrome  MERS  The following are biotech companies with exposure to experimental vaccines whose shares are seeing the biggest boost from this news Novavax Inc   NASDAQ  NVAX  shares were last seen up 1  to  6 90  in a 52 week range of  3 54 to  48 80  The consensus price target is  13 75  Note that shares are up over 72  year to date NanoViricides Inc   NYSE  NNVC  shares were trading up 13 5  at  10 76  The 52 week range is  1 27 to  17 77  Excluding Thursday s move  shares are up 278  in 2020 Aethlon Medical Inc   NASDAQ  AEMD  shares were last seen up 7   at  3 64  in a 52 week range of  0 76 to  21 30  The consensus price target is  3 00  So far in 2020  shares are up 252 Inovio Pharmaceuticals Inc   NASDAQ  INO  shares were up 11 5  to  4 59  The 52 week range is  1 92 to  5 95  and the consensus price target is  9 43  Since the beginning of the year  shares are up 25   


				ALSO READ  America s Most Hated Companies				


By Chris Lange",2020-01-30,247wallst,https://invst.ly/pp0c3,2071936
124958,346473,SRPT,Biotech Stocks Seeing the Biggest Boost From Coronavirus Outbreak,news,"The story that has dominated this past week is that China is facing an outbreak of the coronavirus  and more countries around the world are seeing cases pop up  Global infections of nearly 10 000 people have been reported  but only about 150 of these were outside of mainland China  However  there are concerns that China is underreporting these numbers  and asymptomatic transmission is a troubling issue  In response  experimental vaccine stocks have become increasingly popular  and even more biotechs are jumping at the prospect This harkens back to a few years ago when the Ebola virus poised a threat to the international community and biotech companies were quick to pursue a treatment and vaccine  At that time  practically any company that said it was developing anything related to Ebola saw a boost from the news  As more news poured in  these companies kept running  Sarepta Therapeutics Inc   NASDAQ  SRPT  saw some its biggest gains then As for the coronavirus  there have been roughly 9 900 confirmed infections and at least 213 deaths stemming from an outbreak in Wuhan  Infections have been reported in East Asia  with Japan and Thailand leading the count  A couple European countries have reported infections  and there have been cases in the United States and Canada as well div connatix margin bottom  1 5em   div connatix img  margin  unset  Some quick background  Coronaviruses are a large family of viruses that cause illness ranging from the common cold to pneumonia  It primarily affects the respiratory system  In the past  coronaviruses have manifested as severe acute respiratory syndrome  SARS  and  most recently  Middle East respiratory syndrome  MERS  The following are biotech companies with exposure to experimental vaccines whose shares are seeing the biggest boost from this news Novavax Inc   NASDAQ  NVAX  shares traded above  7 late on Friday  in a 52 week range of  3 54 to  48 80  The consensus price target is  13 75  Note that shares were up over 100  year to date on last look NanoViricides Inc   NYSE  NNVC  shares traded near  16 on Friday  The 52 week range is  1 27 to  19 20  Shares were up more than 500  in 2020 Aethlon Medical Inc   NASDAQ  AEMD  shares traded at  4 or so as the week wound down  in a 52 week range of  0 76 to  21 30  The consensus price target is  3 00  So far in 2020  shares are up over 200  Inovio Pharmaceuticals Inc   NASDAQ  INO  shares were last seen above  4  The 52 week range is  1 92 to  5 95  and the consensus price target is  9 43  Since the beginning of the year  shares are up 30  or so  


				ALSO READ  Gold Races Toward All Time Highs  5 Top Stocks to Buy Now				


By Chris Lange",2020-02-01,247wallst,https://invst.ly/pprgi,2073680
124985,346500,SRPT,Sarepta completes U S  marketing application for DMD candidate golodirsen,news,Sarepta  Therapeutics  NASDAQ SRPT  has completed the rolling submission of its U S  marketing application seeking accelerated approval for golodirsen  SRP 4053  for the treatment of Duchenne muscular dystrophy  DMD  patients amenable to exon 53 skipping Now read ,2018-12-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-completes-us-marketing-application-for-dmd-candidate-golodirsen-1727541,1727541
124986,346501,SRPT,Sarepta down 5  on preliminary Exondys 51 sales,news,Sarepta  Therapeutics  SRPT  4 8   is down on double normal in apparent response to its preliminary sales figures for DMD med EXONDYS 51  eteplirsen  Q4 sales were   84 4M  below consensus of  85 8M  Full year sales were   301M  in line with expectations Current consensus view for 2019 is  418 6M  JPM19Now read ,2019-01-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-down-5-on-preliminary-exondys-51-sales-1739562,1739562
124987,346502,SRPT,Sarepta up 8   Piper sees 60  upside,news,Sarepta  Therapeutics  SRPT  7 6   is up on below average volume  Piper Jaffray  citing the upcoming data readout in Limb girdle muscular dystrophy  has raised its price target to  200  60  upside  from  168 According to MarketBeat  the consensus rating is Buy with a   184 fair value target Now read ,2019-01-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-up-8-piper-sees-60-upside-1763841,1763841
124988,346503,SRPT,MarketPulse  Roche s Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks,news,"Investing com   Swiss based Roche Holding s bumper offer to acquire Spark Therapeutics on Monday propped up the healthcare sector and fueled speculation on Wall Street that more merger activity is in the pipeline for gene therapy stocks 
Roche  OTC RHHBY  said it will buy U S  based Spark Therapeutics  NASDAQ ONCE  for  4 3 billion  or  114 50 per share  a premium of about 122  to Spark s closing price on Feb  22  in a bid to strengthen its presence in gene therapy 
The deal is expected bolster Roche s hemophilia portfolio  which already includes Hemlibra  a drug that treats a rare disorder that stops blood from clotting normally 
At the onset of the year  market participants had said consolidation in the industry was likely  as large biotechnology and pharmaceutical companies will realize that they cannot survive if they are not in the gene therapy space 
 I think what we ll start to see is big guys coming in and swooping in and taking over   said Arthur Tzianabos  Ph D   President and Chief Executive Officer  Homology Medicines
Following the Roche Spark Therapeutics deal  Wall Street has also turned bullish on gene therapy names and suggested that speculation over merger activity could fuel a bull run 
 The deal may increase M A interest among other gene therapy names in our coverage universe  which include BioMarin   Sarepta     Ultragenyx     PTC  and  Solid Biosciences     Credit Suisse First Boston said in a note to clients 
Others on Wall Street see gene therapy stocks as offering a differentiated growth investment 
 Given advancements in manufacturing  de risking on dosing safety and efficacy  fast development times for rare disease  and favorable regulatory environment  the space is appealing and differentiated as a growth investment   Jefferies said in a note 
Biomarin Pharmaceutical Inc  NASDAQ BMRN   Sarepta Therapeutics Inc  NASDAQ SRPT   Ultragenyx  NASDAQ RARE   PTC  NASDAQ PTC  and Solid Biosciences  NASDAQ SLDB  were all sharply higher on the day ",2019-02-25,Investing.com,https://www.investing.com/news/stock-market-news/marketpulse-roches-bumper-deal-for-spark-therapeutics-boosts-health-care-stocks-1789738,1789738
124989,346504,SRPT,Sarepta surges after Pfizer gene therapy data raises safety concerns,news,"By Manas Mishra and Michael Erman  Reuters    Shares of  Sarepta  Therapeutics Inc  O SRPT  surged 15  on Friday after some safety concerns were raised in a small  early stage study of a competing gene therapy for a rare muscle wasting disorder from  Pfizer  Inc  N PFE   Sarepta reported promising data from its study last year and is in a race with Pfizer and  Solid Biosciences  Inc  O SLDB  to first market a gene therapy for the genetic degenerative disorder that affects one in 3 500 to 5 000 males  Shares of Pfizer were marginally up in midday trading  while Sarepta shares were up 15  and Solid Biosciences was up about 10   Baird analyst Brian Skorney said Pfizer fell way short on both safety and efficacy  making Sarepta  position in the space even stronger   Sarepta already has a treatment  Exondys 51  in the market for some form of the disease  People with the condition lack the protein dystrophin needed to keep muscle cells intact  That can lead to life threatening damage to the heart  and over time  death  often at a young age  Pfizer s six patient study tested two different dosages of the gene therapy in boys in the age group of 6 to 12  Two months after receiving the one time therapy  mini dystrophin expression levels ranged from 10  to 60  of normal  Skorney said all measures of expression looked worse   More importantly  it just did not look safe   Two Duchenne muscular dystrophy  DMD  patients in the trial experienced side effects that landed them in the hospital  the company said  The higher tested dose appeared to be more effective  according to data presented by Pfizer at the Parent Project Muscular Dystrophy conference in Orlando  Florida  Pfizer said it had paused enrollment in the study and then modified the study protocol in order to mitigate future risks of similar safety events  The company said future trials will use the higher dose  which had triple the concentration of virus with genetic material  The U S  drugmaker said it also may test an intermediate dose  Both of the boys who required hospital treatment had received the higher dose  One had developed a kidney injury  He was hospitalized for 11 days and received two doses of Alexion s  O ALXN  Soliris  but left the hospital with normal kidney function  
The other suffered nausea and vomiting after the treatment and spent two days in a hospital ",2019-06-28,Reuters,https://www.investing.com/news/stock-market-news/sarepta-surges-after-pfizer-gene-therapy-data-raises-safety-concerns-1910861,1910861
124990,346505,SRPT,Sarepta says adverse event report for DMD gene therapy erroneously submitted,news," Reuters     Sarepta  Therapeutics Inc  O SRPT  said on Thursday it was informed that an adverse event report was erroneously submitted to the U S  health regulator regarding an ongoing study of the company s gene therapy for Duchenne muscular dystrophy  DMD  
Shares of the company plunged as much as 19  earlier after a notice from the Food and Drug Administration showed a patient in the study was reported to have developed a serious illness  The stock pared losses to close down about 7  after the company s statement 
Sarepta said its investigation indicated the report was not submitted by its employee or the study s principal investigator 
The drug safety monitoring board has recommended the study to continue after a review  the company said in a statement 
The incident  which occurred in February  involved a 7 year old boy who developed rhabdomyolysis  a serious condition that can lead to complications such as kidney failure  The patient was hospitalized for observation and discharged the following day  with test results returning to baseline  the company said 
The illness was reported in the FDA adverse events database  which on its own cannot determine whether a drug is the cause of a problem  but can signal potential risks that warrant investigation 
The FDA told Reuters that it was looking into the matter and said it does not have additional information on it 
Sarepta said the study involves two arms with one receiving the drug and the other placebo  and the patient could have been on either 
The event is unlikely to be a major concern as there is a possibility that it could have occurred in a patient on placebo  RBC Capital Markets analyst Brian Abrahams said 
Analysts also pointed out that rhabdomyolysis is a commonly associated risk with DMD 
In June   Pfizer  Inc  N PFE   which is racing Sarepta to be first to market with a gene therapy for DMD  reported results from a tiny early study of its experimental treatment 
At the time  Pfizer said two of the six patients in its trial experienced side effects that landed them in the hospital  after which Wall Street analysts declared Sarepta was leading the charge to market 
Sarepta already has a drug to treat some types of DMD on the market 
DMD is a rare  genetic disorder that hampers muscle movement mainly in men  affecting one in every 3 500 to 5 000 males  A lack of dystrophin can cause life threatening damage to the heart  and over time  death  often at a young age ",2019-08-08,Reuters,https://www.investing.com/news/stock-market-news/sarepta-says-adverse-event-report-for-dmd-gene-therapy-erroneously-submitted-1950584,1950584
124991,346506,SRPT,Sarepta shares sink 17  after shock FDA rejection,news,"By Manas Mishra
 Reuters    Shares of  Sarepta  Therapeutics Inc  O SRPT  plummeted 17  on Tuesday after the U S  health regulator  in a surprise move  declined to approve the drugmaker s newest treatment for a muscle wasting disorder that mainly affects young boys 
Wall Street analysts expressed disbelief at the decision and at least five cut their price targets for the company s shares while stressing they still expected the company s second drug for Duchenne muscular dystophy  DMD  to eventually be approved 
The U S  Food and Drug Administration s so called complete response letter  CRL  on Sarepta s new treatment  called Vyondys 53  cited risks of infection and kidney toxicity and is a blow to the company as it looks to solidify its leadership in treating DMD 
 We believe the setback can only be described as odd and we cannot help but feel there is more to the CRL than the issues cited   William Blair analyst Tim Lugo wrote in a client note 
By Share of the company were trading down nearly 18  at  98 80 in trading before the bell  Wall Street brokerages  median price target for the stock  however  is still  193  a 60 4  upside to current levels 
Exondys 51  the company s first DMD treatment  was approved in 2016 against the advice of the FDA s outside panel of experts and its own reviewers  who had questioned the drug s effectiveness 
The FDA s decision cited risks of infections and kidney toxicity seen in pre clinical studies of Vyondys 53  which is also known as golodirsen 
The company said the doses used in those studies had been ten fold higher than those used in clinical studies 
 Sarepta is being slapped on the wrist for the prior questionable accelerated approval of Exondys 51   said SVB Leerink analyst Joseph Schwartz 
 The FDA may be holding Sarepta to a higher standard now  but we are optimistic that golodirsen can overcome this speedbump on its way to an eventual approval   Schwartz added 
The past few weeks have been eventful for Sarepta 
The company s shares plunged earlier this month after a notice from the FDA showed that a patient on its gene therapy for DMD had developed a serious illness in an ongoing trial 
Sarepta said it was not known whether the patient had received its experimental therapy or a placebo in the trial  and that independent safety monitors decided the study should continue 
 While none of these single events are catastrophic  the cumulative effect is wearing on investor patience   Baird analyst Brian Skorney said 
The Exondys 51 drug targets 13  of DMD patients  while the newest treatment would have treated about 8  of DMD patients  Analysts have forecast annual sales of golodirsen to reach a peak of nearly  400 million in five years 
The company is also developing another similar treatment that would target a further 8  of the population ",2019-08-20,Reuters,https://www.investing.com/news/stock-market-news/sarepta-shares-sink-17-after-shock-fda-rejection-1959094,1959094
124992,346507,SRPT,Pfizer  Novartis lead  2 billion spending spree on gene therapy production,news,"By Carl O Donnell and Tamara Mathias  Reuters    Eleven drugmakers led by  Pfizer  and  Novartis  have set aside a combined  2 billion to invest in gene therapy manufacturing since 2018  according to a Reuters analysis  in a drive to better control production of the world s priciest medicines   The full scope of Novartis   S NOVN   500 million plan  revealed to Reuters in an interview with the company s gene therapy chief  has not been previously disclosed  It is second only to Pfizer  N PFE   which has allocated  600 million to build its own gene therapy manufacturing plants  according to filings and interviews with industry executives  Gene therapies aim to correct certain diseases by replacing the missing or mutated version of a gene found in a patient s cells with healthy copies  With the potential to cure devastating illnesses in a single dose  drugmakers say they justify prices well above  1 million per patient   But the treatments are also extremely complex to make  involving the cultivation of living material  and still pose a risk of serious side effects  Drugmakers say building their own manufacturing plants is a response to rising costs and delays associated with relying on third party contract manufacturers  which are also expanding to capitalize on demand   They say owning their own facilities helps safeguard proprietary production methods and more effectively address any concerns raised by the U S  Food and Drug Administration  FDA   which is keeping a close eye on manufacturing standards   There s so little capacity and capability at contract manufacturers for the novel gene therapy processes being developed by companies   said David Lennon  president of AveXis  Novartis s gene therapy division   We need internal manufacturing capabilities in the long term    The approach is not without risks  Bob Smith  senior vice president of Pfizer s global gene therapy business  acknowledged drugmakers take a  leap of faith  when they make big capital investment outlays for treatments before they have been approved or  in some cases  even produced data demonstrating a benefit  PUSHING THE LIMITS The rewards are potentially great  however   Gene therapy is one of the hottest areas of drug research and  given the life changing possibilities  the FDA is helping to speed treatments to market   It has approved two so far  including Novartis s Zolgensma treatment for a rare muscular disorder priced at  2 million  and expects 40 new gene therapies to reach the U S  market by 2022   There are currently several hundred under development by around 30 drugmakers for conditions from hemophilia to Duchenne muscular dystrophy and sickle cell anemia  The proliferation of these treatments is pushing the limits of the industry s existing manufacturing capacity  Developers of gene therapies that need to outsource manufacturing face wait times of about 18 months to get a production slot  company executives told Reuters   They are also charged fees to reserve space that run into millions of dollars  more than double the cost of a few years ago  according to gene therapy developer RegenxBio   As a result  companies including bluebird bio  O BLUE   PTC Therapeutics  O PTCT  and  Krystal Biotech   O KRYS  are also investing in gene therapy manufacturing  according to a Reuters analysis of public filings and executive interviews   They follow Biomarin Pharmaceutical Inc  O BMRN   developer of a gene therapy for hemophilia  which constructed one of the industry s largest manufacturing facilities in 2017  REGULATORY SCRUTINY The FDA is keeping a close eye on standards   This comes amid the agency s disclosure in August that it is investigating alleged data manipulation by former executives at Novartis  AveXis unit  AveXis had switched its method for measuring Zolgensma s potency in animal studies  When results using the new method didn t meet expectations  the executives allegedly altered the data to cover it up  the FDA and Novartis have said  One of the former executives  Brian Kaspar  denied wrongdoing in a statement to Reuters  Another  his brother Allan Kaspar  could not be reached for comment  Novartis and the FDA say human clinical trials  which found Zolgensma effective in treating the most severe form of spinal muscular atrophy in infants  were not affected  Novartis also says its investments in gene therapy production started long before it became aware of the data manipulation allegations   But the scandal has highlighted the importance of having a consistent manufacturing process for gene therapies  industry executives say   According to four of them  the FDA has stressed in recent meetings the need for continuity in production processes all the way from the development of a drug to its commercialization  By bringing production in house  drugmakers may avoid pitfalls such as the need to switch to a larger facility if contract manufacturers  capacity proves limited  executives say  The FDA is finalizing new guidelines for gene therapy manufacturing  expected at the end of the year    Manufacturing consistency is always a major concern for the agency   FDA spokeswoman Stephanie Caccomo told Reuters  Highlighting the pressures on the industry   Sarepta  Therapeutics  O SRPT   which largely outsources manufacturing  delayed a clinical trial of its Duchenne treatment in August  telling investors it wanted to avoid any questions from regulators about consistency in producing its therapy at commercial scale  ENOUGH GROWTH FOR ALL    Between the trade secrets  the cost schedules and the time lag  it makes a whole lot of sense  if you can do it  to build out your own facilities and more and more gene therapy companies have started to do that   said Krish Krishnan  chief executive of Krystal Biotech Inc   Krystal  which is developing therapies for rare skin diseases  has built one manufacturing facility and plans to invest more than  50 million in a new one it will start constructing in December  MeiraGTx  O MGTX   which focuses on gene therapies for eye conditions  estimates it is currently spending roughly  25 million a year on manufacturing  including process development  Despite such moves  however  contract manufacturers like Lonza  S LONN  and Thermo Fisher  N TMO  are confident their businesses will continue to grow due to the strength of demand   Thermo Fisher has told investors its Brammer gene therapy manufacturing division  acquired in May  could soon earn  500 million in revenue a year  double its projected 2019 earnings  Lonza CEO Marc Funk is also optimistic   
 Demand in gene therapy has increased   he said in an interview   We believe this is going to continue in the coming years  ",2019-11-27,Reuters,https://www.investing.com/news/stock-market-news/pfizer-novartis-lead-pharma-spending-spree-on-gene-therapy-production-2029228,2029228
125026,346541,SRPT,Anthem no longer requires 6MWT to pay for Sarepta s Exondys 51,news,Anthem  ANTM  0 4   has updated its medical policy related to  Sarepta  Therapeutics   SRPT  2 6   Duchenne muscular dystrophy  DMD  med EXONDYS 51  eteplirsen   The Six Minute Walk Test  6MWT  will no longer be required to qualify for coverage The medical qualification will be a confirmed diagnosis of DMD and the patient must be ambulatory  with or without needing an assistive device such as a walker or cane  The patient must also  of course  have a genetic mutation amenable to exon 51 skipping Now read ,2017-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/anthem-no-longer-requires-6mwt-to-pay-for-sareptas-exondys-51-841268,841268
125027,346542,SRPT,Solid Biosciences on deck for IPO,news,Cambridge  MA based Solid Biosciences  Pending SLDB  has filed a preliminary prospectus for a  100M IPO The life sciences firm says its mission is to cure Duchenne muscular dystrophy  DMD   Lead candidate is SGT 001  a gene transfer that restores functional dystrophin protein expression in muscles by delivering a synthetic transgene that produces dystrophin like protein  The delivery vector is an adeno associated virus  AAV  that contains a muscle specific promoter SGT 001 has Rare Pediatric Disease and Orphan Drug designations in the U S  A Phase 1 2 study  IGNITE DMD  was initiated last quarter  According to ClinicalTrials gov  the estimated primary completion date is March 2020 2017 Financials  9 mo    M   Operating Expenses  39 7   134 9    Net Loss   39 7    134 9    Cash Burn   29 2    101 4   DMD related tickers  SRPT BIIB CAPR WVE PTCT CATB SMMT BMRNNow read ,2018-01-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/solid-biosciences-on-deck-for-ipo-1054178,1054178
125028,346543,SRPT,Solid Biosciences moving closer to removal of clinical hold on early stage study of DMD candidate SGT 001  shares up 6 ,news,Thinly traded  Solid Biosciences   SLDB  5 5   is up  albeit on turnover of only 85K shares  on its announcement that it has received a letter from FDA concerning the full clinical hold on its Phase 1 2 study of gene therapy SGT 001 in patients with Duchenne muscular dystrophy  The agency suspended the study after the first participant experienced a severe reaction requiring hospitalization The agency has requested more information related to causes of the serious adverse event  the patient s clinical status and laboratory parameters and any additional measures to address patient safety  It plans to respond to the letter in the next few weeks The company also reports that the FDA has informed it that it has satisfactorily addressed its manufacturing related questions that led to the partial clinical hold on the high dose of SGT 001  thereby avoiding any revision to its current manufacturing process DMD related tickers   SRPT  2   CAPR  1 5   CATB  1 2   PFE  0 3   SMMT  4 5   WVE  0 7  Previously  FDA places Solid Biosciences  DMD study of lead candidate SGT 001 on clinical hold due to adverse event in first patient  shares down 57  premarket  March 15 Now read ,2018-04-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/solid-biosciences-moving-closer-to-removal-of-clinical-hold-on-earlystage-study-of-dmd-candidate-sgt001-shares-up-6-1422219,1422219
125029,346544,SRPT,Sarepta  37 5  as sell side chimes in,news, If you want to own something really transformative  buy this stock   says Baird bull Brian Skorney    If durable  this will transform the lives of DMD patients in the future  Also a bull  RBC s Brain Abrahams sounds a modest note of caution   While dramatic and far exceeding expectations  we acknowledge that there are still some outstanding questions  as the results are early and interim  Chardan s Gbola Amusa says the news is a positive for  Solid Biosciences   SLDB  55 7    seeing  superior elements of the Solid microdystrophin construct   Transitioning to the next emerging large cap   says JPMorgan  NYSE JPM   jacking its price target to  205 HC Wainwright goes further  raising to  267 Source  BloombergSRPT  37 5  to  144 69 Previously   Sarepta  set to pop on encouraging data on DMD gene therapy  June 19 Now read ,2018-06-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-375-as-sellside-chimes-in-1499057,1499057
125030,346545,SRPT,Gene therapy players in the green,news,Gene therapy related stocks are poised to end the session in the green  riding high after  Sarepta  s  SRPT  7 1   bullish news yesterday Seleted tickers   SLDB  18 6   FCSC  5 7   RCKT  2 1   ABEO  2 5   CAPR  2 9   SHPG  2 1   CRSP  6 2   EDIT  3 7   NTLA  5 7   ZIOP  4 7   FLXN  2 8   RGNX  10 7   BMRN  2 6   RARE  6 2   QURE  6 3   VYGR  2 3   BNTC  2 9   KRYS  1 5   SGMO  10 3   ONCE  12 1   ADVM  2 6  Previously  Sarepta set to pop on encouraging data on DMD gene therapy  June 19 Now read ,2018-06-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/gene-therapy-players-in-the-green-1500997,1500997
125057,346572,SRPT,Sarepta readies  250M stock offering  shares slip 2  premarket,news,Sarepta  Therapeutics  NASDAQ SRPT  commences a public offering of  250M of common stock  Price  volume and terms have yet to be announced  Net proceeds will fund clinical trials  commercialization  manufacturing and business development activities and general corporate purposes Shares are down 2  premarket on light volume Now read ,2017-07-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-readies-$250m-stock-offering;-shares-slip-2-premarket-508968,508968
125060,346575,SRPT,Sarepta prices stock offering at  42 50  shares off 1  premarket,news,Sarepta  Therapeutics  NASDAQ SRPT  is down 1  premarket on modest volume in response to the pricing of its public offering of 7 65M shares of common stock at  42 50 per share  Underwriters over allotment is an additional 1 15M shares  Closing date is July 27 Yesterday s close was  43 95 Now read ,2017-07-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-prices-stock-offering-at-$42.50;-shares-off-1-premarket-509510,509510
125061,346576,SRPT,Sarepta CEO Ingram bullish on company s prospects  buys  2M of stock,news,Sarepta  Therapeutics  SRPT  0 3   President   CEO Doug Ingram discloses that he has purchased 47K shares of the company s common stock at the public offering price of  42 50 for a total value of   2M Now read ,2017-07-28,Seeking Alpha,"https://www.investing.com/news/stock-market-news/sarepta-ceo-ingram-bullish-on-company's-prospects,-buys-$2m-of-stock-511744",511744
125062,346577,SRPT,Sarepta shares jump on positive DMD drug study results,news,"Investing com    Sarepta  Therapeutics Inc  NASDAQ SRPT  shares jumped on Wednesday after the company reported positive results from a Phase 1 2 study for golodirsen  SRP 4053  treatment for Duchenne muscular dystrophy  DMD  
All 25 boys in Part 2 of the study experienced an increase in skipping exon 53 over baseline levels at week 48  DMD is a rare  and often deadly genetic disease  Patients with DMD lack dystrophin  a protein that helps keep muscle cells intact  Symptom onset is in early childhood  usually between ages 3 and 5  The disease primarily affects boys 
Sarepta s share jumped Wednesday  as these results sparked hopes for an accelerated approval for the drug  The latest study comes just a year after the company was granted approval for another DMD drug  Eteplirsen   Eteplirsen was the first U S  drug approved for DMD   but its approval was marred by significant controversy and a great deal of disagreement at the Food and Drug Administration 
Complete study results will be submitted for presentation at a future medical conference  Sarepta s shares were recently up over 14  ",2017-09-06,Investing.com,https://www.investing.com/news/stock-market-news/sarepta-shares-jump-on-positive-dmd-drug-study-results-526103,526103
125063,346578,SRPT,Investors shaken by PTC s briefing docs ahead of Ad Com for DMD candidate Translarna  shares down 14  premarket,news,PTC Therapeutics  NASDAQ PTCT  slumps 14  premarket on increased volume in apparent response to the release of briefing documents ahead of Thursday s FDA Advisory Committee review of its marketing application for Duchenne muscular dystrophy  DMD  candidate Translarna  ataluren  This a rare case of an advisory committee review of an application  filed over protest  in which the applicant insists that the FDA further review the data that was initially regarded as insufficient to support approval  On two prior occasions  2011 and 2016  the FDA rejected the company s application under  Refuse to File  which means the filing was not complete enough to permit a substantive review The present situation is the result of the FDA s controversial approval of  Sarepta  Therapeutics   NASDAQ SRPT  application for EXONDYS 51 in September 2016 that many observers perceived lacked sufficient proof that the drug works FDA briefing docAddendum to FDA briefing docErrata to FDA briefing docPTC briefing docAddendum to PTC briefing doc Now read ,2017-09-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/investors-shaken-by-ptcs-briefing-docs-ahead-of-ad-com-for-dmd-candidate-translarna-shares-down-14-premarket-532838,532838
125064,346579,SRPT,FDA action date today for PTC Therapeutics   filing over protest  NDA for DMD med Translarna  shares down 5 ,news,Investors are sending a clear signal that they do not expect good news today from the FDA regarding PTC Therapeutics   PTCT  4 6   New Drug Application  NDA  seeking approval for Translarna  ataluren  for the treatment of Duchenne muscular dystrophy  DMD   Today is the agency s action date under  filing under protest  regulations  Last month  an advisory committee voted 10   1 that the efficacy data supporting the application was inconclusive Shares have sold off more than 22  this month  Sarepta  Therapeutics  SRPT  4 7    maker of DMD med EXONDYS 51  eteplirsen   is also under pressure ahead of tomorrow s Q3 earnings report Previously  FDA to review PTC s marketing application for DMD candidate Translarna under protest regulations  action date October 24  shares ahead 15  premarket  March 6 Previously  FDA Ad Com says data on PTC s Translarna inclusive  more needed to prove efficacy  Sept  28 Now read ,2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-action-date-today-for-ptc-therapeutics-filing-over-protest-nda-for-dmd-med-translarna-shares-down-5-546863,546863
125065,346580,SRPT,Sarepta inks research collaboration with Duke University for use of gene editing technology to restore dystrophin expression in DMD patients,news,Sarepta  Therapeutics  NASDAQ SRPT  signs a research collaboration agreement with Duke University under which it has the option to exclusively license the intellectual property related to the use of gene editing technology CRISPR Cas9 to restore dystrophin expression in patients with Duchenne muscular dystrophy  DMD  The company will collaborate with the laboratory of Charles A  Gersbach  Ph D   to advance the platform and will take the lead on clinical development Dr  Gerbach says   Although early  CRISPR technology represents hope for a large percentage of individuals with DMD  Excising certain exons has the potential to correct a majority of DMD mutations  Toward that goal  we ve shown in mouse models that we can excise exons from the dystrophin gene  leading to restoration of a functional dystrophin protein and improvements in muscle strength  Financial terms are not disclosed Now read ,2017-10-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-inks-research-collaboration-with-duke-university-for-use-of-gene-editing-technology-to-restore-dystrophin-expression-in-dmd-patients-760998,760998
125066,346581,SRPT,FDA OKs Nationwide Children s Hospital s IND for Sarepta s microdystrophin gene therapy for DMD  shares up 2 ,news,The FDA has signed off on Nationwide Children s Hospital s IND application seeking approval to begin a Phase 1 2a study of evaluating a new gene therapy candidate  AAVrh74 MHCK7 micro Dystrophin  in patients with Duchenne muscular dystrophy  DMD  The study is the first in DMD patients as young as three months old  Enrollment is now open The gene therapy uses a construct called MHCK7 which was optimized for the trial after demonstrating high levels of gene expression in preclinical studies  Sarepta  Therapeutics  SRPT  1 5   has the option to global exclusive rights Now read ,2017-11-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-nationwide-childrens-hospitals-ind-for-sareptas-microdystrophin-gene-therapy-for-dmd-shares-up-2-765041,765041
125088,346603,SRPT,Trump nominates FDA head with deep ties to drug companies,news,By Toni Clarke WASHINGTON  Reuters    U S  President Donald Trump has chosen Dr  Scott Gottlieb  a conservative health policy expert with deep ties to the pharmaceutical industry  to lead the U S  Food and Drug Administration  a White House official said on Friday  If confirmed by the Senate  Gottlieb would be in charge of implementing Trump s plan to dramatically cut regulations governing food  drugs  cosmetics  dietary supplements and tobacco  Gottlieb is well known on Capitol Hill  where he has testified multiple times on hot button health issues  including complex drug pricing matters  and is viewed favorably by drug companies and pharmaceutical investors  A former FDA official  Gottlieb also sits on the board of pharmaceutical companies   Thank God it s Gottlieb   Brian Skorney  an investment analyst at Robert W  Baird  wrote in a research note   We view this as a favorable development for the sector   Gottlieb  44  is a resident fellow at the conservative American Enterprise Institute think tank and a partner at a large venture capital fund  He is a former FDA deputy commissioner who has frequently advocated a loosening of requirements needed for approval of new medical products   Scott knows how the agency works and he will move it forwards  though maybe not always in ways the agency is comfortable with   said John Taylor  a lawyer and president of compliance and regulatory affairs with the consulting firm Greenleaf Health and a former acting FDA deputy commissioner  Gottlieb was chosen over Jim O Neill  a libertarian investor close to Silicon Valley billionaire Peter Thiel  a PayPal co founder who now advises Trump on technology and science matters  O Neill s stated view that drugs should be approved before being proven effective generated widespread alarm  Gottlieb  who declined to comment on the nomination  is unlikely to up end the FDA in the way O Neill might have  but he is nonetheless expected to bring significant change  including moving the agency to increase flexibility in the clinical trial development process  In this he will be supported by the recently passed 21st Century Cures Act which instructs the FDA among other things to consider the use of  real world evidence  to support new drug applications  This could include anecdotal data  observational studies and patient reports   People don t want to take chances with safety  but there s increasingly some clamor to be more flexible on the efficacy side   said Kathleen Sanzo  who leads the FDA practice at the law firm Morgan  Lewis   Bockius   You need to have some signal of efficacy  The question is  how much   One of Gottlieb s priorities will likely be to streamline the process for approving generic versions of complex  difficult to copy therapeutics  He has stated publicly that he does not believe the FDA has good tools or policies to move such products and has advocated the creation of different approval standards   A survey conducted by Mizuho Securities USA Inc of 53 pharmaceutical executives found that 72 percent favored Gottlieb over other potential candidates  Many described him as knowledgeable  experienced and balanced   He will be a pragmatic leader with an eye toward both expedited approvals and safety   one executive wrote  Others were less sanguine  citing his deep ties to industry  including his seat on multiple pharmaceutical company boards  as potential conflicts of interest  Dr  Michael Carome  director of Public Citizen s Health Research Group  said Gottlieb  has spent most of his career dedicated to promoting the financial interests of the pharmaceutical industry   If confirmed  he added   he will have to be recused from key decisions time and time again    CLINICAL TRIAL FLEXIBILITY The FDA has attempted to push back against moves to sideline randomized clinical trials  long considered the gold standard  In January it issued a report documenting 22 cases in which drugs that appeared to show promise in early trials turned out to be either ineffective or unsafe or both in larger trials  But it has already moved to decrease the requirements for proving that a drug works  Last year  Dr  Janet Woodcock  the agency s powerful head of pharmaceuticals  ordered the approval of  Sarepta  Therapeutics Inc s  O SRPT  drug to treat Duchenne muscular dystrophy based on little more than a hint of efficacy  In doing so she overrode the recommendation of a panel of outside advisors and top scientists at the agency and set what some say is a precedent for approving drugs based on minimal data   How can you say it s OK for this company but not that company   Mark Mansour  a partner with the law firm Mayer Brown LLP said   The administration is going to be pushing for quicker approval of drugs for all sorts of diseases with similar  vociferous patient populations who are crying out for a solution   Other companies that may benefit from Gottlieb s presence are manufacturers of electronic nicotine delivery systems such as e cigarettes  The American Enterprise Institute has consistently argued that there is no evidence to show that the risk of vaping comes near to the risk of smoking   Between 2005 and 2007 he was FDA deputy commissioner for medical and scientific affairs  Previously he was a senior advisor to the commissioner and acted as the agency s director of medical policy development ,2017-03-10,Reuters,https://www.investing.com/news/politics-news/trump-nominates-fda-head-with-deep-ties-to-drug-companies-465356,465356
125089,346604,SRPT,Premarket analyst action   healthcare,news,Neos Therapeutics  NASDAQ NEOS  initiated with Outperform rating and  20  178  upside  price target by Cowen and Company  ACADIA Pharmaceuticals   NASDAQ ACAD  initiated withAnthem  NYSE ANTM  initiated with a Hold rating and  166  0  upside  price target by  Deutsche Bank   DE DBKGn  Cigna  NYSE CI  initiated with a Buy rating and  172  14  upside  price target by Deutsche Bank Humana  NYSE HUM  initiated with a Hold rating and  216  2  upside  price target by Deutsche Bank United Health  NYSE UNH  initiated with a Buy rating and  183  11  upside  price target by Deutsche Bank  Community Health  Systems  NYSE CYH  initiated with Hold rating and  11  27  upside  price target by Deutsche Bank  Sarepta  Therapeutics  NASDAQ SRPT  upgraded to Buy with a  45  55  upside  price target by SunTrust Roche  OTCQX RHHBY  upgraded to Outperform with a  38  19  upside  price target by Cowen Amgen  NASDAQ AMGN  downgraded to Hold with a  180  10  upside  price target by Jefferies Novartis  NYSE NVS  downgraded to Market Perform with a  77  3  upside  price target by Cowen ,2017-04-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action---healthcare-471604,471604
125090,346605,SRPT,Premarket Gainers as of 9 05 am,news,PRAN  21  TNGO  16  on entering into definitive agreement with Marlin Equity Partners SRPT  7  WDC  7  SWN  6  TGTX  5  RCL  5  RBS  5  on reporting Q1 result Now read  TG Therapeutics  More Upside For This   10 Biotech Stock,2017-04-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-gainers-as-of-9:05-am-478503,478503
125091,346606,SRPT, Benign  briefing papers send Sarepta up more than 3 ,news,The FDA s Pediatric Advisory Committee and Pediatric Ethics Subcommittee released briefing documents ahead of its vote for whether children with Duchenne Muscular Dystrophy in Sarepta s  SRPT  3 3   placebo controlled  Essence  study should be able to get ports for drug delivery Calling the docs  relatively benign   William Blair s Tim Lugo says it s likely the May 18 vote will be mostly procedural via Bloomberg First WordNow read ,2017-05-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/'benign'-briefing-papers-send-sarepta-up-more-than-3-483810,483810
125092,346607,SRPT,Sarepta perks up 3  after Tourbillon s Karp says he s long the stock,news,Sarepta  Therapeutics  SRPT  3 4   jumps on average volume after Tourbillion investment chief Jason Karp said he has a long position  During the SALT investment conference  he commented that he sees as much as a 200  upside in the stock over the next two years Source  The FlyNow read ,2017-05-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-perks-up-3-after-tourbillon's-karp-says-he's-long-the-stock-486158,486158
125093,346608,SRPT,Sarepta and Genethon team up to develop gene therapies to treat DMD,news,Sarepta  Therapeutics  NASDAQ SRPT  and non profit R D outfit Genethon ink a research collaboration agreement to jointly develop gene therapies to treat Duchenne muscular dystrophy  DMD  Under the terms of the partnership  Genethon will be responsible for early development activities and Sarepta will have the option to co develop Genethon s micro dystrophin program  including exclusive commercial rights in the U S  Financial terms are not disclosed Now read ,2017-06-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/sarepta-and-genethon-team-up-to-develop-gene-therapies-to-treat-dmd-497747,497747
125098,346613,SRPT,After Hours Gainers   Losers,news,Top gainers  as of 5 25 p m   HPJ  22 0   AVA  19 3   SRPT  14 3   PLXS  6 4   KMI  4 4  Top losers  as of 5 25p m   PTC  11 7   KMDA  8 9   CHRW  8 2   WES  4 7   SPN  3 7   Now read ,2017-07-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/after-hours-gainers---losers-507583,507583
125116,346631,SRPT,Pharmaceutical Companies See Stocks Jump After News Of First Ebola Case In US ,news,"By    Stocks of pharmaceutical companies such as Tekmira Pharmaceuticals Corporation  NASDAQ TKMR   Glaxosmithkline  NYSE GSK  and Sarepta Therapeutics Inc  NASDAQ SRPT  rose significantly on Tuesday after the Centers for Disease Control and Prevention confirmed the first case of Ebola in the United States at a hospital in Dallas  Texas 
These firms  many of which have been working on Ebola research  thanks to millions of dollars of funding from the U S  government  have already seen their stock grow stronger as the Ebola outbreak in West Africa continues  The deadly virus has killed more than 3 000 people in Sierra Leone  Guinea and Liberia in the largest outbreak ever recorded 

When news of the American patient broke Tuesday afternoon  Tekmira Pharmaceuticals Corp  stock jumped jumped 26 6 percent between 4 35 p m  and 5 35 p m 
The Canadian firm has been working with the U S  Department of Defense to develop its TKM Ebola treatment  which has emerged as one of the leading drug candidates for use in the current outbreak 

Sarepta Therapeutics also saw an 11 3 percent increase in after hours trading  NewLink Genetics Corporation stock jumped 16 percent  GlaxoSmithKline  which is also at the forefront of Ebola research  also saw a slight increase 
The U S  government has spent millions of dollars on grants and contracts to biopharmaceutical research companies to research Ebola for more than a decade ",2014-09-30,International Business Times,https://www.investing.com/news/stock-market-news/pharmaceutical-companies-see-stocks-jump-after-news-of-first-ebola-case-in-us-311380,311380
125117,346632,SRPT,Biotech Stocks Up On Ebola News ,news,"By    Biotech stocks are up this morning on news of the first reported case of Ebola in the United States 
Yesterday  the Centres for Disease Control and Prevention announced that a patient was being treated at Texas Health Presbyterian Hospital in Dallas  The adult had traveled to West Africa  and developed symptoms after returning to the U S   which means health workers are currently tracking down every person the patient had contact with 
On Wednesday morning  stocks of Tekmira Pharmaceuticals Corporation NASDAQ TKMR were up 26 54 percent in premarket trading  The Canadian company has been working with the U S  Department of Defense to develop its treatment  TKM Ebola  which was approved for use during the current outbreak 
BioCryst Pharmaceuticals  Inc  NASDAQ BCRXsaw its stock jump is up 5 32 percent this morning  The company  based in Research Triangle Park  North Carolina  announced in August that its drug  BCX 4430 would soon be studied in non human primates 

But they re not the only biotech firms doing well  A handful of other companies are also researching Ebola treatments and vaccines  Though many have yet to reach human trials  their stocks all received a major boost after Monday s news 
Sarepta Therapeutics Inc  NASDAQ SRPT shares were up 4 98 percent  NewLink Genetics Corp   NASDAQ NLNK   which is currently developing an Ebola vaccine  saw its stock jump 2 08 percent  Inovio Pharmaceuticals Inc   NASDAQ INO  is up 4 37 percent  NanoViricides Inc NYSE NNVC is up  15 percent ",2014-10-01,International Business Times,https://www.investing.com/news/stock-market-news/biotech-stocks-up-on-ebola-news-311477,311477
125118,346633,SRPT,BioMarin to buy Prosensa in  840 million deal,news," Reuters    BioMarin Pharmaceuticals Inc  O BMRN  said it would buy Dutch drug developer Prosensa Holding NV  O RNA  for about  840 million including milestone payments  aiming to add to its portfolio of drugs to treat rare diseases   The acquisition will give BioMarin worldwide rights to several orphan drug candidates including drisapersen  which is being developed to treat Duchenne muscular dystrophy  DMD   a rare muscle degeneration disease   Drisapersen could be the first approved treatment for the rare genetic disease that affects one in 3 600 newborn boys  most of whom die by age 30   BioMarin will offer  17 75 for every Prosensa share and make two milestone payments of  80 million each following U S  and European approvals for Prosensa s lead drug  drisapersen   Excluding milestone payments  the offer represents a premium of 55 percent to Prosensa s last closing price of  11 44   Prosensa s shares were trading at  18 50 premarket on Monday   Prosensa has filed for marketing approval of drisapersen  stealing a march on rival Sarepta Therapeutics Inc  O SRPT   which is conducting mid stage studies for its DMD drug eteplirsen   Sarepta received a major setback last month when U S  regulators asked for more data on eteplirsen  a move that could delay the drug further   Wedbush Securities analyst Liana Moussatos said the deal made sense for BioMarin  given its history with developing drugs for the indication   The company dropped its own DMD candidate in 2010  after the drug failed early stage studies      Both Sarepta and Prosensa from use the same mechanism in their DMD treatments  The drugs skip a faulty section of a gene to produce a protein called dystrophin  the lack of which causes the disease   Prosensa is developing two other DMD drugs  which are currently being tested in early and mid stage studies  It is also testing drugs to treat Huntington s disease   
BioMarin s shares were unchanged before the bell     Reporting by Vidya L Nathan and Amrutha Penumudi in Bangalore  Editing by Saumyadeb Chakrabarty ",2014-11-24,Reuters,https://www.investing.com/news/stock-market-news/biomarin-to-buy-prosensa-in-$840-million-deal-317852,317852
125123,346638,SRPT,U S  stocks higher at close of trade  Dow Jones Industrial Average up 0 82 ,news,"Investing com   U S  stocks were higher after the close on Wednesday  as gains in the Oil   Gas  Basic Materials and Technology sectors led shares higher 
At the close in NYSE  the Dow Jones Industrial Average rose 0 82   while the S P 500 index climbed 0 70   and the NASDAQ Composite index added 0 70  
The best performers of the session on the Dow Jones Industrial Average were  Goldman Sachs Group  Inc  NYSE GS   which rose 2 37  or 3 74 points to trade at 161 25 at the close  Meanwhile  International Business Machines  NYSE IBM  added 2 28  or 3 38 points to end at 151 69 and  Caterpillar  Inc  NYSE CAT  was up 2 08  or 1 48 points to 72 57 in late trade 
The worst performers of the session were  Nike  Inc  NYSE NKE   which fell 1 06  or 0 60 points to trade at 55 99 at the close  McDonald s Corporation  NYSE MCD  declined 0 56  or 0 69 points to end at 123 26 and  Visa Inc   NYSE V  was down 0 40  or 0 32 points to 79 06 
The top performers on the S P 500 were  Transocean Ltd   NYSE RIG  which rose 9 65  to 10 11  Chesapeake Energy Corporation  NYSE CHK  which was up 7 41  to settle at 4 35 and CF Industries Holdings Inc  NYSE CF  which gained 6 76  to close at 29 52 
The worst performers were Yahoo  Inc  NASDAQ YHOO  which was down 5 17  to 35 59 in late trade  Williams Companies Inc  NYSE WMB  which lost 3 98  to settle at 21 25 and Citrix Systems Inc  NASDAQ CTXS  which was down 3 20  to 83 14 at the close 
The top performers on the NASDAQ Composite were  Innocoll AG   NASDAQ INNL  which rose 47 82  to 10 51   Opexa Therapeutics  Inc  NASDAQ OPXA  which was up 27 52  to settle at 3 290 and  Sarepta  Therapeutics Inc  NASDAQ SRPT  which gained 26 63  to close at 23 350 
The worst performers were  OXiGENE  Inc  NASDAQ OXGN  which was down 19 84  to 0 6717 in late trade  xG Technology Inc  NASDAQ XGTI  which lost 15 68  to settle at 0 1500 and Euro Tech Holdings Company Limited  NASDAQ CLWT  which was down 14 19  to 1 802 at the close 
Rising stocks outnumbered declining ones on the New York Stock Exchange by 2210 to 1091 and 38 ended unchanged  on the Nasdaq Stock Exchange  1580 rose and 963 declined  while 79 ended unchanged 
Shares in Euro Tech Holdings Company Limited  NASDAQ CLWT  fell to 5 year lows  losing 14 19  or 0 298 to 1 802  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 3 33  to 13 94 
Gold for June delivery was down 0 39  or 4 85 to  1224 35 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July rose 2 24  or 1 09 to hit  49 71 a barrel  while the July Brent oil contract rose 2 67  or 1 30 to trade at  49 91 a barrel 
EUR USD was up 0 12  to 1 1154  while USD JPY rose 0 16  to 110 18 
The US Dollar Index was down 0 21  at 95 39 ",2016-05-25,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-higher-at-close-of-trade;-dow-jones-industrial-average-up-0.82-404522,404522
125137,346652,SRPT,U S  futures edge lower ahead of ISM report  Dow Jones down 0 11 ,news,Investing com   U S  stock futures edged lower on Monday  as investors eyed the release of a U S  report on manufacturing activity after weak euro zone data sparked new fears that the region is slipping into a recession  Ahead of the open  the Dow Jones Industrial Average futures pointed to a fall of 0 11   S P 500 futures signaled a 0 04  loss  while the Nasdaq 100 futures indicated a 0 03  decline Investor confidence weakened after official data showed that the unemployment rate in the region ticked up to a record high of 10 8  in February from 10 7  the previous month  broadly in line with expectations Market sentiment found support earlier as concerns over Chinese economic growth eased after data showed that the manufacturing activity in China rose more than expected in March In addition  euro zone finance ministers agreed on Friday to strengthen the bloc s debt firewall  but fears remained over whether the measures would be enough to prevent contagion to Spain and Italy The energy sector was expected to be active as French oil major Total was preparing to fly experts to a North Sea oil platform to plan how to cap a well that has been spewing gas for the past week Meanwhile  a Brazilian prosecutor requested an injunction this week barring U S  oil company Chevron and drill rig operator Transocean from operating in Brazil as part of a record USD10 9 billion environmental lawsuit over a November oil spill  Shares in Transocean rose 0 66  in pre market trade Elsewhere  AVI BioPharma was also slated to be in focus as markets were waiting to see whether the company s treatment for Duchenne muscular dystrophy showed promising results in clinical trials  In the financial sector  Visa dropped payment processor Global Payments from its list of approved service providers after a major cyber intrusion that could expose Visa  MasterCard  American Express and Discover card holders to fraud  Global Payments said it believes fewer than 1 5 million credit card numbers were stolen in the cyber security breach In addition  Goldman Sachs was reported to be mulling setting up a USD3 billion fund to provide loans to property investors that would target riskier  but higher yielding investments Apple shares added 0 48  in pre market trade after Foxconn  one of the company s suppliers  pledged on Sunday to keep increasing salaries at its Chinese factories and cutting the hours of work In earnings  Groupon was expected to move after the deal of the day website said it reduced its revenue for the fourth quarter due to customer returns Across the Atlantic  European stock markets were mixed  The EURO STOXX 50 tumbled 0 56   France s CAC 40 dropped 0 34   Germany s DAX added 0 12   while Britain s FTSE 100 declined 0 13  During the Asian trading session  Hong Kong s Hang Seng Index fell 0 6   while Japan s Nikkei 225 Index eased up 0 2  Later in the day  the U S  was to release a report by the Institute of Supply Management on manufacturing activity ,2012-04-02,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-futures-edge-lower-ahead-of-ism-report;-dow-jones-down-0.11-232117,232117
125140,346655,SRPT,U S  forecasts more than 500 000 Ebola cases in West Africa,news,"By Sharon Begley and Tom Miles
NEW YORK GENEVA  Reuters    Global experts issued stark new warnings of the scale of West Africa s Ebola outbreak on Tuesday  with the U S  government estimating between 550 000 and 1 4 million people might be infected in the region by January 
The U S  Centers for Disease Control and Prevention  CDC  said its projection was based on data from late August and did not take into account a planned U S  mission to fight the disease  so the upper end of the forecast was unlikely 
However  it followed research by experts from the World Health Organization  WHO  and Imperial College  which estimated that 20 000 people risked infection within six weeks    months earlier than previous forecasts  It warned that the disease might become a permanent feature of life in West Africa 
The worst Ebola outbreak on record has already killed over 2 800 people   more than the combined total of all previous outbreaks  The disease has marched across much of Guinea  Liberia and Sierra Leone  killing dozens of health workers and crippling economies recovering from years of conflict 
Outbreaks in Nigeria and Senegal appear for now to have been contained  But nations across the region fear contagion and  against expert advise  have shuttered borders and restricted travel  complicating international efforts to fight the disease 
 I am confident the most dire projections will not come to pass   CDC director Dr  Thomas Frieden told reporters 
The worst case scenario assumes that there are 2 5 times the number of recorded cases  currently at 5 864 
 A surge now can break the back of the epidemic   Frieden said   If you get enough people effectively isolated  the epidemic can be stopped  
Amid complaints from aid workers and regional leaders that the world was doing too little  U S  President Barack Obama last week announced plans to send 3 000 troops to build 17 treatment centers and train thousands of healthcare workers 
The U S  move has been welcomed  but it was accompanied by calls for other nations to follow suit  since the disease was still spreading faster than the moves being made to contain it 
Underscoring this gap  a senior U N  official in Liberia  the worst hit nation  said on Tuesday that 150 foreign experts were in the country but another 600 to 700 were needed 
Antonio Vigilante  head of the U N  Development Programme in Liberia  said Liberia now had 350 to 400 beds for Ebola patients  but that fell far short of the 2 000 needed 
 Even if we are at 2 000 beds two or three weeks from now  the cases we ll have in any single day may be more than that   he said 
HORRENDOUS  SCARY
Much of the international medical assistance has been provided by French medical charity Medecins Sans Frontieres  MSF   However  the group says it is overwhelmed and has called for states to send their medics to the region  The response so far has been muted 
 We have announcements that more will come but very small numbers   Vigilante added   The American military are bringing in a camp hospital  but it is for 25 beds with medical staff  And so there are still very few  
In a bid to fill the void  Liberia is now planning to train some 40 000 community workers 
Liberian President Ellen Johnson Sirleaf called the CDC predictions  horrendous  and  scary   But now that structures had been put in place  he said  the U S  effort would help ensure the outbreak would decline as fast as it spread 
 I believe that  given another couple of weeks  we shall see that this major effort begins to show results   she said  via Skype to an audience at Georgetown University in Washington  DC 
Experts from the WHO and Imperial College were less optimistic  In an article published in the New England Journal of Medicine  they warned that infections could reach 20 000 by November if strict controls were not put in place 
 With exponential growth  you ll see that the case numbers per week go up  so that by the second of November  over these three countries our best estimate is over 20 000 cases  confirmed and suspected cases   said Dr  Christopher Dye  WHO director of strategy and co author of the article 
The WHO forecast last month it would take nine months to reach this level of infections  Dye said nearly 10 000 of those would be in Liberia  5 000 in Sierra Leone and nearly 6 000 in Guinea 
EBOLA PERMANENT
A spokesman for Sierra Leone s army said it had sealed off its borders with Liberia and Guinea  joining similar actions by countries in the region  The move went against a pledge by Africa s leaders at the African Union to lift restrictions 
 Our troops are on the borders to stop the movement  especially of vehicles   said army spokesman Col  Michael Samura  Witnesses in Kambia  a town bordering Guinea  said dozens of vehicles were turned back on both sides of the frontier 
With the United States taking the lead in Liberia  a nation established by freed American slaves  the British government said on Tuesday it was stepping up its military and humanitarian mission in Sierra Leone  a former colony whose civil war it helped end just over a decade ago 
About 40 military personnel are on the ground helping install a planned 700 new beds  and 164 staff from Britain s National Health Service have volunteered to work in West Africa  They join nations like Cuba  China  Uganda and France who have already promised or sent medics to the region 
Underscoring the economic impact of the crisis  Malaysian palm oil firm Sime Darby  KL SIME  has delayed construction of a mill for its Liberia plantation and has frozen talks to expand its planted acreage there because of the outbreak 
Meanwhile  the Wellcome Trust said experimental drugs  including compounds from Mapp Biopharmaceutical  Sarepta  O SRPT  and Tekmira  TO TKM   will be tested in affected states for the first time in a bid to fast track trials 
Dye  the WHO expert  said that if current efforts are fully successful  Ebola will disappear from the human population and return to its animal reservoir  as it has done in other outbreaks in Central Africa where it is relatively common 
But he warned that if control efforts are only partly successful  Ebola viral disease in the human population could become  a permanent feature of life in West Africa  

 Quite honestly if you ask  can we stamp Ebola out of Liberia   I m not sure  In principle we know how to do it  but can we do it on the ground  It remains to be seen  
 Additional reporting by Stephanie Nebehay in Geneval  Kate Kelland in London  David Morgan in Washington  Umaru Fofana in Freetown  Writing by David Lewis  Editing by Daniel Flynn  Larry King ",2014-09-23,Reuters,"https://www.investing.com/news/stock-market-news/u.s.-forecasts-more-than-500,000-ebola-cases-in-west-africa-310499",310499
125156,346671,SRPT,Roche  RHHBY  2019 Sales Solid On Robust Show By New Drugs,opinion,Swiss pharma giant Roche Holding  SIX ROG  AG   OTC RHHBY   reported solid sales growth in the fourth quarter and 2019  propelled by strong performance of new drugs The company also provided an encouraging annual guidance for 2020 Roche s stock has gained 24 6  in the past year compared with the  s growth of 12 1   The company reported sales of CHF 15 4 billion in the fourth quarter of 2019  up 6  from the year ago quarter  Sales for 2019 came in at CHF 61 5 billion  up 8  from the year ago period  Earnings per share came in at CHF 20 16 in 2019  up from CHF 18 14 in 2018 The company reports results under two divisions   Pharmaceuticals and Diagnostics  All growth rates mentioned below are on a year over year basis and at constant exchange rates Sales at the Pharmaceuticals division increased 11   driven by strong growth in multiple sclerosis drug Ocrevus  the new hemophilia drug Hemlibra and oncology drugs Tecentriq and Perjeta  This more than offset the impact of the biosimilar competition for MabThera Rituxan and Herceptin in Europe and Japan and that for MabThera Rituxan  Herceptin and Avastin in the United States Diagnostics division sales climbed 3   primarily on the back of strong immunodiagnostic business Results in Detail    Herceptin sales fell 12  due to biosimilar competition in Europe and Japan  Sales in the United States declined due to the switch to Kadcyla in the adjuvant setting along with the entry of biosimilars in July 2019 Perjeta sales grew 29   owing to increased demand for adjuvant early breast cancer therapy   Kadcyla sales soared 45  due to strong demand in the United States Sales of Avastin  approved for multiple oncology indications  were up 4   However  sales in the United States in the second half were affected by the first biosimilar launch in July 2019 Sales of Rituxan MabThera declined 4  due to the entry of biosimilars in Europe and Japan Sales of Ocrevus  the drug used to treat two forms of multiple sclerosis  surged 57  on continued global growth Immuno oncology drug  Tecentriq  for advanced bladder cancer and advanced lung cancer   recorded 143  year over year growth in sales  driven by the inclusion of new indications   extensive stage small cell lung cancer and triple negative breast cancer Sales of lung cancer drug  Alecensa  surged 38  on solid growth across all regions Performance of the immunology franchise was driven by 8  growth in Actemra RoActemra sales and 1  in Xolair sales  Gazyva Gazyvaro sales jumped 43   Sales of hemophilia A drug  Hemlibra  surged more than 500   fueled by strong uptake in the United States  Japan and Europe Sales of ophthalmology drug  Lucentis  grew 8   Roche has a collaboration agreement with Novartis   NYSE NVS   for this drug Revenues at the Diagnostics division rose 3   owing to 6  growth in Molecular Diagnostics  Centralized and Point of Care Solutions grew on the back of the immunodiagnostics business 2020 OutlookSales are expected to grow in low  to mid single digits  Core earnings per share are estimated to rise broadly in line with sales Pipeline Progress   Roche made encouraging pipeline progress in the fourth quarter  The FDA approved immuno oncology drug Tecentriq in combination with chemotherapy for the initial  first line  treatment of adults with metastatic non squamous non small cell lung cancer  NSCLC  with no EGFR or ALK genomic tumor aberrations The FDA also approved a supplemental New Drug Application  sNDA  for Xofluza  baloxavir marboxil  for the treatment of acute  uncomplicated influenza  or flu  in patients 12 years of age or older The European Commission approved Kadcyla as an adjuvant  after surgery  treatment of HER2 positive early breast cancer The FDA also accepted risdiplam for Priority Review for the treatment of spinal muscular atrophy  SMA  In December  Roche acquired Spark Therapeutics  Inc  The company also signed a licensing agreement with Sarepta Therapeutics  Inc     NASDAQ SRPT    which provided the former with exclusive commercial rights to SRP 9001  the latter s investigational gene therapy for Duchenne muscular dystrophy  DMD   outside the United States  SRP 9001 is currently in clinical development for the same Our TakeRoche s performance in 2019 was impressive as strong growth in Ocrevus  Perjeta  Tecentriq and Hemlibra countered biosimilar competition for Herceptin and MabThera from the likes of Amgen   NASDAQ AMGN   Meanwhile  the company continues to progress with its pipeline  as it looks to restructure the portfolio beyond oncology into MS and hemophilia  among others  The approvals of Polivy and Rozlytrek should further drive sales Roche currently carries a Zacks Rank  2  Buy   You can see Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-2019-sales-solid-on-robust-show-by-new-drugs-200503014,200503014
125157,346672,SRPT,BTIG  New Data Could Propel These 3 Biotech Stocks Higher in 2020,opinion,For those who like patterns  biotech names  growth stories tend to look remarkably similar  These stocks are less reliant on earnings reports and more on a few select markers which can decide what direction they will take in the near term  A favorable outcome from a regulatory committee or promising data from a clinical trial can send the stock soaring  Conversely  rejection or disappointing readouts can send the company s share price tumbling down  While they present possible mercurial upside  these tickers aren t for the faint of heart because although the patterns usually play out  the direction they might take is very hard to predict So  how should investors choose which biotechs to invest in  There are different strategies  of course  but one trusted way is to listen to the experts  Investment bank BTIG is a well known name on the Street  housing several top analysts  The company has identified three companies in the sector that will present new data over the coming months  and BTIG analysts think positive results can propel each of them forward Using the Stock Comparison tool from TipRanks  a company that tracks and measures the performance of analysts  we were able to zero in on their choices and find out why the firm finds them so compelling  Let s get familiar with the data at hand Sarepta Therapeutics  SRPT Let s start off with a good example of the impact regulatory forces can have on a stock  Sarepta Therapeutics made headlines towards the end of 2019  when the FDA approved Vyondys 53  the company s treatment for Duchenne muscular dystrophy  DMD  patients with exon 53 mutations  The approval came as a surprise as only a few months earlier  Sarepta received the dreaded CRL  complete response letter  from the FDA following its original submission  As is de rigueur in the sector  Sarepta stock responded to the announcement by soaring over 30  in a day In addition to the recently approved drug  the genetic disorder focused biotech has a robust pipeline  with gene therapy programs in DMD and LGMD  Limb Girdle Muscular Dystrophy   BTIG s Tim Chiang believes the company is steadily progressing with these key programs The analyst said   We believe SRPT is making progress on the gene therapy manufacturing front  and has achieved yields sufficient to begin study 301  which we think could enroll up to a hundred or more patients   We believe SRPT plans to provide an interim look at data from this study in  15 patients dosed  evaluating expression levels at  3 months post dosing   In LGMD2E  SRPT has dosed two patients in the higher dose cohort  with a third patient to be dosed shortly  We expect a data read out from this high dose arm in early 2Q  Chiang expects that US gene therapy sales in the DMD market will reach a peak in 2024  with the figure landing at roughly  2 billion  There are three companies currently in the race to develop gene therapies for the treatment of DMD  Sarepta  according to the analyst  is leading the way and could be the first to enter the US market with its gene therapy for DMD in the second half of 2021 Chiang added   We think one of the key differences among the 3 micro dystrophin gene therapy programs in the clinic are that both Solid Biosciences  SLDB  Neutral  and Pfizer have studies where ascending dose cohorts are being utilized  In contrast  Sarepta s study incorporates just one dose  2E14 vg kg   So  what does this mean  It means Chiang kept his Buy rating on Sarepta  along with a price target of  190  Should the target be met  investors stand to see a handsome 64  gain over the next year   To watch Chiang s track record  click here The Street  too  is bullish on the DMD fighter  A Strong Buy consensus rating breaks down into 18 Buys and a single Hold  The average price target comes in at  204 33 and indicates potential upside of 76    See Sarepta stock analysis on TipRanks IMV Inc   IMV IMV s market performance in 2019 was a disappointing affair  The stock lost 39  of its value along the way  By contrast  2020 s performance so far has been the exact opposite   and some  The stock is up by 58  year to date  According to BTIG s Thomas Shrader  there is more to come  too The cancer fighter s lead candidate is DPX Survivac  which targets the surviving TAA  tumor associated antigen  that is overexpressed in more than 20 different types of cancers  Clinical data so far has been promising  with long disease free intervals in the ovarian cancer  OC  adjuvant setting and compelling treatment response rates in both OC and DLBCL  diffuse large B cell lymphoma   Important DPX Survivac data is expected this quarter which Shrader notes  could greatly de risk the current programs and potentially demonstrate the utility of the low COGS DPX platform to deliver many other TAAs and neoantigens  The 5 star analyst added   The drug has shown robust and prolonged CD8 TCell responses in the adjuvant setting and a Phase 1b 2 trial has shown a 100  DCR and 60  ORR in the subgroup of patients with non bulky disease  tumor burden   5 cm  most of which are platinum resistant  few treatment options   The company expects to provide topline Phase 2 monotherapy data in mid February 2020 that we expect to be an important catalyst for the story  Ahead of this upcoming data readout  Shrader is siding with the bulls  The analyst initiated coverage of IMV with a Buy rating along with an  8 price target  The implication  Further gains in the shape of 75  over the next 12 months   To watch Shrader s track record  click here The Street agrees  A total of 6 Buys add up to a unanimous Strong Buy consensus rating  With an average price target of  9 31  the analysts see potential upside of 104  for IMV over the coming 12 months   See IMV stock analysis on TipRanks Cue Biopharma Inc   CUE A fellow company taking the fight to cancer is Cue Biopharma  In 2019  Cue s exceptional performance beat the market considerably  The stock added an astounding 238  to its share price throughout the year  Following such a surge  though  is this the right time to get in on this high flying biotech Yes  it is  according to BTIG s Thomas Shrader  In fact  the 5 star analyst just recently initiated coverage of Cue with an emphatic Buy rating  The thumbs up comes with a price target of  26  indicating Shrader believes an additional 71  will be added to Cue s share price over the next 12 months So  what s all the fuss about  then  A cure for cancer is one of modern medicine s most coveted prizes  Cue is working on an immunotherapy platform which will assist immune systems by recognizing solid tumor cells and repeatedly attacking them until they stop working The company s lead candidate is CUE 101  which was developed for patients with head and neck cancer driven by human papillomavirus  HPV   Topline results from a Phase 1 trial are expected later this year  and so far  results have been promising Shrader said   Data to date is preclinical but the lead programs termed CUE 101 has exploited well defined subunits and demonstrated tumor antigen specific T cells responses without the accompanying systemic immune toxicities that characterize many competing approaches  Preclinical data confirm both robust T Cell responses and an attractive safety profile setting the stage for clinical studies  These studies have stated  first dosing September 2019  and  based on the preclinical safety profile  will begin with doses that could be efficacious   Clinical data validating the overall approach are expected around 3Q20 and  if promising  a significant pipeline in additional applications should be de risked  Currently  the rest of the Street remains rather quiet on Cue  with only one other analyst chipping in with a take on the biotech s prospects  The additional Buy recommendation means Cue receives a Moderate Buy consensus rating  The average price target comes in at  24 and implies upside potential of 58    See Cue Biopharma stock analysis on TipRanks ,2020-02-03,TipRanks,https://invst.ly/pqa3l,200503861
125174,346689,SRPT,Solid Biosciences Surges On DMD Gene Therapy Study Amendments,opinion,"Shares of Solid Biosciences Inc    NASDAQ SLDB   have gained 70 4  since Aug 14 as investors cheered the amendments made to a gene therapy study protocol evaluating its lead candidate  SGT 001 as a potential treatment for Duchenne muscular dystrophy   DMD    The company announced the update in its second quarter earnings release The company is evaluating SGT 001  a novel adeno associated viral  AAV  vector mediated gene therapy  in a phase I II study   IGNITE DMD   for treating DMD by increasing level of dystrophin protein in patients  Per the amended protocol  the company has limited new patient selection up to a weight of 25kg  The company has also removed the matched patient control arm in the second cohort of the study  These changes are expected to expedite the data readout from the IGNITE DMD study  Faster progress of SGT 001 is necessary for growth of Solid Biosciences as several companies are developing gene therapies for treating DMD with Sarepta Therapeutics   NASDAQ SRPT   leading the space The company also stated that it has initiated dosing of the second patient in the higher dose  2E14 vg kg  cohort in the IGNITE DMD study  It anticipates to announce updated data from the study later this year Meanwhile  Solid Biosciences  shares have declined 67 1  so far this year compared with the  s decrease of 2 5  The development of SGT 001 for DMD has faced multiple hurdles so far this year  In February  the company announced preliminary data from IGNITE DMD study  which showed that lower dose  5E13 vg kg  of SGT 001 was unable to achieve expected level of dystrophin protein in patients  Based on this result  the company expedited dose escalation activities to evaluate the higher dose in patients  In March 2018  one patient receiving the lower dose of SGT 001 was hospitalized following an adverse event  which led the FDA to put the study on clinical hold  Investors remain skeptical of the dose escalation as higher dose of the candidate can result in more severe adverse events  However  the company has not reported any such adverse event from the higher as well the lower dose cohort since June 2018  The clinical hold on the study was removed in June 2018 Meanwhile  Solid Biosciences also announced in its earnings release that it has raised  60 million from a private placement  The company expects its cash resources as of Jun 30  2019 along with the raised fund to be able to support the company s operations into the fourth quarter of 2020 from the previously expected timeline of first quarter of 2020 The company is developing SGT 001 in several early stage studies for indications other than DMD  Please note that the gene therapy space is getting crowded with several pharma biotech companies developing their pipeline  targeting multiple indications  Apart from Solid Biosciences and Sarepta  companies developing gene therapy for DMD include Pfizer   NYSE PFE    Audentes Therapeutics   NASDAQ BOLD    Wave Life Sciences and others Sarepta Therapeutics  Inc  Price
    Zacks RankSolid Biosciences currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-08-19,Zacks Investment Research,https://www.investing.com/analysis/solid-biosciences-surges-on-dmd-gene-therapy-study-amendments-200456341,200456341
125175,346690,SRPT,Sarepta Stock Falls As FDA Denies Approval To Golodirsen,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   announced that the FDA has rejected the application for the approval of its exon 53 skipping candidate  golodirsen  The company had filed a new drug application   NDA   in December last year seeking accelerated approval for the candidate as a potential treatment for Duchenne muscular dystrophy   DMD   The FDA issued a complete response letter   CRL   against the NDA for golodirsen  citing two concerns   the risk of infections related to intravenous infusion ports and renal toxicity seen in pre clinical models Sarepta stated that renal toxicity in pre clinical models was observed in doses ten times the dose used in clinical studies  The renal toxicity issue raised in the CRL were not observed in the clinical study   Study 4053 101   which formed the basis for golodirsen NDA Shares of the company fell more than 13  in after hours market on Aug 19  following the announcement  However  the stock has gained 10 3  so far this year against the  s decrease of 2  as demand for its sole marketed DMD drug  Exondys 51  remains strong  The CRL comes as a surprise for investors and the company as no issues related to golodirsen NDA were raised by the FDA during the entire review period that could have led to non approval of the candidate  In February  the FDA had granted priority review to the NDA  Moreover  on its second quarter earnings release  the company announced that the FDA has conditionally approved the trade name of Vyondys 53 for golodirsen  Sarepta was ready to launch the drug immediately following the potential approval The company has one marketed drug   Exondys51   for treating exon 51 skipping DMD  The drug has the potential to address up to 13  of the total DMD population  The FDA s decision to reject golodirsen NDA is likely to hit the company s near term growth as the approval would have increased the eligible DMD patient population by 8  Sarepta will work with the FDA to address the issues raised in the CRL and find a path to get the candidate approved as early as possible  The company is planning to request a meeting with the FDA soon  Meanwhile  the company is evaluating the safety profile of golodirsen in an ongoing phase III study   ESSENCE   along with another DMD candidate  casimersen  The company is also evaluating golodirsen and casimersen in a phase III open label extension study  which is currently enrolling patients Casimersen is an exon 45 skipping DMD candidate and the company is likely to file an NDA seeking approval for the candidate by the year end Apart from golodirsen and casimersen  Sarepta is also developing next generation PPMO platform candidate  SRP 5051  in DMD patients amenable to exon 51 skipping and gene therapies targeting DMD and other muscular dystrophies as well as central nervous system disorders Meanwhile  there are several other companies developing gene therapies for treating DMD including Solid Biosciences   NASDAQ SLDB    Audentes Therapeutics   NASDAQ BOLD   and Pfizer   NYSE PFE   Sarepta Therapeutics  Inc  Price
    Zacks RankSarepta currently carries a Zacks Rank  3  Hold   You can see  Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ",2019-08-19,Zacks Investment Research,https://www.investing.com/analysis/sarepta-stock-falls-as-fda-denies-approval-to-golodirsen-200456749,200456749
125176,346691,SRPT,Company News For Aug 21  2019,opinion,Kohl s Corporation s   NYSE KSS   shares fell 6 9  after the company reported second quarter fiscal 2019 revenues of  4 430 million  lower than the Zacks Consensus Estimate of  4 455 millionMedtronic plc s   NYSE MDT   shares gained 2 6  after the company reported first quarter fiscal 2020 earnings per share of  1 26  surpassing the Zacks Consensus Estimate of  1 18Shares of Baidu  Inc    NASDAQ BIDU   rallied 4 3  after the company reported second quarter 2019 earnings per share of  1 47  higher than the Zacks Consensus Estimate of  0 94Shares of Sarepta Therapeutics  Inc    NASDAQ SRPT   fell 15 2  afterthe company announced that U S  Food and Drug Administration  FDA  did not approve its newest treatment for Duchenne muscular dystrophy  DMD ,2019-08-20,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-aug-21-2019-200457190,200457190
125177,346692,SRPT,Company News For Oct 7  2019,opinion,Shares of Costco Wholesale Corporation   NASDAQ COST   gained 0 9   after the company reported fiscal fourth quarter 2019 earnings per share of  2 69  surpassing the Zacks Consensus Estimate of  2 54 a shareShares of BP  LON BP  p l c    NYSE BP   surged 1 6  after the company named its upstream operations chief Bernard Looney as the next CEOHP Inc  s   NYSE HPQ   shares tanked 9 6  after the company announced that it was planning to cut its workforce by 16 Shares of Sarepta Therapeutics  Inc    NASDAQ SRPT   gained 8 5  after the company reported positive results from its SRP 9003 gene therapy trial for limb girdle muscular dystrophy,2019-10-07,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-oct-7-2019-200471144,200471144
125195,346710,SRPT,What s In The Cards For Sarepta  SRPT  This Earnings Season ,opinion,"Investors are likely to focus on the progress of Sarepta Therapeutics  Inc  s   NASDAQ SRPT   muscular dystrophy pipeline when it reports first quarter 2019 results The company s earnings beat estimates in two of the past four quarters and missed the same twice with the average being negative 18 12  Shares of Sarepta have increased 11  so far this year compared with the  s rise of 5  In the last reported quarter  Sarepta reported a negative earnings surprise of 28 79  Let s see how things are shaping up for this announcement Factors at PlaySarepta s sole marketed drug  Exondys 51  is likely to drive its revenues higher in the first quarter of 2019  The drug has shown a strong uptrend since its launch in 2016 and is the only approved treatment for Duchenne muscular dystrophy   DMD   in the United States Apart from Exondys 51  the company is developing multiple pipeline candidates  which include exon skipping and gene therapies  for treating DMD  The company is likely to provide update on the progress of these candidates in clinical studies The most advanced pipeline candidate   golodirsen  an exon skipping candidate   is under review in the United States  In February  the new drug application   NDA   seeking approval for golodirsen was granted priority review  The PDUFA date is Aug 19  2019 In March  the company announced positive interim data from a late stage study evaluating another exon skipping candidate  casimersen  Data showed that treatment with casimersen led to statistically significant mean increase of dystrophin protein production  which leads to improvement in muscle dystrophy  compared to baseline and placebo Gene TherapySarepta is also focused on developing gene therapies for the treatment of central nervous system   CNS   disorders as well as DMD The company has initiated a phase II III study to evaluate gene therapy  LYS SAF302  as a treatment for mucopolysaccharidosis Type IIIA  a progressive CNS disorder  along with a partner during the quarter  Moreover  Sarepta acquired Myonexus Therapeutics in February  which added a gene therapy candidate  MYO 101  for treating Limb girdle muscular dystrophy    LGMD   to the pipeline  The candidate has shown robust protein expression in muscles in an early stage clinical study We expect Sarepta to provide further details on its gene therapy pipeline on its first quarter earnings call With several clinical studies underway  we expect operating expenses to increase in the soon to be reported quarter  Moreover  commercial initiatives to support golodirsen potential launch will also drive expenses higher Earnings WhispersOur proven model does not conclusively show that Sarepta is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below Earnings ESP  Sarepta s Earnings ESP is 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of  2 05  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Although Sarepta s Zacks Rank  3 increases the predictive power of ESP  its 0 00  ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into an earnings announcement  especially when the company is seeing negative estimate revisions Sarepta Therapeutics  Inc  Price and Consensus
    Stocks That Warrant a LookHere are some biotech stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  28 57  and a Zacks Rank  3  The company is scheduled to release first quarter results on Apr 30  You can see  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  1 54  and a Zacks Rank  2  The company is scheduled to release first quarter results on May 2 Horizon Pharma   NASDAQ HZNP   has an Earnings ESP of  25  and a Zacks Rank  3  The company is scheduled to release first quarter results on May 8 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-sarepta-srpt-this-earnings-season-200412245,200412245
125197,346712,SRPT,Pfizer s DMD Gene Therapy Shows Severe Side Effects In Study,opinion,Pfizer  Inc    NYSE PFE   announced promising data from an early stage study on its investigational gene therapy for the treatment of Duchenne muscular dystrophy  DMD   a rare muscular degenerative disease  However  further dosing in the study has been stopped as serious side effects were observed in two participants in the study The phase Ib study is an open label  non randomized  ascending dose assessment  to be conducted on approximately 12 boys with DMD  The study is designed to evaluate the safety and tolerability of PF 06939926 and assess muscle strength  quality and function in the given patient population In the phase Ib study  two doses of PF 06939926 were tested in six boys with DMD aged 6 to 12 years  Preliminary safety data from the study showed that one of the six boys was hospitalized for two days for severe nausea and vomiting  Moreover  one of the boys also developed a severe immune response  which led to renal complications  Pfizer said that no other participants will be dosed until specific additional safety monitoring obtains all appropriate approvals The data also showed that two months after being administered one time intravenous dose of PF 06939926  mini dystrophin expression levels ranged from 10  to 60  of normal  The data was promising enough for Pfizer to announce plans to begin a phase III study in the first half of 2020 Pfizer s shares have declined 0 8  this year so far against an increase of 2 2  for the    Duchenne muscular dystrophy is a rare genetic disease and a severe form of muscular dystrophy  primarily affecting males  It progressively weakens and degenerates skeletal and heart muscles  DMD is caused by the absence of a particular gene  dystrophin  which the body uses to keep the muscle cells intact  Sarepta Therapeutics  Inc  s   NASDAQ SRPT   Exondys 51 and PTC Therapeutics  Inc  s   NASDAQ PTCT   Emflaza are among the approved treatments of DMD in the United States  However  the focus for DMD treatment is currently shifting to development of gene therapies  Gene therapies deliver a functional copy of the dystrophin to muscle cells to restore its productionIn response to the safety concerns observed in Pfizer s study  shares of Sarepta rose more than 17   Sarepta is also conducting studies to evaluate gene therapies for DMD  Solid Biosciences Inc    NASDAQ SLDB   also has an early stage gene therapy candidate  SGT 001  which is being developed for DMD  Solid Biosciences  shares were up around 14  on Friday Pfizer currently carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-30,Zacks Investment Research,https://www.investing.com/analysis/pfizers-dmd-gene-therapy-shows-severe-side-effects-in-study-200436117,200436117
125198,346713,SRPT,Sarepta Up As Pfizer s DMD Gene Therapy Faces Safety Issues,opinion,"Shares of Sarepta Therapeutics  Inc    NASDAQ SRPT   increased 17 1  on Jun 28 after Pfizer   NYSE PFE   announced initial data from its phase Ib study evaluating gene therapy candidate  PF 06939926  as a treatment for Duchenne muscular dystrophy   DMD    Serious side effects were observed in two participants in the study Two patients dosed with PF 06939926 were hospitalized  one for severe nausea and vomiting and the other for a severe immune response  which resulted in renal complications  Pfizer has stopped further dosing in the study until specific additional safety monitoring obtains all appropriate approvals  Moreover  improvement in dystrophin levels in patients seemed inferior to Sarepta s gene therapy candidate Sarepta is evaluating its micro Dystrophin gene therapy candidate  SRP 9001  in early  to mid stage studies  Preliminary data from the studies showed that treatment with SRP 9001 had no adverse effects on patients  A mean of 81 2  of muscle fibers were dystrophin positive after nine months of dosing based on Western blot method  Pfizer s PF 06939926 achieved a mean of 69  dystrophin positive fibers for the higher dose  3E14 vg kg  after one year of treatment  based on Pfizer s proprietary measurement technique Although gene therapies of both the companies are in early stage of development  preliminary data suggests better prospects for Sarepta s candidate  Sarepta also has better knowledge and more experience of the DMD disease due to its string of therapies  We remind investors that Pfizer  clinical development of its DMD candidate  domagrozumab  last year due to its failure in meeting primary endpoints in clinical studies DMD is a genetic disorder caused by a mutation that prevents the body from producing dystrophin  a protein that muscles need to function properly Shares of Solid Biosciences Inc    NASDAQ SLDB    another company developing gene therapy for treating DMD  also increased 13 9  last Friday following Pfizer s setback Sarepta s shares have rallied 39 2  so far this year compared with the  s increase of 5 3  Sarepta holds a strong position in the DMD segment with its sole marketed drug  Exondys 51 approved for  treating DMD patients with certain mutation in their gene  The drug generated sales of  87 million in the first quarter of 2019  up almost 35  year over year and   sequentially The company s another DMD candidate  golodirsen  is  in the United States  A decision in expected by the end of August  It also has a late stage DMD candidate  casimersen  In March  Sarepta announced  from the phase III study evaluating casimersen  It showed that treatment with the candidate led to statistically significant mean increase of dystrophin protein production compared to baseline and placebo with 100  response rate  A new drug application seeking approval for casimersen is expected to be filed shortly The company expects to double the eligible DMD patient population for its marketed products in 2020 compared to 2018 on potential approval of golodirsen and casimersen Other companies developing therapies targeting DMD include Wave Life Sciences   NASDAQ WVE   and PTC Therapeutics Sarepta Therapeutics  Inc  Price
    Zacks RankSarepta currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-06-30,Zacks Investment Research,https://www.investing.com/analysis/sarepta-up-as-pfizers-dmd-gene-therapy-faces-safety-issues-200436100,200436100
125200,346715,SRPT,Sarepta Stock Up Almost 40  This Year So Far  Here s Why,opinion,"Shares of Sarepta Therapeutics  Inc    NASDAQ SRPT   have displayed a solid uptrend so far this year  The biotech company s stock has rallied 38 1  compared with 3 8  increase of the  in the said period  The company has only one marketed product in its portfolio  Exondys 51  which received accelerated approval in September 2016  The drug is approved for treating patients with Duchenne muscular dystrophy   DMD    a rare genetic disorder affecting children who have confirmed mutation of the DMD gene susceptible to exon 51 skipping  The company is also developing other pipeline candidates including gene therapies for treating DMD The company has progressed well with the commercialization of Exondys 51  development of its lead pipeline candidate and collaboration for gene therapies in 2019 so far Exondys 51 s Impressive PerformanceThe drug generated sales of  87 million in the first quarter of 2019  an increase of 34 7  year over year on the back of strong demand trends  The drug has also grown sequentially over the past few quarters  Sales of the drug in 2018 were  301 million  The Zacks Consensus Estimate for second quarter and full year sales stands at  91 16 million and  390 million  respectively  representing significant growth The launch of a Managed Access Program in Europe and North America last year is also favorably impacting sales as the drug is now available to a larger patient population  The company remains on track with its post marketing phase III PROMOVI study evaluating Exondys 51  Data is expected in 2019 and will form the basis for continued approval of the drug Moreover  settlement of a global patent litigation related to exon skipping technology used in DMD therapies with BioMarin Pharmaceutical Inc    NASDAQ BMRN   in mid 2017 removed a major overhang for Sarepta  Per the settlement terms  BioMarin has granted Sarepta global exclusive rights to its DMD patent estate for Exondys 51 and all future exon skipping products Exon Skipping Pipeline ProgressSarepta is focused on building its DMD pipeline beyond Exondys 51 by developing other exon skipping treatments  In fact  the company has about eight exon skipping candidates in its pipeline  including golodirsen and casimersen  which  if approved  can treat75 80  of the DMD population Sarepta s lead candidate  golodirsen  has shown improved outcome in patients in a mid stage clinical study compared to results achieved by Exondys 51  The candidate has demonstrated 100  response rate with 10 7 times increase in mean dystrophin protein production from baseline  whereas Exondys 51 achieved nearly three times increase in DMD patients  A new drug application   NDA   is under review in the United States  The FDA will provide its decision related to the approval of the candidate next month Sarepta remains on track to submit a NDA for casimersen shortly  The company is developing casimersen in a phase III study  Interim data from the study has shown that casimersen has achieved a 100  response rate with statistically significant mean increase of dystrophin protein production compared to placebo Gene TherapiesSarepta is also developing gene therapies for treating DMD and other nervous disorders  The gene therapies have shown promising results so far in treating DMD patients by restoring dystrophin production in muscles throughout the body by delivering microdystrophin via adeno associated virus  Sarepta is evaluating its most advanced gene therapy  SRP 9001  in a phase I II study in DMD patients It is collaborating with other companies and academic institutions to boost its pipeline or manufacturing capacity for gene therapy  The company s gene therapy portfolio currently has multiple programs in pre clinical or early stages of development targeting several muscular dystrophy disorder Sarepta Therapeutics  Inc  Price
    Zacks Rank   Stocks to ConsiderSarepta currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the pharma sector include Aytu Bioscience  Inc    NASDAQ AYTU   and Axovant Sciences Ltd    NASDAQ AXGT    Both the stocks carry a Zacks Rank  2  Buy   You can see  Aytu s loss estimates have narrowed from  2 39 to  2 20 for 2019 and from  1 15 to 80 cents for 2020 over the past 60 days  The stock has rallied 133 4  so far this year Axovant s loss estimates have narrowed from  7 00 to  5 71 for 2019 and from  6 48 to  3 59 for 2020 over the past 60 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-07,Zacks Investment Research,https://www.investing.com/analysis/sarepta-stock-up-almost-40-this-year-so-far-heres-why-200437653,200437653
125201,346716,SRPT,Sarepta Therapeutics Sees Hammer Chart Pattern  Time To Buy ,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   has been struggling lately  but the selling pressure may be coming to an end soon  That is because SRPT recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom What is a Hammer Chart Pattern  A hammer chart pattern is a popular technical indicator that is used in candlestick charting  The hammer appears when a stock tumbles during the day  but then finds strength at some point in the session to close near or above its opening price  This forms a candlestick that resembles a hammer  and it can suggest that the market has found a low point in the stock  and that better days are ahead Other FactorsPlus  earnings estimates have been rising for this company  even despite the sluggish trading lately  In just the past 60 days alone 2 estimates have gone higher  compared to none lower  while the consensus estimate has also moved in the right direction Estimates have actually risen so much that the stock now has a Zacks Rank  2  Buy  suggesting this relatively unloved stock could be due for a breakout soon  This will be especially true if SRPT stock can build momentum from here and find a way to continue higher of off this encouraging trading development  You can see 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-09,Zacks Investment Research,https://www.investing.com/analysis/sarepta-therapeutics-sees-hammer-chart-pattern-time-to-buy-200453514,200453514
125218,346733,SRPT,Sarepta Stock More Than Doubles This Year So Far  Here s Why,opinion,"Shares of Sarepta Therapeutics  Inc    NASDAQ SRPT   have displayed a solid uptrend so far this year  The biotech company s stock has surged 110 3  against the 20 3  decline of the industry in this period The company has only one marketed product in its portfolio  Exondys 51  which received accelerated approval in September 2016  The drug is approved for treating patients with Duchenne muscular dystrophy   DMD    a rare genetic disorder affecting children who have confirmed mutation of the DMD gene susceptible to exon 51 skipping  The company is also developing other pipeline candidates including gene therapies for treating DMD The company has progressed well with the commercialization of Exondys 51  development of its lead pipeline candidate and collaboration for gene therapies in 2018 so far Exondys 51 s Impressive PerformanceThe drug generated sales of  216 6 million in the first nine months of 2018  a significant increase of 122 6  year over year on the back of strong demand trends  The drugs has also grown sequentially so far in 2018  Sales of the drug in 2017 were  154 6 million  Based on sales trends witnessed so far in 2018  Sarepta expects Exondys 51 sales to be almost  300 million for the year The launch of a Managed Access Program in Europe and North America last year is also favorably impacting sales as the drug is now available to a larger patient population  The company remains on track with its phase III PROMOVI study evaluating Exondys 51  Data is expected in 2019 and will form the basis for continued approval of the drug Moreover  settlement of a global patent litigation related to exon skipping technology used in DMD therapies with BioMarin Pharmaceutical Inc    NASDAQ BMRN   in mid 2017 removed a major overhang for Sarepta  Per the settlement terms  BioMarin has granted Sarepta global exclusive rights to its DMD patent estate for Exondys 51 and all future exon skipping products 
Exon Skipping Pipeline ProgressSarepta is focused on building its DMD pipeline beyond Exondys 51 by developing other exon skipping treatments  In fact  the company has about eight exon skipping candidates in its pipeline  including golodirsen and casimersen  which are expected to treat 75 80  of the DMD population Sarepta s lead candidate  golodirsen  showed better improvement in patients in a mid stage clinical study compared to results achieved by Exondys 51  The candidate has demonstrated 100  response rate with 10 7 times increase in mean dystrophin protein production from baseline  whereas Exondys 51 had achieved nearly three times  in DMD patients  A phase III study is currently enrolling patients Sarepta remains on track to submit a new drug application for this DMD candidate by the end of this year  The company is developing casimersen in a phase II study Gene TherapiesSarepta is also developing gene therapies for treating DMD and other nervous disorders  The gene therapies have shown promising results so far in treating DMD patients by restoring dystrophin production in muscles throughout the body by delivering microdystrophin via adeno associated virus  Sarepta is evaluating it most advanced gene therapy  AAVrh74 MHCK7 micro Dystrophin  in a phase I II study in DMD patients Sarepta is collaborating with other companies and academic institutions to boost its pipeline or manufacturing capacity for gene therapy  The company s gene therapy portfolio currently has 14 programs in several early stages of development Sarepta Therapeutics  Inc  Price

   Zacks Rank   Stocks to ConsiderSarepta currently carries a Zacks Rank  4  Sell  A couple of better ranked stocks in the pharma sector include Exelixis  Inc    NASDAQ EXEL   and Corvus Pharmaceuticals  Inc    NASDAQ CRVS    Both the stocks carry a Zacks Rank  2  Buy   You can see  Exelixis  earnings estimates have moved up from  1 03 to  1 30 for 2018 and from  1 09 to  1 25 for 2019 over the past 30 days  The company delivered positive earnings surprise in all the trailing four quarters with the average beat being 83 43  Corvus Pharmaceuticals  loss estimates have narrowed from  1 98 to  1 78 for 2018 and from  1 79 to  1 59 for 2019 over the past 30 days  The company came up with a positive earnings surprise in all the four trailing quarters with the average beat being 20 41  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/sarepta-stock-more-than-doubles-this-year-so-far-heres-why-200361961,200361961
125219,346734,SRPT,4 Biotechs That Are Potential Buyouts Post Celgene Deal  ,opinion,"The new year began with a bang for the pharmaceuticals biotech industry  Bristol Myers Squibb Company   NYSE BMY    one of the largest pharma giants  announced that it will acquire the leading biotech company Celgene   NASDAQ CELG   for a whopping  74 billion in what could be one of the largest acquisitions in recent times   Following suit  another large cap pharma company Eli Lilly   NYSE LLY   is all set to acquire Loxo Oncology for  8 0 billion to broaden its oncology portfolio   Meanwhile  Japan based Takeda Pharmaceutical completed its buyout of Irish company Shire plc The biotech sector took a beating in 2018 which makes the valuations more attractive  Evidently  the spotlight is back on mergers   acquisitions in the healthcare space  While it is true that last year too started on a cheerful note with expectations of a ramp up in M A activity  propelled by the implementation of the new tax law  thereby leaving more cash in the hands of companies  the deals however  dried up after the initial euphoria Key acquisitions in 2018 included Bayer s takeover of Monsanto  NYSE MON  for  63 billion  Novartis snapping up AveXis  Inc  and Endocyte plus Sanofi  PA SASY  grabbing Ablynx and Bioverativ  Celgene s buyout of Juno Therapeutics  Alexion s acquisition of Sweden based Wilson Therapeutics and Syntimmune et al  GlaxoSmithKline plc has also announced an agreement to acquire commercial stage biopharmaceutical company Tesaro  Inc with a focus on oncology The landscape in the drug biotech sector is rapidly changing  A slowdown in mature products due to increasing competition and rise of biosimilars has forced most pharma bigwigs to eye lucrative acquisitions to bolster their pipeline  Small tuck in acquisitions are quite frequent too  While amalgamation of complementary product portfolios and overlapping pipelines are a key reason for mega deals  smaller biotechs are generally bought owing to innovative pipelines Cost synergies in research and development  R D  plus sales and marketing are also added benefits  The larger players with huge wads of cash are under a lot of pressure to make strategic acquisitions and diversify their revenue base  Moreover  it makes sense for these companies to buy innovative small mid cap biotech companies and boost their pipeline rather than developing a drug from scratch and invest both several years and millions in it However  these acquisitions do not always shape up as planned and come with their respective set of risks  Companies like Bausch Health among others kept acquiring smaller and mid size players irrespective of the burden it imposed on the balance sheet  which eventually resulted in shambles  While the Celgene acquisition does look positive prima facie for Bristol Myers  it will induce a huge debt load as well for the latter  In addition  any acquisition of this magnitude comes with its own set of integration perils  Moreover  some of Celgene s shareholders also believe that the company has better prospects on a standalone basis and might not give a nod to the acquisition 
Nevertheless  walking the lines of Bristol Myers and Eli Lilly  we expect a surge in M A activity during 2019 in the overall drug biotech sector as the companies look to use huge cash trunks and combat rivalry woes  Oncology and Immuno oncology are a key area of focus  Quite a few biotechs with promising oncology treatments are on the radar as companies like Pfizer  NYSE PFE  and Roche gear up to strengthen their portfolio Here  we discuss a few large mid cap biotech companies  which are likely acquisition targets with rewarding product portfolios and a deep pipeline of candidates with innovative treatments for diseases like NASH with an unmet need promising huge potential Alexion Pharmaceuticals  Inc    NASDAQ ALXN  Alexion primarily focuses on developing and commercializing drugs for the treatment of patients with ultra rare disorders  The market potential of such drugs is significant with less competitive pressure  Alexion s blockbuster drug  Soliris  approved for the treatment of two severe and ultra rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system   paroxysmal nocturnal hemoglobinuria  PNH    and atypical hemolytic uremic syndrome  aHUS    continues to perform well  The FDA approval of the generalized myasthenia gravis indication has boosted the drug prospects further Alexion received a substantial boost from the recent FDA approval of its long acting C5 complement inhibitor  Ultomiris  for treating adult patients with PNH  to be administered every eight weeks  The FDA approval comes well ahead of its action date set for Feb 18  2019  The nod will strengthen Alexion s PNH franchise With a market capitalization of  24 1 billion  this company is a hot target for the big shots looking to build up a place in the rare diseases market Incyte Corporation   NASDAQ INCY  Wilmington  DE based Incyte Corporation is another company on the horizon with a first in class JAK1 JAK2 inhibitor  Jakafi  approved for the treatment of patients with polycythemia vera  PV   Its label has been updated several times since the approval and the prospects look good  The company is keen to expand the drug s label further  which should boost sales  Its second JAK1 and JAK2 inhibitor  Olumiant  baricitinib  JAK1 JAK2 inhibitor   was developed in collaboration with Eli Lilly  The drug is approved for rheumatoid arthritis  RA  both in the United States and Europe  Moreover  the company has several candidates in early to mid stage development in its pipeline including both targeted and immune therapies that are currently developed in oncology and outside it With a market capitalization of  15 8 billion  Incyte has high chances of being acquired by one of its co developers like Novartis or Eli Lilly or another behemoth from the same space like Gilead  NASDAQ GILD  Regeneron Pharmaceuticals  Inc    NASDAQ REGN  Tarrytown  NY based Regeneron is one of the leading biotech companies with a very strong and varied portfolio  Its pipeline boasts marketed drugs like Eylea  for several eye diseases   Dupixent  atopic dermatitis  and Praluent  heterozygous familial hypercholesterolemia  among others  Regeneron s key growth driver  Eylea  consistently performs well and its label expansion into additional indications has further boosted growth for the company  Dupixent too has driven overall performance  The company is working to expand Dupixent s label further for several other indications  This should widen the company s revenue stream and reduce dependence on Eylea  Last September  the FDA approved its immuno oncology therapy  Libtayo  for treating patients with metastatic or locally advanced CSCC  The company has a deep and diverse pipeline With a market cap of  42 9 billion  this top biotech has surely grabbed eyeballs and a bidding war can be expected in the near term Sarepta Therapeutics  Inc    NASDAQ SRPT  A relatively smaller biotech company as compared to the ones mentioned above with a market cap of  7 7 billion  Sarepta Therapeutics has arrested attention  mainly because of the prospects of it sole marketed drug Exondys 51  which has witnessed impressive growth  Exondys 51 is the first approved disease modifying therapy for Duchenne muscular dystrophy  DMD  in the United States  The company primarily focuses on the discovery and development of RNA based therapeutics targeting rare and infectious diseases  Sarepta is looking to build its DMD pipeline beyond Exondys 51 by developing other exon skipping treatments and the company has about eight exon skipping candidates in its pipeline A few setbacks notwithstanding  the company s follow on exon skipping and gene therapy pipeline candidates represent the most comprehensive approach to treat DMD ConclusionGiven the money spinning valuations  we expect a lot of M A activity in the biotech space in 2019 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/4-biotechs-that-are-potential-buyouts-post-celgene-deal-200373592,200373592
125222,346737,SRPT,Sarepta s NDA For DMD Drug Golodirsen Gets Priority Review,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   announced that the FDA has accepted its new drug application   NDA   seeking accelerated approval for its second Duchenne Muscular Dystrophy   DMD   drug  golodirsen  The regulatory authority also granted priority review to the NDA with a decision expected by Aug 19  2019 The company had completed the submission of a rolling NDA in December last year  The candidate  golodirsen  also enjoys Orphan Drug designation for treating DMD Sarepta already has a marketed DMD drug  Exondys 51  which performed well since launch with sales set to reach  300 million in 2018  The approval of golodirsen will expand the patient population by 8  Sarepta s shares have risen 4 1  in the past six months against the  s decline of 12 9  in the same time frame The NDA was submitted based on data from the phase I II 4053 101 study  which demonstrated that treatment with golodirsen achieved 100  response rate with 10 7 times increase in mean dystrophin protein  muscle protein  from baseline  The increase in muscle protein was also better compared to three times for Exondys 51 Meanwhile  the ongoing phase III study  4045 301  ESSENCE  on golodirsen will serve as the post marketing confirmatory study Sarepta has a strong pipeline of exon skipping and gene therapy candidates  which are in various stages of development as a treatment for DMD  In fact  the company has about eight exon skipping candidates in its pipeline  including golodirsen  Casimersen  the second most advanced candidate  is being evaluated in a phase I II Study 4045 101 for treating DMD patients aged 7 to 21 years  The company expects that successful development of its exon skipping candidate will help it treat 75 80  of the DMD population The company is also developing gene therapies for DMD as well as central nervous system diseases   CNS    A phase I II study is evaluating its micro Dystrophin gene therapy  which has demonstrated potential as a treatment for patients with DMD  The company has also collaborated with partners to develop gene therapies In a separate press release  Sarepta and its partner  Lysogene  announced the initiation of a phase II III study to evaluate gene therapy  LYS SAF302  as a treatment for mucopolysaccharidosis Type IIIA  a progressive CNS disorder Currently  Sarepta is growing on the strong uptake of Exondys 51  However  competition in the DMD market is low as there are very few therapies available   Potential approval of golodirsen will also boost Sarepta s prospects as it will expand the eligible patient population  However  competition is expected to intensify  Successful development of gene therapy candidates by Pfizer   NYSE PFE    Solid Biosciences   NASDAQ SLDB   and Scholar Rock   NASDAQ SRRK   may impact Sarepta s top line adversely Sarepta Therapeutics  Inc  Price
    Zacks RankSarepta currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/sareptas-nda-for-dmd-drug-golodirsen-gets-priority-review-200388725,200388725
125223,346738,SRPT,Sarepta  SRPT  Jumps  Stock Rises 8 3 ,opinion,Sarepta Therapeutics  Inc    NASDAQ SRPT   was a big mover last session  as the company saw its shares rise more than 8  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This continues the recent uptrend for the company as the stock is now up 23 5  in the past one month time frame The move came after the company reported solid fourth quarter 2018 results The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Sarepta currently has a Zacks Rank  3  Hold  while its is 0 00   Investors interested in the Medical   Biomedical and Genetics industry may consider Fortress Biotech  Inc    NASDAQ FBIO    which has a Zacks Rank  1  Strong Buy   You can see Is SRPT going up  Or down  Predict to see what others think Up or DownZacks  Top 10 Stocks for 2019 In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year  Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-27,Zacks Investment Research,https://www.investing.com/analysis/sarepta-srpt-jumps-stock-rises-83-200393449,200393449
125224,346739,SRPT,Sarepta  SRPT  Q4 Earnings Lag Estimates  Exondys 51 Sales Up,opinion,Sarepta Therapeutics  Inc    NASDAQ SRPT   incurred an adjusted loss of 85 cents per share in the fourth quarter of 2018  wider than the year ago loss of 21 cents per share as well as the Zacks Consensus Estimate of a loss of 66 cents  The widening year over year loss can be primarily attributed to a significant rise in operating expenses Notably  the adjusted figure excluded one time items  depreciation   amortization expenses  interest expenses  and income tax benefit  Including all these items  the company incurred a loss of  2 05 per share compared with a loss of 37 cents in the year ago quarter Meanwhile  Sarepta s Exondys 51   the first Duchenne muscular dystrophy   DMD   treatment to gain approval in the United States   continued with its strong performance  Sarepta recorded total revenues of  84 4 million  up 7 5  sequentially  entirely from the sale of Exondys 51  The demand for the drug has increased during the quarter  However  the top line marginally missed the Zacks Consensus Estimate of  84 91 million  In the prior year quarter  Sarepta had earned revenues of  57 3 million Consequently  shares of Sarepta were down 2 3  in after hours trading  However  Sarepta has rallied 144 2  in a year s time Duchenne muscular dystrophy   DMD   is a rare muscular degenerative disease that mostly affects boys and can be fatal before patients turn 30 Operating ExpensesAdjusted research and development  R D  expenses totaled  77 million in the fourth quarter  up 87 8  year over year  The upside was driven by increased patient enrollment in late stage golodirsen study and ramp up of manufacturing activities for pipeline candidates  including gene therapies  and higher costs due to pipeline expansion  The metric was partially offset by lower cost related to clinical studies evaluating Exondus 52 Selling  general   administrative  SG A  expenses were  52 9 million  up 101 9  year over year  Higher costs related to the global commercial expansion of its products and increased personnel expenses led to the uptick Cost of sales was also higher  reflecting higher inventory costs due to rising demand for Exondys 51 and royalty payments to BioMarin   NASDAQ BMRN    per the terms of the 2017 settlement and license agreements related to the latter s exon skipping technology used in DMD therapies Full Year ResultsSarepta recorded 2018 sales of  30 1 million  up 94 7  year over year  solely from the sale of Exondys 51  The company incurred adjusted loss of  2 14 per share  wider than the year ago loss of  1 34 per share  The year over year loss despite solid sales growth was due to rising costs to support global expansion for Exondys 51 and development of golodirsen  and gene therapies as well as higher royalty payments to BioMarin Exon Skipping Pipeline UpdateSarepta is building its DMD pipeline  which will enhance its approved drug portfolio  The pipeline candidates  on approval  will be eligible to treat a larger patient population than Exondys 51  Currently  the company has about eight exon skipping pipeline candidates  which can treat 75 80  of DMD patients  Sarepta is also developing gene therapies for treating DMD Earlier this month  the FDA granted priority review to the new drug application   NDA   seeking accelerated approval for golodirsen  A decision is expected by mid August  This apart  Sarepta is planning to submit a new drug application for its second DMD candidate  casimersen  by mid 2019  if study data confirms preclinical dystrophin expression An approval to golodirsen NDA is likely to boost Sarepta s top line as the drug will increase the eligible patient population by 8   The company is planning to have three approved exon skipping drugs   including Exondys 51  golodirsen and casimersen   in its portfolio by the first quarter of 2020  following which it expects the eligible patient population to double New Gene Therapy UpdateConcurrent with press release  Sarepta announced positive preliminary results from an early stage study evaluating gene therapy  MY 101  for treating Limb girdle muscular dystrophy  LGMD   Data showed robust protein expression in muscles  which was significantly higher than the pre defined threshold value  Moreover  Sarepta exercised its option to acquire Myonexus Therapeutics for a purchase consideration of  165 million that will add the latter s five LGMD candidates to its pipeline  It is important to note that MYO 101 was also developed by Myonexus In October  Sarepta signed a license agreement with French gene therapy company   Lysogene   to develop the latter s central nervous system   CNS   targeting candidate  LYS SAF302  The candidate  an AAV mediated gene therapy  is being evaluated in a phase II III study  AAVance  for the treatment of Mucopolysaccharidosis type IIIA  MPS IIIA   First patient in the study was dosed earlier this month Zacks Rank   Key PicksSarepta currently carries a Zacks Rank  3  Hold   Better ranked stocks in the healthcare sector include Celgene Corporation   NASDAQ CELG   and Genomic Health  Inc    NASDAQ GHDX    While Celgene sports a Zacks Rank  1  Strong Buy   Genomic Health carries a Zacks Rank  2  Buy   You can see  Celgene s earnings estimates have been revised 5 3  upward for 2019 and 9 2  for 2020 over the past 60 days  The stock has rallied almost 42  so far this year Genomic Health s earnings estimates have moved north 17 9  for 2019 and 13 9  for 2020 over the past 60 days  The stock has gained 18 9  so far this year Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-27,Zacks Investment Research,https://www.investing.com/analysis/sarepta-srpt-q4-earnings-lag-estimates-exondys-51-sales-up-200393531,200393531
125226,346741,SRPT,Sarepta  SRPT  Reports Positive Interim Results For DMD Drug,opinion,Sarepta Therapeutics  Inc    NASDAQ SRPT   announced positive interim data from a phase III study on its duchenne muscular dystrophy  DMD  candidate casimersen  Data from the ESSENCE study showed that treatment with casimersen led to statistically significant mean increase of dystrophin protein production  as measured by western blot  compared to baseline and placebo DMD is a genetic disorder caused by a mutation that prevents the body from producing dystrophin  a protein that muscles need to function properly  Casimersen works through a method called exon skipping  which helps the body s cellular machinery make functional dystrophin  Sarepta already has a marketed drug  Exondys 51 in its portfolio  which is the first approved disease modifying therapy for DMD in the United States In the past year  the company s shares have increased 60 2  against the  s decline of 13 9  In the study  22 patients receiving casimersen displayed an increase in skipping exon 45 over their baseline levels  representing a 100  response rate  The company plans to submit a new drug application  NDA  to the FDA in mid 2019  after holding apre NDA meeting with the agency  Sarepta is looking to build its DMD pipeline beyond Exondys 51 by developing other exon skipping treatments  In fact  the company has about 13 exon skipping candidates in its pipeline  the most advanced ones being golodirsen and casimersen  In December 2018  the company completed a rolling NDA submission  seeking accelerated approval for golodirsen  A decision is expected by Aug 19  2019                        The company expects to double the eligible DMD patient population for its marketed products in 2020 compared to 2018  on potential approval of golodirsen and casimersen Other companies also involved in developing DMD therapies include Catabasis Pharmaceuticals  Inc    NASDAQ CATB    Summit  PTC Therapeutics  Pfizer Inc    NYSE PFE    BioMarin   NASDAQ BMRN   et al      Sarepta Therapeutics  Inc  Price    Zacks Rank Sarepta currently carries a Zacks Rank  3  Hold          You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/sarepta-srpt-reports-positive-interim-results-for-dmd-drug-200402279,200402279
125227,346742,SRPT,4 Gene Therapy Players Likely To Become Buyout Targets In 2019 ,opinion,"The biotech industry has had a good start in 2019  The  industry has gained 16 1   outperforming the broader S P 500  which is up 15 3   so far in 2019  The rise in merger and acquisitions  M A  activity this year is one of the major driving forces behind this rally  The biotech industry is ranked 86 among the 256 Zacks industries Several large cap pharma companies are facing patent expirations of their major drugs and pricing challenges in the U S  market  This has led to consolidation through M A in the pharma space  In a landmark   Bristol Myers has offered to acquire big biotech  Celgene  NASDAQ CELG   for  74 billion  The large cap companies are looking to acquire or partner with smaller biotech companies to boost their pipeline with newer technologies  Acquisitions  which are done generally by giving a premium on current price  and partnerships  which provide funds to smaller companies to support continued development of pipeline candidates  boost the stock price of the target companies 
A few of the M A deals so far in 2019 involve companies with promising gene therapy candidates  Gene therapy  a new wave of innovation in pharma space  enables to mitigate the adverse effects of a malfunctioning disease causing gene  These therapies have a different approach from traditional drug therapies as the underlying cause can be treated instead of the symptoms  These therapies generally target rare indications including hemophilia  Duchenne muscular dystrophy   DMD   and Parkinson s disease among others  which will likely lead to higher price realization  The gene therapy segment is expected to attract a lot more attention from pharma players going forward  Better efficacy achieved by gene therapies in clinical studies and likely rise in involvement of pharma companies may lead to higher M A activity in the gene therapy segment In 2018  Novartis acquired AveXis for its gene therapy candidates and Celgene acquired Juno Therapeutics to add CAR T cell therapy for cancer  In 2019  Roche and Biogen  NASDAQ BIIB  offered to buy Spark Therapeutics   NASDAQ ONCE   and Nightstar Therapeutics   NASDAQ NITE    respectively  Both Spark and Nightstar are developing gene therapies targeting rare indications  Pfizer  NYSE PFE  collaborated with innovative gene therapy developer Vivet Therapeutics  a privately held company  There are several companies in the biotech industry  which are developing gene therapy candidates or shifting their focus to developing similar therapies  Looking at this trend  we expect some more deals targeting gene therapy makers We present four companies with promising gene therapy candidates in their pipelines  These companies may become acquisition targets going forward uniQure N V    NASDAQ QURE   The company is a promising player in the space  It is engaged in creating a pipeline of innovative gene therapies that have been developed both internally and through its collaboration  focused on cardiovascular diseases  with Bristol Myers Squibb The company s lead candidate AMT 061  an experimental AAV5 based gene therapy incorporating the FIX Padua variant  is being evaluated in the phase III HOPE B pivotal study for the treatment of patients with severe and moderately severe hemophilia B  In January 2019  the company received clearance from the FDA to initiate clinical study for AMT 130 for the treatment of Huntington s disease uniQure s stock has moved up 115 4  so far this year against the industry s decline  The company currently carries a Zacks Rank  3  Hold   You can see  Audentes Therapeutics   NASDAQ BOLD   It is another biotechnology company with a pipeline of innovative gene therapy products for patients living with rare diseases   The company is currently conducting phase I II studies for its lead product candidates  AT132 for the treatment of X linked myotubular myopathy   XLMTM    and AT342 for the treatment of Crigler Najjar syndrome   The company currently has two additional product candidates in its pipeline  AT845 for the treatment of Pompe disease and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia  CASQ2 CPVT   which are likely to enter clinical development Audentes currently carries a Zacks Rank  3  Shares have gained 82 9  year to date REGENXBIO Inc    NASDAQ RGNX   The company is a clinical stage biotechnology company that focuses on the development  commercialization and licensing of recombinant adeno associated virus gene therapy  The company s most advanced candidate  RGX 314  is being evaluated in a phase I IIa for treating wet age related macular degeneration   AMD     The company is planning to initiate a mid stage study on the candidate for treating an additional chronic retinal condition in the second half of 2019  Apart from RGX 314  the company is also developing three other gene therapy candidates for treating certain rare neurological symptoms REGENXBIO currently carries a Zacks Rank  3  So far this year  shares have gained 41 3  Solid Biosciences Inc    NASDAQ SLDB   The company s lead product candidate is SGT 001  a microdystrophin gene therapy that is in phase I II clinical studies  intended to restore functional dystrophin protein expression in DMD patients Solid Biosciences currently carries a Zacks Rank  3 Solid Biosciences Inc  Price
    Some other companies with gene therapy candidates in their pipeline include Sarepta Therapeutics   NASDAQ SRPT   and Ophthotech   NASDAQ OPHT    which are developing treatments for DMD and retinal disorder  respectively What s Ahead Investors should keep an eye on this space as potential approvals and data read outs from late stage studies on several candidates are likely to drive the related stocks Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-07,Zacks Investment Research,https://www.investing.com/analysis/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-200404831,200404831
125254,346769,SRPT,Pfizer Starts Phase Ib For Duchenne Muscular Dystrophy Drug,opinion,Pfizer Inc    NYSE PFE   has announced initiation of dosing in a phase Ib study  evaluating its mini dystrophin gene therapy candidate  PF 06939926  for the treatment of boys aged from five to 12 years with duchenne muscular dystrophy  DMD   Notably  DMD is a genetic disease characterized by muscle degeneration and weakness  The company anticipates initial data from the study in the first half of 2019 The phase Ib study is an open label  non randomized  ascending dose assessment  to be conducted on approximately 12 boys with DMD  The study is designed to evaluate the safety and tolerability of PF 06939926 and also assess muscle strength  quality and function in a given patient population Shares of Pfizer were up almost 1 5  on Apr 12  following the above news release  However  the stock has gained 7 2  in the past year  marginally underperforming the  s increase of 7 4   We remind investors that PF 06939926 is added to Pfizer s portfolio following the acquisition of Bamboo Therapeutics in August 2016  The acquisition complements Pfizer s rare disease portfolio and enhanced its leadership position in gene therapy Additionally  last year  Pfizer entered into a collaboration agreement with other companies for advancing gene therapy programs  Notably  in May 2017  Pfizer inked agreement deal with Sangamo Therapeutics to develop and commercialize gene therapy programs for Hemophilia A  Meanwhile  last November  the company amended its contract with Spark Therapeutics   NASDAQ ONCE   to advance a Hemophilia B gene therapy candidate  which is being evaluated in a phase I II study Nonetheless  this April 2018  Pfizer announced an alliance with private biotech  Allogene Therapeutics  to expedite the development of its allogeneic CAR T candidate  UCART19  for the treatment of CD19 expressing hematological malignancies Notably  DMD is one of the most common fatal genetic disorders affecting children around the world  It is a devastating and incurable muscle wasting disease  Per data provided by the National Human Genome Research Institute  DMD is a devastating and debilitating disease affecting up to one in 3 500 5 000 male births globally  Thus  there is a significant unmet need for DMD treatments At present  two approved therapies for the disease in the U S  market are Serepta Therapeutics    NASDAQ SRPT   Exondys 51  eteplirsen  and Marathon Pharmaceuticals  Emflaza  deflazacort   the first therapy approved for DMD in the country Importantly  Pfizer is not the only company working on developing treatments for DMD  Other companies also involved in developing DMD therapies include Catabasis  Summit  PTC Therapeutics  BioMarin   NASDAQ BMRN   et al Pfizer Inc  Price    Zacks RankPfizer carries a Zacks Rank  2  Buy   You can  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-04-12,Zacks Investment Research,https://www.investing.com/analysis/pfizer-starts-phase-ib-for-duchenne-muscular-dystrophy-drug-200305429,200305429
125255,346770,SRPT,Sarepta  SRPT  Q1 Loss Narrows  Exondys 51 Sales Impress,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   incurred a loss of 28 cents per share in the first quarter of 2017  narrower than the year ago loss of 57 cents and the Zacks Consensus Estimate of a loss of 32 cents Sarepta s Exondys 51  the first duchenne muscular dystrophy   DMD   treatment to gain approval in the United States in September 2016  continued its strong performance  Sarepta recorded revenues of  64 6 million  up 12 7  sequentially  primarily attributable to higher sales of Exondys 51  The drug is under review in EU  However  revenues slightly missed the Zacks Consensus Estimate of  65 25 million  In the prior year quarter  Sarepta had earned revenues of  16 3 million The company received a negative trend vote on its marketing approval application  seeking approval of Exondys 51 in Europe  following its oral explanation to the Committee for Medicinal Products for Human Use Shares were down almost 1 9  in after hours trading on negative trend vote  So far this year  Sarepta s shares have rallied 40 5  against a 12  decrease registered by the   Operating ExpensesResearch and development  R D  expenses were  43 3 million in the first quarter  up 62 4  year over year  The increase was attributable to increased clinical costs  higher shared collaboration cost related to utrophin platform and increased employee count Selling  general   administrative  SG A  expenses were  33 7 million  up 59 8  year over year  due to worldwide commercial initiatives  compensation and other personnel expenses Other UpdatesThe company completed a type C meeting with the FDA for guidance on development pathway for its exon 53 skipping candidate  golodirsen  for the treatment of DMD  Following the meeting  Sarepta remains on track to complete a rolling submission of a new drug application for this DMD candidate by the end of this year In a separate press release  Sarepta announced a partnership with Ohio based Myonexus Therapeutics to develop five gene therapies for the treatment of Limb girdle muscular dystrophies Zacks Rank   Stocks to ConsiderSarepta Therapeutics currently carries a Zacks Rank  3  Hold  Some better ranked stocks from the same space are Ligand Pharmaceuticals   NASDAQ LGND    Protagonist Therapeutics   NASDAQ PTGX   and Catabasis Pharmaceuticals   NASDAQ CATB    While Ligand and Protagonist Therapeutics sport a Zacks Rank  1  Strong Buy   Catabasis carries a Zacks Rank  2  Buy  You can see  Ligand s earnings per share estimates moved up from  4 24 to  4 43 for 2018 and remained stable at  5 32 for 2019 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 14 6  year to date Protagonist Therapeutics  loss estimates narrowed from  1 68 to 66 cents for 2018 and from  2 43 to  1 26 for 2019 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 95  Catabasis  loss estimates narrowed from 92 cents to 90 cents for 2018 and from  1 48 to  1 43 for 2019 in the last 30 days  The company came up with positive earnings surprise in all the preceding four quarters  with an average beat of 14 56   The stock has rallied 7 4  year to dateSarepta Therapeutics  Inc  Price  Consensus and EPS Surprise
    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-05-03,Zacks Investment Research,https://www.investing.com/analysis/sarepta-srpt-q1-loss-narrows-exondys-51-sales-impress-200313099,200313099
125256,346771,SRPT,Sarepta Inks Manufacturing Deal For Gene Therapy Program,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   announced that it has entered into a long term strategic manufacturing partnership with privately held Brammer Bio for the manufacturing and commercial supply of its potential micro dystrophin gene therapy and other neuromuscular pipeline products The partnership will help Sarepta to focus on process development by leveraging Brammer Bio s world class manufacturing capabilities for clinical and commercial supply of its micro dystrophin Duchenne muscular dystrophy   DMD   gene therapy products  Sarepta will also access Brammer Bio s manufacturing facilities for future gene therapy programs such as Limb girdle muscular dystrophy   LGMD   Sarepta is planning to initiate clinical studies to evaluate gene therapies by mid 2018 Brammer Bio is a biotech company  which provides services for development and early phase to commercial manufacturing services for cell and gene therapies So far this year  Sarepta s shares have rallied 73 9  against a 6 5  decrease registered by the   The rally can be attributed to strong product sales and its key pipeline candidate s progress Sarepta has only one product in its commercial portfolio  Exondys 51  which is available for the treatment of DMD in the United States  The drug has performed well in 2017  generating sales of more than  150 million in its first full year of commercialization  The sales are expected to double in 2018  The drug is under review in EU Moreover  Sarepta s most advanced pipeline candidate  golodirsen  demonstrated encouraging results in a mid stage clinical study evaluating it in DMD patients  The candidate has also shown better efficacy than Exondys 51  Sarepta is planning to file regulatory application seeking golodirsen s approval in the United States by the end of this year Apart from golodirsen  there are several other DMD candidates in early to mid stage studies We remind investors that Pfizer   NYSE PFE   is also developing a gene therapy for the treatment of DMD  An early stage study was initiated in April Sarepta Therapeutics  Inc  Price
    Zacks Rank   Stocks to ConsiderSarepta currently carries a Zacks Rank  4  Sell  A couple of better ranked stocks in the pharma sector include Aeglea BioTherapeutics  Inc    NASDAQ AGLE   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    Both the stocks carry a Zacks Rank  2  Buy   You can see  Aeglea s loss estimates narrowed from  1 93 to  1 67 for 2018 and from  3 86 to  3 57 for 2019 over the last 60 days  The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 19 32   Its share price has increased 86 5  so far this year ANI Pharmaceuticals  earnings estimates increased from  5 54 to  5 79 for 2018 and from  5 72 to  5 80 for 2019 over the last 60 days  The company came up with a positive earnings surprise in three of the four trailing quarters with an average beat of 8 69  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-06-13,Zacks Investment Research,https://www.investing.com/analysis/sarepta-inks-manufacturing-deal-for-gene-therapy-program-200325036,200325036
125257,346772,SRPT,Solid  SLDB  Surges As FDA Lifts Clinical Hold On DMD Drug ,opinion,"Shares of Solid Biosciences Inc    NASDAQ SLDB   surged 10 9  after the company announced that the FDA has lifted the clinical hold on its phase I II trial  IGNITE DMD  for its experimental candidate  SGT 001 
SGT 001  Solid Biosciences  lead candidate  is a microdystrophin gene transfer  which is being evaluated for the treatment of Duchenne muscular dystrophy  DMD  
The clinical hold was lifted as the FDA acknowledged that Solid Biosciences satisfactorily addressed all the issues raised 
The news gave investors much to cheer as SGT 001 is Solid Biosciences  lead candidate  Solid Biosciences  stock has gained 29 9  in the year so far  compared to the  s loss of 6 8  

 
It has been a bumpy ride for Solid Biosciences so far  with the development of SGT 001 
We remind investors that the FDA had placed a clinical hold on IGNITE DMD  following the report of a serious adverse event  SAE  in the first patient dosed with SGT 001  The first patient dosed in the trial was a non ambulatory adolescent  who received 5E13 vg kg of SGT 001 on Feb 14  2018 
However  the patient was hospitalized due to laboratory findings  which included a decrease in platelet count  followed by a reduction in red blood cell count and evidence of complement activation  The event was classified as a Suspected Unexpected Serious Adverse Reaction  SUSAR  
Earlier  Solid Biosciences filed an Investigational New Drug application  IND  for SGT 001 in September 2017 and initiated a phase I II trial during the fourth quarter of 2017  In November 2017  the FDA notified Solid Biosciences that the company was not permitted to dose patients in the higher dose group of IGNITE DMD  due to a partial clinical hold primarily related to the number of vials and manufacturing lots utilized per patient as well as manufacturing processes to support the higher dose group  The issue was subsequently resolved 
Nevertheless  since the hold has been lifted  Solid Biosciences plans to resume the trial and reinitiate enrollment as quickly as possible after making the required changes 
We note that SGT 001 has been granted Rare Pediatric Disease Designation  or RPDD  in the United States  and Orphan Drug Designations in both the United States and the European Union 
Solid Biosciences plans to enroll and dose several children  prior to dosing additional adolescents  Moreover  Solid Biosciences can now also obtain the intermediate muscle biopsy at 45 days  post administration of SGT 001  to collect additional information about the time course of microdystrophin expression  Initial data from a pre specified interim analysis of IGNITE DMD is expected in the second half of 2019 
Another company with a presence in the DMD market is Sarpeta Therapeutics   NASDAQ SRPT   with Exondys 51  which is the first approved disease modifying therapy for DMD in the United States 
Gene therapy has gained a lot of attention  of late  as quite a few companies are investing a lot of their R D spend for developing candidates using gene therapy  Axovant Sciences   NASDAQ AXON   recently licensed the exclusive worldwide rights to develop and commercialize AXO LentiPD from Oxford BioMedica for Parkinsons  disease 
uniQure   NASDAQ QURE   is another gene therapy company  which is advancing a pipeline of proprietary and partnered gene therapies to treat patients with liver metabolic  central nervous system and cardiovascular diseases 
Zacks Rank
Solid Biosciences carries a Zacks Rank  4  Sell   You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-19,Zacks Investment Research,https://www.investing.com/analysis/solid-sldb-surges-as-fda-lifts-clinical-hold-on-dmd-drug-200326204,200326204
125258,346773,SRPT,DMD Research Veers Toward Gene Therapy  3 Stocks In Focus,opinion,"Duchenne muscular dystrophy   DMD   is a rare genetic disease and a severe form of muscular dystrophy  primarily affecting males  It progressively weakens and degenerates skeletal and heart muscles The symptoms of muscle weakness generally start to appear as early as four years of age in boys and progresses quickly Duchenne muscular dystrophy is one of the nine types of muscular dystrophy caused by the absence of a particular gene  dystrophin  which the body uses to keep the muscle cells intact  The disease starts to affect the muscles in the hips  pelvic area  thighs and shoulders in early stages and leads to degeneration of voluntary muscles in the arms  legs and trunk gradually  As the disease progresses  it affects the heart and respiratory muscles in early teen patients Life expectancy of DMD patients is as low as early adulthood  However  the scenario is changing with advances in cardiac and respiratory care with patients living till their 50s Due to the severity and rarity of DMD  the FDA is also incentivizing the companies developing treatments to treat this rare muscular degenerative disease by granting orphan drug designation to several candidates  This designation gives seven years of marketing exclusivity upon approval  research funding eligibility  tax credits for certain research costs  and a waiver of the FDA application user fee However  there are very few companies developing DMD treatments due to lower number of patients  Sarepta Therapeutics  Inc  s   NASDAQ SRPT   Exondys 51 is the first approved drug in the United States  which has been available since late 2016  The drug is a small molecule  which targets mutation of the DMD gene susceptible to exon 51 skipping  Exondys 51 and PTC Therapeutics  Inc  s   NASDAQ PTCT   Emflaza are among the approved treatments of DMD in the United States The focus is currently shifting to development of gene therapies for the treatment of the disease  Gene therapies deliver a functional copy of the dystrophin to muscle cells to restore its production 3 Pharma Biotech Companies Developing Gene Therapy to Treat DMDHere we discuss three companies  which are researching and developing advance treatments for DMD 
Sarepta has about eight exon skipping candidates in its pipeline  Its lead candidate  golodirsen  is an exon 53 skipping candidate  which has demonstrated better efficacy than Exondys 51 with 100  response rate in a mid stage study  A new drug application   NDA   is expected to be filed by the end of this year Apart from exon skipping candidates  Sarepta is focusing on gene therapies for developing treatments for DMD  The company also initiated two phase I II studies in the fourth quarter of 2017  which will evaluate gene therapies for DMD  Earlier this week  it announced promising preliminary results from an early stage study evaluating the gene therapy  AAVrh74 MHCK7 micro dystrophin   Read more   Sarepta currently carries a Zacks Rank  4  Sell  Sarepta Therapeutics  Inc  Price
    Pfizer Inc    NYSE PFE   is a large pharma company  which is also developing its gene therapy for the treatment of DMD  In April  the company initiated dosing of patients in a phase Ib study  which is evaluating its mini dystrophin gene therapy candidate  PF 06939926  for treating DMD  The company is developing the therapy for the treatment of boys aged five to 12 years  Pfizer added the candidate to its pipeline with the 2016 acquisition of Bamboo Therapeutics   Read more   Pfizer currently carries a Zacks Rank  3  Hold   You can see  Pfizer Inc  Price
    Solid Biosciences Inc  s   NASDAQ SLDB   lead candidate  SGT 001  is a microdystrophin gene transfer  which is being evaluated for the treatment of DMD  The candidate is in early stage of development  However  the company had received a setback with the FDA putting its phase I II IGNITE DMD study   initiated during the fourth quarter of 2017   under clinical hold in February  Earlier this week  the FDA lifted the clinical hold on this study  which boosted the company s stock   Read more   Solid Biosciences currently carries a Zacks Rank  4 Solid Biosciences Inc  Price
    Apart from the above mentioned companies  Catabasis Pharmaceuticals  Inc    NASDAQ CATB   is developing its oral small molecule candidate  edasalonexent  for the treatment of DMD irrespective of the underlying dystrophin mutation Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-22,Zacks Investment Research,https://www.investing.com/analysis/dmd-research-veers-toward-gene-therapy-3-stocks-in-focus-200327150,200327150
125293,346808,SRPT,The Zacks Analyst Blog Highlights  Sangamo Therapeutics  Sarepta Therapeutics  Akebia Therapeutics  Calithera Biosciences And GlycoMimetics,opinion,For Immediate ReleaseChicago  IL   December 6  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog includeSangamo Therapeutics  Inc    NASDAQ SGMO    Sarepta Therapeutics  Inc    NASDAQ SRPT    Akebia Therapeutics  Inc    NASDAQ AKBA    Calithera Biosciences  Inc    NASDAQ CALA   and GlycoMimetics  Inc    NASDAQ GLYC   Here are highlights from Tuesday s Analyst Blog  5 Top Ranked Drug Stocks That Are Broker FavoritesThe pharma and biotech sectors have made a nice comeback this year with the NYSE ARCA Pharmaceutical Index gaining 11 7   while the Nasdaq Biotechnology Index is up 17 7  year to date  This is in sharp contrast to 2016  which saw pharma and biotech stocks under a lot of pressure with the sector facing intense criticism for rising drug prices Drug pricing was not the only reason for the sector s underperformance last year  A fewer number of drug approvals  high profile pipeline failures  slower than expected new product launches and increasing competition were some of the other factors that weighed on the sector However  factors like ramp up in new product sales  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from key products have contributed to a sustained recovery in the sector in 2017 Importantly  investors now seem more comfortable with the drug pricing scenario and are focusing more on the fundamentals of the sector  So what are the factors that could drive the sector s performance  First and foremost  this is an industry that will continue to witness demand for its products given an aging population and the increasing prevalence of a wide variety of diseases  Strong pipelines  innovative treatments  impressive results  and increased health care spending should support growth  A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also provide benefits  The sector will receive an additional boost if more mergers   acquisitions  M As  are announced in the coming quarters But drug pricing will remain a headline risk until there is more clarity on the situation  Other challenges for the sector include the growing presence of biosimilars  generic competition  a slowdown in the growth of legacy products and major pipeline setbacks How to Pick WinnersAnyone interested in biotech and pharma stocks will know that it could be challenging to pick winners in this  high risk   high returns  industry which is constantly growing and changing  Companies which hit the bull s eye become overnight success stories with shares doubling or even tripling on positive news  However  negative outcomes have an equally strong effect on the shares and failure may very well spell doom for these companies In such a scenario  let s take a look at stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies  We have zeroed in on five stocks with the help of our    these stocks have been given a Strong Buy or Buy rating by 80  or more brokers and sport a favorable Zacks Rank  1  Strong Buy  or  2  Buy  Sangamo Therapeutics  Inc   California based Sangamo is a clinical stage biotech company that is focused on translating ground breaking science into genomic therapies using its platform technologies in genome editing  gene therapy  gene regulation and cell therapy  The company has partnership agreements with big players like Pfizer  NYSE PFE   hemophilia A   Shire  Huntington s disease  and Bioverativ  beta thalassemia and sickle cell disease   In the next 8 12 months  Sangamo expects proof of concept data on SB 525  hemophilia A   SB FIX  hemophilia B   SB 318  MPS I  and SB 319  MPS II   Other value drivers could be the signing of partnership deals for the company s central nervous system tau and oncology assets Sangamo is a Zacks Rank  2 stock with 85 7  Strong Buy or Buy broker rating  Shares of Sangamo are up 445 9  year to date  significantly outperforming the  s 2 6  rally You can see  Sarepta Therapeutics  Inc   Cambridge  MA based Sarepta is a commercial stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases  The company s key focus area is Duchenne muscular dystrophy   DMD    Sarepta s DMD drug  Exondys 51  is performing well with the company raising its revenue outlook for 2017 following the release of third quarter results  The company is also progressing with its pipeline Sarepta is a Zacks Rank  2 stock with 93 3  Strong Buy or Buy broker rating  Shares of Sarepta are up 97 9  year to date  significantly outperforming the  s 2 6  rally Akebia Therapeutics  Inc   Akebia  a biopharmaceutical company headquartered in Cambridge  MA  is focused on delivering treatments to patients with kidney disease through hypoxia inducible factor biology  The company s lead pipeline candidate  vadadustat  is in development for the treatment of anemia related to chronic kidney disease in both non dialysis and dialysis patients  Vadadustat is currently in late stage development  Akebia has a collaboration and license agreement in the United States for vadadustat with Otsuka Shares of Akebia are up 47 8  year to date  significantly outperforming the  s 5 2  rally  Akebia is a Zacks Rank  2 stock with 80  Strong Buy or Buy broker rating Calithera Biosciences  Inc   South San Francisco  CA based clinical stage pharmaceutical company  Calithera  is focused on the discovery and development of novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer  Lead pipeline candidate  CB 839  is being studied in combination with standard of care agents  The company also has a collaboration and license agreement with Incyte for its small molecule arginase inhibitors for hematology and oncology indications   Calithera s shares are up 200  year to date  significantly outperforming the  s 5 2  rally  Calithera is a Zacks Rank  2 stock with 100  Strong Buy or Buy broker rating  GlycoMimetics  Inc   Rockville  MD based clinical stage biotech company  GlycoMimetics is focused on the discovery and development of novel glycomimetic drugs that will address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role  The company s most advanced pipeline candidate is rivipansel  a pan selectin antagonist being developed for the treatment of vaso occlusive crisis in sickle cell disease  Rivipansel is in a phase III study being conducted by partner  Pfizer  with the study expected to complete in the second half of 2018  GlycoMimetics  wholly owned pipeline candidate  GMI 1271  is in a phase I II study for acute myeloid leukemia   AML   and a phase I study for multiple myeloma GlycoMimetics s shares are up 134 4  year to date  significantly outperforming the  s 5 2  rally  GlycoMimetics is a Zacks Rank  2 stock with 100  Strong Buy or Buy broker rating Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana       Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look   Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-12-05,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-sangamo-therapeutics-sarepta-therapeutics-akebia-therapeutics-calithera-biosciences-and-glycomimetics-200270969,200270969
125294,346809,SRPT,7 Stocks Ready To Climb 30  In 2018,opinion,"Stock Market Momentum Continues
Here are seven momentum stocks that increased by at least 30  this year and still have another 30  upside going into 2018 
For the 86th time since the 2016 presidential election  the Dow Jones industrial average closed at a record high on Monday  December 18  This means that 34  of all trading sessions in 2017 closed at new highs and there are still eight trading days left in the year  251 total trading days in 2017  
The S P 500 also increased on Monday by roughly 0 5   to finish at its own record high of 2 690  The market continues to gain momentum heading into 2018 as the long awaited tax bill inches closer to passing  Many expect a deal to be achieved before the end of the year 
As a result  the S P 500 has climbed 20 1  in 2017 while the Dow Jones has moved 25 4  higher  Many academics are calling this bull market a  momentum effect  which is simply the tendency of winning stocks to keep winning and losing stocks to keep losing due to investor behavioral biases  It is based on the idea that once a stock establishes a trend  it is more likely to continue in that direction instead of moving against the drift even if the stock s valuation becomes unreasonable 
With no signs of this  momentum market  cooling down anytime soon  I decided to search for momentum stocks that have  1  increased by at least 30  in 2017 and  2  still have another 30  upside potential going into 2018 
I determined which stocks still have upside potential by using the finbox io Fair Value estimate  This estimate is derived by applying a combination of valuation and risk models like discounted cash flow analysis  dividend discount model  comparable companies multiples  earnings power value and more 
To find these momentum stocks  I applied the following filters in finbox io s stock screener 
YTD Stock Price Change   30 0 
finbox io Upside   30 0 
Fair Value Uncertainty is not very high
Market Capitalization    500 million
The latest results can be found here    Here are the seven momentum stocks I found that could rise another 30  in 2018 
Stocks Ready To Jump Another 30  in 2018
Abeona Therapeutics
Abeona Therapeutics  NASDAQ ABEO   a clinical stage biopharmaceutical company  focuses on developing and delivering gene therapy and plasma based products for severe and life threatening rare diseases  The company was formerly known as PlasmaTech Biopharmaceuticals and changed its name to Abeona Therapeutics in June 2015 
Maxim Group raised its fair value target to  17 00 per share on July 18 citing positive prospects for its lead gene therapy candidate for the treatment of an inherited disorder characterized by large painful blisters on the skin  The stock sky rocketed when the FDA confirmed Abeona as the lead cell therapy candidate on August 29 

source  finbox ioShares of the biopharma company are up an enormous 250  since the beginning of the year  The stock last traded at  15 20 as of Monday afternoon and five separate valuation analyses imply there is still another  60  upside potential going into 2018 
Lantheus
Lantheus Holdings  NASDAQ LNTH  develops  manufactures and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide  The company sells its products to hospitals  clinics  group practices and radiopharmacies 
Lantheus inked a deal with GE Healthcare on February 21 for the continued development of an investigational agent that could improve the diagnosis of coronary artery disease  The partnership news led to a number of upgrades from analysts covering the company and the stock has continued to reach new heights 

source  finbox ioShares of Lantheus are up 125  year to date and finbox io s fair value estimate of  25 27 per share calculated from eight cash flow models imply another 23 6  upside  The average price target from four Wall Street analysts of  24 50 also implies similar upside 
Ultra Clean
Ultra Clean Holdings  NASDAQ UCTT  designs  manufactures and tests production tools  modules and subsystems for the semiconductor capital equipment and equipment industry segments primarily in North America  Asia and Europe  Ultra Clean was founded in 1991 and is headquartered in Hayward  California 
The Semiconductor   Semiconductor Equipment industry has significantly outperformed this year reporting 42  YoY earnings growth in the latest quarter  As a result  Ultra Clean has seen increasing demand for its tools and its stock has appreciated 115  in 2017 
source  finbox ioHowever  Ultra Clean s shares have pulled back recently leading to Stifel upgrading the company to a  Buy  rating on December 4  Stifel noted that Ultra Clean is well positioned to benefit from another strong year in wafer fan equipment and display spending  Finbox io s nine separate cash flow analyses support the recent buy rating 
Adamas Pharmaceuticals
Adamas Pharma  NASDAQ ADMS  discovers  develops and sells chrono synchronous therapies for chronic neurologic disorders  The company s product portfolio comprises therapies for the treatment of patients with Parkinson s disease  Alzheimer s disease and patients with epilepsy 
The FDA approved Adamas  new Parkinson s therapy in August  However  shares were relatively flat until Steve Cohen s Point72 Asset Management reported a 5 1  stake in the company on October 30  In addition  Evercore upgraded its rating on the stock to Outperform along with an  85 00 per share price target  Shares of the company eventually reached as high as  37 15 per share 
source  finbox ioAdamas  stock is currently trading at  31 70 per share as of Monday  more than 100  higher since the beginning of the year  What s more  finbox io s six valuation analyses suggest that shares could increase another 50  in 2018 
Plug Power
Plug Power  NASDAQ PLUG  engages in the design  development and manufacture of hydrogen fuel cell systems primarily for the material handling and stationary power markets in the United States  The company offers its products to businesses and government agencies through direct product sales force  original equipment manufacturers  and dealer networks 
Plug Power stock jumped nearly 75  on April 5th following news that it signed an agreement with Amazon com  NASDAQ AMZN  for multi site GenKey deployments  The deal involved the company supplying batteries to power forklifts used by Amazon in the online retailer s warehouses in exchange for the right to buy up to 23  of Plug Power 
source  finbox ioShares of the company are trading nearly 80  higher on a year to date basis  But the stock price could end up trading another 47 1  higher in 2018 based on Plug Power s future cash flows 
Arcos Dorados
Arcos Dorados Holdings  NYSE ARCO  operates as a franchisee of McDonald s  NYSE MCD  restaurants  It has the exclusive right to own  operate  and grant franchises of McDonald s restaurants in 20 countries and territories in Latin America and the Caribbean  As of December 31  2016  the company operated and franchised 2 156 McDonald s branded restaurants 
Shares of Arcos Dorados have steadily increased throughout the year as favorable consumer recovery trends have played out across Brazil and Argentina in 2017  The franchisee has also benefited from lower beef prices 
source  finbox ioArcos Dorados  stock last traded at  9 85 as of Monday  near its 52 week high and nearly 40  higher year to date  On a fundamental basis  the company s stock is still trading at a 39 8  discount to finbox io s intrinsic value 
Looking to next year  the company has signed international soccer superstar Neymar to an exclusive contract in front of the 2018 World Cup  Neymar will serve as an ambassador in Arcos Dorados  media and marketing campaigns related to next year s World Cup 
Sarepta
Sarepta Therapeutics Inc  NASDAQ SRPT   a biopharmaceutical company  focuses on the discovery and development of RNA based therapeutics for the treatment of rare neuromuscular diseases  The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States  Sarepta Therapeutics  Inc  was founded in 1980 and is headquartered in Cambridge  Massachusetts 
On September 6  the company s stock jumped by more than 15  in response to its announcement of positive results from a study assessing golodirsen in 53 boys with Duchenne muscular dystrophy  The company then reported Q3 sales of  46 million compared to  0 the previous year and lifted its full year revenue guidance 

source  finbox ioShares of the biotech company are up 33 3  year to date and have momentum going into 2018  Five of finbox io s valuation models calculate an average fair value estimate of  67 13 per share implying almost 25  upside potential 
In conclusion  the table below ranks all seven stocks by their year to date returns 
This momentum investing strategy is not for the faint hearted as it typically calls for investors to  buy high   Many value investors dislike the strategy because it can often result in purchasing shares at a premium valuation 
However  this is why I added finbox io s fair estimates to the stock screen to make sure each stock is still trading at a reasonable level  Therefore  investors looking to ride the current bull market into 2018 may want to consider the companies listed above 
 ",2017-12-19,Finbox io,https://www.investing.com/analysis/7-stocks-ready-to-climb-another-30-in-2018-200274295,200274295
125295,346810,SRPT,Bioscience IPOs Takes Advantage Of Biotech Bull Market,opinion,"The biotech market has recovered from its doldrums of the past two years while not reaching the excessive heights of 2015  and we have already witnessed a few biotech companies go public with good results such as Menlo Therapeutics  NASDAQ MNLO   And on Friday  Solid Biosciences  NASDAQ SLDB  debuted with a strong start  with the stock reaching a high of  29 25 before falling down to  23 at the close of trading  The company set an initial price of  16 and raised  125 million 
However   16 was not Solid s original price  as it was forced to lower the price from  18 to  19 after a disclosure which should spark some concerns  In fact  while there is no doubt that Solid s treatment is useful  there are warning signs about this company s drug pipeline and the degree of its losses  Investing in biotech always carries risks  but Solid Biosciences  especially at its current elevated price  has too much for the moment 
Viable Gene Therapy 
Solid Biosciences is a gene therapy company that is working on developing a treatment for Duchenne muscular dystrophy  DMD   Solid Biosciences states in its SEC report that  DMD is a progressive  irreversible and ultimately fatal disease that affects approximately one in every 3 500 to 5 000 live male births and has an estimated prevalence of 10 000 to 15 000 cases in the United States alone  
There is only one FDA approved treatment for DMD called Exondys 51  which is held by Sarepta Therapeutics  NASDAQ SRPT   Exondys 51 only works on 13 percent of DMD patients and yet Sarepta s stock has more than doubled over the past year 
Sarepta s example shows that if Solid Biosciences can develop a successful DMD treatment  the sky is the limit  Solid Biosciences intends to use a gene therapy treatment called SGT 001  and a Phase I II clinical study began in the fourth quarter 
But there are serious questions about SGT 001 s viability  James Wilson  a scientist who has been working on gene therapy s abilities to cure hereditary diseases like DMD for decades  recently resigned from Solid s Scientific Advisory Board due to concerns of the possible risks of some of its methods 
And on Thursday  one day before its IPO  Solid announced that SGT 001 had been placed on a late clinical hold by the FDA in November  The company can still do the clinical study with a low dose group of patients  but cannot evaluate SGT 001 s effects at a high dosage  Solid was forced to lower its IPO price as noted above 
Solid states of the hold that they do  not expect that the overall timing for clinical development of SGT 001 will be affected  by the hold  However  they do state that if the hold is not lifted  it would negatively affect overall development  And there is also the ethical problem of that Solid knew about this hold back in November  but sat on this information during the roadshow until the very last moment and has not provided a satisfactory explanation why they concealed it  Many companies would have cancelled the IPO completely in response to news like this  but Solid just made a slight revision to its initial price 
Getting More Cash
Like most emerging biotech companies  Solid has no revenue worth mentioning and will not see its treatment successfully developed for years  Furthermore  its current losses will continue to increase as development becomes more complicated  Solid Biosciences had a net loss of  6 6 million in 2015  which increased to  38 6 million in the first nine months of 2017  By comparison  Solid s total assets are at just  35 million  Solid states in its SEC report that the amount raised in this IPO will let the company operate for another 12 months  like the time it takes to buy engagement rings  which is less than other biotech companies such as Menlo  Solid clearly needs money as soon as possible  which may have factored into why its response to the clinical hold has been so inadequate 
In addition to the concerns of the hold and Solid s needs of cash  there are other problems as well  The company is betting everything on SGT 001 s success  as it only has one other therapy named SB 001 which is not even in preclinical trials  It does not have sufficient manufacturing capabilities of its own  And while its IPO is a success  this initial uptick in value shows that this company could have raised more cash it clearly needs as soon as possible 
Too Much Risk
If Solid Biosciences and SGT 001 succeed in treating DMD  this company s stock will skyrocket  But right now  that looks like a large if for all the reasons described above  Solid needs to show that its next clinical trial for SGT 001 is a success without concealing information and move further along in the development process given the complexities of gene therapy  There are other good biotech IPOs which have either just come out or will go public soon  Investors should not feel pressured to invest in any biotech firm right away  and Solid Biosciences is currently not worth the risk ",2018-01-30,Alex Newman,https://www.investing.com/analysis/solid-biosciences-ipo-taking-advantage-of-biotech-bull-market-200285021,200285021
125296,346811,SRPT,Why Earnings Season Could Be Great For Sarepta Therapeutics  SRPT ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Therapeutics  Inc    NASDAQ SRPT   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Sarepta Therapeutics is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for SRPT in this report In fact  the Most Accurate Estimate for the current quarter is currently at a loss of 32 cents per share for SRPT  compared to a broader Zacks Consensus Estimate of a loss of 34 cents per share  This suggests that analysts have very recently bumped up their estimates for SRPT  giving the stock a Zacks Earnings ESP of  5 54  heading into earnings season Sarepta Therapeutics  Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that SRPT has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Sarepta Therapeutics  and that a beat might be in the cards for the upcoming report Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-27,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-sarepta-therapeutics-srpt-200295097,200295097
125297,346812,SRPT,Sarepta  SRPT  Narrows Q4 Loss  Exondys 51 Sales Impress,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   reported narrower than expected loss in the fourth quarter of 2017  The biotech expects 2018 sales to double for Exondys 51  the only marketed drug for Duchenne muscular dystrophy   DMD    Shares were up almost 1 4  in after hours tradings 
So far this year  Sarepta s shares have recorded a growth of 90 4   This compares favorably with the 6 9  decrease registered by the  during this period 

Narrower Loss
Sarepta incurred a loss of 37 cents per share in the fourth quarter of 2017  narrower than the year ago loss of 71 cents  However  it surpassed the Zacks Consensus Estimate of a loss of 31 cents 
Quarterly Details
Sarepta s Exondys 51  the first DMD treatment to gain approval in the United States in September 2016  has shown strong performance in the fourth quarter  Sarepta recorded revenues of  57 3 million  up 24 6  sequentially  primarily attributable to the sales of Exondys 51 
The drug is under review in EU  However  revenues slightly missed the Zacks Consensus Estimate of  57 38 million  In the prior year quarter  Sarepta earned revenues amounting  5 4 million 
Research and development  R D  expenses were  44 4 million in the fourth quarter  down 37 2  year over year  The company remunerated an up front payment of  40 0 million to Summit  Oxford  Ltd  in the year ago quarter 
Selling  general   administrative  SG A  expenses were  32 2 million  up 40 5  year over year  due to worldwide commercial initiatives  compensation and other personnel expenses 
2017 Performance
For the full year 2017  adjusted loss was 86 cents per share compared with  5 49 in 2016  The loss was wider than the Zacks Consensus Estimate of 77 cents 
Revenues for 2017 came in at  154 6 million  which was almost in line with the Zacks Consensus Estimate of  154 67 million 
Outlook
Based on sales trends witnessed in 2017  Sarepta expects Exondys 51 sales to double in 2018  The Zacks Consensus Estimate for 2018 sales is pegged at  300 47 million Sarepta Therapeutics  Inc  Price  Consensus and EPS Surprise
 

    
Zacks Rank   Stock to Consider
Sarepta Therapeutics carries a Zacks Rank  3  Hold  
Some better ranked stocks in the healthcare sector are Ligand Pharmaceuticals Inc    NASDAQ LGND    Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Enanta Pharmaceuticals  Inc    NASDAQ ENTA    Regeneron carries a Zacks Rank  1  Strong Buy  while Ligand and Enanta carry a Zacks Rank  2  Buy   You can see  
Ligand s earnings per share estimates have moved up from  3 78 to  4 15 for 2018 over the last 30 days  The company pulled off positive earnings surprises in three of the trailing four quarters  with an average beat of 24 88   The share price of the company increased 51 6  over a year 
Regeneron s earnings per share estimates have moved up from  17 13 to  18 65 and from  20 38 to  21 56 for 2018 and 2019  respectively  in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  
Enanta Pharma delivered a positive earnings surprise in three of the last four quarters  with an average beat of 373 1   The share price of the company surged 169 9  over a year 
Don t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 
Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-03-02,Zacks Investment Research,https://www.investing.com/analysis/sarepta-srpt-narrows-q4-loss-exondys-51-sales-impress-200295634,200295634
125298,346813,SRPT,Zacks Investment Ideas Feature Highlights  Sangamo  Bluebird  Editas  Sarepta And Juno,opinion,For Immediate Release Chicago  IL   March 9  2018   Today  Zacks Investment Ideas feature highlights Features  Sangamo Therapeutics   NASDAQ SGMO    bluebird bio   NASDAQ BLUE    Editas Medicine   NASDAQ EDIT    Sarepta Therapeutics   NASDAQ SRPT   and Juno Therapeutics  Healthcare Heroes that Aren t Done YetI ve been investing and trading in healthcare stocks successfully for a decade  During the depths of the financial crisis in the first week of March 2009  I went on national TV for the first time and was asked to pick some stocks And I was nervous about potentially giving bad advice to millions of people I didn t know the market would bottom that week  so I asked myself    What are 2 sure things I would tell retail investors they could buy right now that would put their money to work at incredible levels  let them sleep at night during the volatility  and make them very happy 5 years from now  The Technology play was probably obvious to anyone who had just bought a smartphone or new car full of semiconductors  But the Biotech one might still seem risky to some How could I be so confident it was a  sure thing   Because I started identifying the key  megatrends  that made the frontiers of the life sciences and medical R D so promising for decades to come You can read my latest description of those growth drivers in this report   In 2013  I ran a trading portfolio at Zacks that racked up a 66  return primarily on the back of Biotech stocks in that strong bull run they had  2014 and 2015 proved much more difficult with big corrections and then a peak But my  megatrends  proved profoundly resilient  And they inspired us to start a new long term portfolio at Zacks focused directly on them We called it  and launched in April of 2017 Since then  some of the gains have been fantastic   Sangamo Therapeutics 155 61   closed trade bluebird bio  138 17   still holding after JUNO buyout Editas Medicine  115 33   still holding on gene editing innovation Sarepta Therapeutics  106 84   still holding as leading company in Duchenne muscular dystrophy Juno Therapeutics  98 06   sold after Celgene  NASDAQ CELG  acquisition Note  BLUE  EDIT  and SRPT are still open trades showing these gains as of Thursday morning on 3 8 2018 That JUNO closed trade was following the buyout by Celgene in January  And we had already executed and closed a big swing trade in JUNO for 70  gains in 2017 And for a wonderful and profitable  fat tail  event  the same day JUNO was acquired  our Bioverativ was purchased by the French pharma giant Sanofi  PA SASY  for a big premium which handed us a 75  winner A Robust Research ProcessTo be clear  not every investment is a winner  We take a lot of shots    about 25 open positions on average in any given month    and one big loser was NewLink Genetics which cost us 53   This is proof I m not infallible and that Biotech investing remains very risky  with large and binary asymmetric payoffs due to the gauntlet of human clinical trials and FDA rulings But I employ a clear and definable research process that has 5 key steps and it allows me to find at least 3 winners for every wipe out in the treacherous Biotech landscape We took a chance on gene editing company Editas at  25 and watching the trends in BioPharma M A  I decided we could do the same with peer Intellia Therapeutics Notably  Intellia saw a price target boost yesterday by Barclays  LON BARC  from  33 to  46 and today coverage was initiated by JMP Securities with a  76 price target  projecting over 150  upside Plus  it helped my conviction in these CRISPR gene editing companies that I read as much as I could about the science and its founders  Dr  Jennifer Doudna and Dr  Emmanuelle Charpentier Beyond BiotechBut my Healthcare Innovators portfolio is not solely focused on Biotech  We have enjoyed sizable gains with large pharma companies like AbbVie  surgical device companies like Edwards Lifesciences  NYSE EW   and HMO s like Centene  all of which I believe have more room to run And one of my proudest runners making our members smile is Align Technology  maker of the Invisalign  teeth straighteners   a great alternative to traditional braces  The company is posting consistent 30  growth quarter after quarter as both American teens and their dentists realize the beautiful fit of their digitally mastered dental solutions Plus  the international growth opportunity is what has kept us in the stock for the long term since  133  even during big pullbacks from all time highs above  260 I hope I have convinced you that the Healthcare Megatrends are in full force and will be for many more years Besides making profitable investments  there is also one other fantastic benefit I didn t describe  studying the lifesciences companies is a never ending journey of discovery that can expand your knowledge of human physiology  wellness  disease  nutrition and the future of medicine Once you re hooked on so much to learn and wonder about  you ll never be bored again in your life Disclosure  I own shares of BLUE  EDIT  SRPT  NTLA  and ALGN for the Zacks Healthcare Innovators portfolio Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/zacks-investment-ideas-feature-highlights-sangamo-bluebird-editas-sarepta-and-juno-200296918,200296918
125299,346814,SRPT,Biotech Stock Roundup  REGN Cuts Praluent Price  OREX To File For Bankruptcy,opinion,"Key highlights of the week include Regeneron announcing positive data on Praluent  Sarepta seeking rapid approval of second DMD drug  while Orexigen filing for bankruptcy Recap of the Week s Most Important StoriesRegeneron Sanofi Announce Positive Data on Praluent  Cuts Price  Regeneron Pharmaceuticals   NASDAQ REGN   and partner Sanofi   NYSE SNY   announced positive results from the ODYSSEY OUTCOMES trial on Praluent during a late breaker session at the American College of Cardiology s 67th Annual Scientific Session in Orlando  FL  The trial met the primary endpoint as results showed that Praluent significantly reduced the risk of major adverse cardiovascular events   MACE   in patients with a recent acute coronary syndrome   ACS   event such as a heart attack  In June 2017  Regeneron and Sanofi announced that two phase IIIb IV ODYSSEY DM trials in patients with diabetes met their primary endpoints  Though the uptake of the drug hasn t been encouraging  the cholesterol management market holds huge commercial potential  Both companies also announced a reduction in net price for Praluent in alignment with a new value assessment for high risk patients from the Institute for Clinical and Economic Review   Meanwhile  a phase III study evaluating Praluent in homozygous familial hypercholesterolemia was initiated in the fourth quarter of 2017   Read more   Regeneron is a Zacks Rank  1  Strong Buy  stock  You can see  Sarepta to Seek Rapid Approval of Second DMD Drug  Sarepta Therapeutics    NASDAQ SRPT   stock scaled a fresh 52 week high as the company announced accelerated approval of its second drug  golodirsen  to treat Duchenne Muscular Dystrophy   DMD    the most common type of muscular dystrophy  Sarepta had met with the FDA Division of Neurology Products in February 2018 to obtain guidance on the regulatory pathway for golodirsen   Sarepta will file a rolling new drug application  NDA  with the FDA  seeking accelerated approval of golodirsen for DMD in patients who have a confirmed mutation of the DMD gene susceptible to exon 53 skipping  Sarepta intends to complete a rolling NDA submission for golodirsen by year end 2018   Sarepta s only approved drug Exondys 51 is approved in the United States as a once weekly intravenous infusion  specifically targeting patients who have a confirmed mutation of the DMD gene susceptible to exon 51 skipping    Read more   Orexigen to File for Bankruptcy  Orexigen Therapeutics   NASDAQ OREX   announced that it has decided to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U S  Bankruptcy Court for the District of Delaware  The company also plans to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U S  Bankruptcy Code  The bidding process is expected to conclude by May 18   The news comes in the wake of an unimpressive performance of its weight loss drug Contrave which is marketed as Mysimba in the European Union Orexigen has filed a series of motions with the court thereby seeking to ensure the continuation of normal operations during this tenure   Read more   Biogen to Buy Cognitive Impairment Asset From Pfizer  Biogen   NASDAQ BIIB   announced that it will acquire a phase IIb ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia from Pfizer   NYSE PFE   for an upfront payment of  75 million along with milestone payments of up to  515 million as well as tiered royalties in the low to mid teen percentages  The company is looking to diversify its portfolio beyond the core therapeutic area   multiple sclerosis   to neurodegenerative disorders  Biogen will initiate a phase IIb study on PF 04958242 to determine if the AMPA receptor potentiator is safe and effective for the treatment of cognitive dysfunction in schizophrenia patients in the second half of 2018    Read more   PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The NASDAQ Biotechnology Index lost 0 02  over the last five trading sessions  Among major biotech stocks  Vertex gained 2 81   Over the last six months  Celgene  NASDAQ CELG  lost 34 88  while Vertex gained 14 1   see the last biotech stock roundup here    What s Next in the Biotech World Stay tuned for more regulatory and pipeline updates from the ongoing Cowen Healthcare Conference Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-regn-cuts-praluent-price-orex-to-file-for-bankruptcy-200298163,200298163
125325,346840,SRPT,Sarepta s Golodirsen Positive In DMD Study  Shares Soar,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   announced positive results from a phase I II study   4053 101   evaluating its Exon 53 skipping candidate  golodirsen  for the treatment of Duchenne Muscular Dystrophy  DMD  patients DMD is a genetic disorder in which the absence of a protein called dystrophin progressively weakens the muscles Golodirsen achieved a 100  response rate with 10 7 times increase in mean dystrophin protein from baseline We remind investors that Sarepta s Exondys 51  the only approved treatment for DMD  is an Exon 51 skipping DMD treatment and had achieved nearly three times increase in mean dystrophin protein from baseline  Golodirsen s better efficacy in terms of dystrophin production than Exondys 51 raised investor skeptism that golodirsen could prove to be a new and better treatment option for DMD patientsIt is also anticipated that golodirsen may receive an earlier than expected approval  further strengthening Sarepta s DMD franchise  Shares of Sarepta surged 13 75  on Wednesday on this optimism  In fact shares of the company have increased 70 4   significantly outperforming the  s gain of 15 7  so far this year The data from the 4053 101 study showed that after 48 weeks of treatment with golodirsen  mean dystrophin protein increased to 1 019  of the amount found in normal human from the baseline of 0 095  of the normal level  In its clinical study  Exondys 51 had increased the pre treatment dystrophin level of 0 16  of normal to 0 44  The phase I II study will be continued for 144 weeks Exondys 51 was approved in September 2016 and it generated sales of more than  51 million in the first half of 2017  Full year sales are expected to be in the range of  125 to  130 million Sarepta has seven other potential DMD therapies under investigation Sarepta has multiple collaborations agreements for developing treatment for DMD  These include a deal with Summit Therapeutics plc   NASDAQ SMMT   for developing the latter s ezutromid and other utrophin modulator pipeline and Catabasis Pharmaceuticals  Inc    NASDAQ CATB   for combination drug treatment Moreover  in July 2017  Sarepta signed a settlement agreement with BioMarin Pharmaceutical Inc    NASDAQ BMRN   for resolving global patent proceedings related to the sale of Exondys 51 and development of future DMD exon skipping products Sarepta Therapeutics  Inc  Price and Consensus
    Sarepta has a Zacks Rank  3  Hold   You can see  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-09-07,Zacks Investment Research,https://www.investing.com/analysis/sareptas-golodirsen-positive-in-dmd-study-shares-soar-200212015,200212015
125326,346841,SRPT,Here s Why Sarepta Stock Is Up More Than 60  So Far In 2017,opinion,Shares of Sarepta Therapeutics  Inc    NASDAQ SRPT   have been rising since the beginning of this year  This biotech company is up 64 7  so far this year  outperforming the 15 6  increase registered by the  during this period Let s analyze the factors that have driven the rally so far The company s Exondys 51 is the first drug approved for the treatment of duchenne muscular dystrophy  DMD  in the United States  It was approved in September last year  Exondys 51 sales have witnessed an impressive rise so far this year  Sarepta registered sales of  51 4 million in the first half of 2017  The company  based on the positive trend  increased the 2017 sales outlook from  95 million to the range of  125 million to  130 million in its second quarter earnings press release Exondys 51 is a RNA based therapy for treating DMD  which is a fatal genetic disorder affecting the muscles in children around the world  There is a significant unmet need for this indication and Exondys 51 has the potential to address 13  of the total patient population  Meanwhile  the drug is under review in Europe Sarepta has other pipeline candidates  which are being developed for the treatment of DMD  which target other genes  Two late stage studies are currently ongoing The company has also collaborated with Catabasis Pharmaceuticals  Inc    NASDAQ CATB   and French company Genethon for developing solo and combination drugs for the treatment of DMD In a bid to develop drugs beyond DMD  Sarepta signed a collaboration agreement with Summit Therapeutics to acquire the rights to latter s utrophin modulator pipeline  The collaborations also generate revenues for Sarepta in the form of milestone payments The settlement of the patent litigation with BioMarin Pharmaceutical Inc    NASDAQ BMRN   in July 2017  pertaining to exon skipping technology used in DMD therapies was also a positive  Without this settlement  BioMarin could have restricted Sarepta from commercializing Exondys in certain jurisdictions  However  the settlement cost Sarepta a one time payment of  35 million and also future milestone and royalty payments However  Sarepta s dependence on a single product  Exondys 51  for near term growth is concerning  Lower than expected sales will be a setback for the company  Also  there are several companies developing RNA based therapies for DMD like Pfizer  NYSE PFE   BioMarin  PTC Therapeutics  Inc    NASDAQ PTCT   to name a few Sarepta has a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-09-24,Zacks Investment Research,https://www.investing.com/analysis/heres-why-sarepta-stock-is-up-more-than-60-so-far-in-2017-200215198,200215198
125327,346842,SRPT,4 Stocks To Watch Today  DVAX  IMGN  SGMO  SRPT,opinion,"Dynavax Technologies Corporation  NASDAQ DVAX   one of our swing trades  is doing great  jumping another 1 75  or 8   to 23 25  on 3 6 million shares traded on Monday  After the pop  explosive move  and wedge  we gave you a buy on it  This stock has gone from 15 00 to 23 00  and change  and it looks like it can go higher  My next target is in the 28 9 zone  It has 4 5  
ImmunoGen Inc  NASDAQ IMGN  is one of our swing trades that has worked beautifully this year  It stair stepped up beautifully  formed a recent falling wedge  popped out of it  and has been up every day  or seven days  since then  It s now up against resistance  On Monday  it was up 27 cents  or 3 53   to 7 92  on 4 million shares traded  It pulled back enough to close under 8 00  We ll just have to keep an eye on it  Resistance is at 8 84  If it gets through that  I m looking for 9 1 2  and then 12 00 as the next targets 
Swing trade Sangamo Therapeutics Inc  NASDAQ SGMO  broke out on Friday  followed through on Monday with a nice pop of 1 20  or 8   to 16 20  on 2 4 million shares traded  I like the action  I like the look of it  Lateral resistance is at 20 00  That s also the top of the channel  I m looking for a move to the 19 20 zone 
Sarepta Therapeutics Inc  NASDAQ SRPT   one of our swing trades  is working well  jumping 4 19  or 9   to 49 55  on 4 55 million shares traded on Monday  It crossed the consolidation zone  and closed at the high for the day going away  That s the best volume on an up day in a month  It looks to me like it s headed for 56 00  It has five  
On the long side  stocks included Abeona Therapeutics Inc  NASDAQ ABEO  Arbutus Biopharma Corp  NASDAQ ABUS   AcelRx Pharmaceuticals  Inc   ACRX   Bristol Myers Squibb Company  NYSE BMY   Dicerna Pharmaceuticals Inc  NASDAQ DRNA   Dynavax Technologies Corporation  DVAX   Endocyte  Inc   ECYT   General Motors Company  NYSE GM   Helios and Matheson Analytics Inc   HMNY   ImmunoGen  Inc   IMGN   Inovalon Holdings  Inc   INOV   Impax Laboratories Inc  NASDAQ IPXL   Kandi Technologies Group  Inc   KNDI   Kronos Worldwide  Inc   KRO   Pieris Pharmaceuticals  Inc   PIRS   uniQure N V   QURE   Rigel Pharmaceuticals  Inc   RIGL   Seattle Genetics  Inc   SGEN   Sangamo Therapeutics  Inc   SGMO   Spectrum Pharmaceuticals  Inc   SPPI   Square  Inc   NYSE SQ   Sarepta Therapeutics  Inc   SRPT   VirnetX Holding Corp  VHC   Voyager Therapeutics  Inc   VYGR   and Zogenix Inc  NASDAQ ZGNX  ",2017-10-02,Harry Boxer,https://www.investing.com/analysis/dvax-imgn-sgmo-srpt-200216552,200216552
125328,346843,SRPT,Sarepta  SRPT  Q3 Loss Narrows  Exondys 51 Sales View Raised,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   reported narrower than expected loss in the third quarter of 2017  The biotech also increased its 2017 sales outlook for Exondys 51  a treatment for Duchenne muscular dystrophy  DMD  and its only marketed drug  Shares were up almost 3 4  in after hours trading So far this year  Sarepta s shares are up 76 3   This compares favorably with 6 9  increase registered by the  during this period Narrower LossSarepta incurred a loss of 78 cents per share in the third quarter of 2017  narrower than the year ago loss of  1 18 as well as the Zacks Consensus Estimate of a loss of 86 cents Quarterly DetailsSarepta s Exondys 51  the first DMD treatment to gain approval in the United States  has shown strong performance in the quarter  In the third quarter  Sarepta recorded revenues of  46 million  up 31 4  sequentially  primarily attributable to sales of Exondys 51  The drug is under review in the EU  Revenues beat the Zacks Consensus Estimate of  38 7 million  In the prior year quarter  Sarepta had recognized no revenues Research and development  R D  expenses were  34 2 million in the second quarter  almost flat year over year  Although the company incurred lower manufacturing expense  it was partly offset by increased expenses in preclinical studies on PPMO platform  other follow on exons and increased patient enrollment in ongoing clinical studies Selling  general   administrative  SG A  expenses were  28 2 million  up 28 2  year over year  due to increased legal fees and worldwide commercial initiatives  compensation and other personnel expenses During the quarter  Sarepta incurred an expense of  25 6 million for settlement and license agreements related to a patent on exon skipping technology used in DMD therapies  The settlement with BioMarin Pharmaceutical Inc    NASDAQ BMRN   removed a major overhang on Sarepta In July 2017  Sarepta launched a Managed Access Program along with UK based Clinigen to ensure availability of Exondys 51 to DMD patients in certain geographic regions outside the United States  Moreover  it also signed a gene therapy research collaboration agreement with Genethon to jointly develop treatments for DMD Subsequent to the quarter in September 2017  Sarepta announced positive results from a phase I II study   4053 101   evaluating its Exon 53 skipping candidate  golodirsen  for the treatment of DMD patients  Golodirsen achieved a 100  response rate with 10 7 times increase in mean dystrophin protein from baseline  showing better efficiency than Exondys 51  The potential of golodirsen is impressive  and the company is planning a meeting with the FDA in the first quarter of 2018 to discuss the future course of action OutlookBased on sales trends witnessed in the third quarter  Sarepta updated its guidance for Exondys 51 sales to  150 million to  155 million in 2017  higher than its prior guidance of  125 million to  130 million  The Zacks Consensus Estimate for 2017 sales is pegged at  135 16 million Meanwhile Sarepta is looking to build its own DMD pipeline beyond Exondys 51 by developing other exon skipping treatments  Sarepta will have seven exon skipping candidates in its pipeline by the end of this year that could treat 75  80  of the DMD population Sarepta Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderSarepta Therapeutics carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the health care sector are Adaptimmune Therapeutics PLC   NASDAQ ADAP   and Agenus Inc    NASDAQ AGEN    Both the stocks carry a Zacks Rank  2  Buy   You can see  Adaptimmune s loss estimates narrowed from  1 03 to 95 cents for 2017 and from 95 cents to 90 for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the four trailing quarters with an average beat of 2 56   The company s shares are up 72 1  so far this year Agenus  loss estimates remained flat for 2017 and narrowed from  1 40 to  1 36 for 2018 over the last 60 days  The company came up with positive earnings surprises in three of the four trailing quarters with an average beat of 4 27  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/sarepta-srpt-q3-loss-narrows-exondys-51-sales-view-raised-200221290,200221290
125329,346844,SRPT,BioMarin  BMRN  Q3 Loss Narrows  Profit Guidance Raised,opinion,BioMarin Pharmaceutical Inc    NASDAQ BMRN   reported narrower than expected loss in the third quarter of 2017 but missed estimates for sales  The biotech also raised its previously issued adjusted net income guidance for 2017 So far this year  BioMarin s shares have underperformed the industry  While BioMarin s shares are down 0 4   the has witnessed an increase of 3 7  Loss Narrower than ExpectedThird quarter loss of 7 cents per share was narrower than the Zacks Consensus Estimate of a loss of 13 cents as well as the year ago loss of 22 cents  A one time upfront payment received from Sarepta Therapeutics  Inc    NASDAQ SRPT   primarily led to the narrower loss in the quarter  In July  BioMarin entered into a license and settlement agreement with Sarepta resolving the exon skipping patent litigation  Excluding this one time upfront payment of  31 5 million and a contingent consideration gain  adjusted loss per share was 27 cents in the third quarter Sales MissTotal revenue came in at  334 1 million  up 19  from the year ago quarter  Revenues  however  missed the Zacks Consensus Estimate of  348 million Quarterly DetailsProduct revenues were  298 8 million in the quarter  up 7  year over year Kuvan revenues rose 16  to  105 8 million  reflecting patient growth in North America and continued growth in the ex North American territories acquired in 2016  The number of patients on Kuvan therapy in the United States increased 9  in the third quarter Naglazyme sales declined 7  year over year to  72 1 million Vimizim contributed  90 3 million to total revenue  up 12  year over year  However  Vimizim sales declined 12 5  sequentially Naglazyme and Vimzim revenues vary on a quarterly basis  primarily due to the timing of central government orders from some countries  mainly Brazil Earlier this month  at its R D day  BioMarin had said that a slowdown in federal purchasing orders in Brazil have hurt Naglazyme and Vimizim product revenues in the third quarter Moreover  at that time  BioMarin had said that if the slowdown continues in the fourth quarter  it will only be able to meet the lower end of the total product revenue guidance   1 25 billion and  1 3 billion  not including milestone payment from Sarepta   However  in the earnings release  BioMarin said that since the R D day  the Brazilian Ministry of Health has initiated a purchasing process and it expects 2017 revenues to be within the guidance BioMarin received Aldurazyme royalties   totaling  22 4 million  down 5     from Sanofi s   NYSE SNY   Genzyme in the quarter Brineura received approval for the treatment of children with CLN2 disease   a form of Batten disease   both in the United States and the EU in the second quarter  The newest drug in BioMarin s portfolio generated sales of  3 1 million in the third quarter compared to  0 3 million in the second quarter  The company said the worldwide launch of Brineura was in line with expectations and it achieved sales in the United States and in the European countries of Germany  France  Italy and Argentina Research and development  R D  expenses declined 4 2  owning to lower spending on the Brineura program and the discontinuance of the Kyndrisa program last year  Selling  general and administrative  SG A  expenses increased 9 8  primarily due to increased expenses related to the acquisition of international Kuvan rights  costs associated with the Brineura launch and higher stock compensation expenses Pipeline UpdateRegarding pegvaliase  which has been developed to treat phenylketonuria  PKU   the company plans to submit a marketing application in Europe in the first quarter of 2018  slightly delayed from the end of 2017 as guided previously  In the United States  pegvaliase Biologics License Application  BLA  is currently under priority review  Last month  BioMarin announced that the FDA is not looking to hold an advisory panel meeting for the company s BLA for pegvaliase  Earlier this month  the company said the FDA is expected to give its decision in the first half of 2018 Meanwhile  two phase III studies  one in high dose  6e13 vg kg  and one in mid dose  4e13 vg kg   on its hemophilia A candidate valoctocogene roxaparvovec  formerly BMN 270  are expected to be initiated before the end of the year  Concurrent with the earnings release  BioMarin announced that the FDA has granted Breakthrough Therapy Designation to valoctocogene roxaparvovec based on positive data from phase I II study Earlier this month  BioMarin also announced that it has selected BMN 290  a small molecule drug  as its next development candidate  BMN 290 will be evaluated for the treatment of Friedreich s Ataxia  FA   a rare autosomal recessive disorder for which no disease modifying therapies are currently approved  An Investigational New Drug  IND  application to begin phase I studies is expected to be submitted in the second half of next year 2017 Outlook The company tightened its previously issued 2017 sales guidance  However  it raised its adjusted earnings guidance while lowering its expectations for operating costs BioMarin expects total revenue in the range of  1 29   1 32 billion  including milestone payment from Sarepta  compared with  1 285   1 335 billion previously   This represents year over year growth of 15 5  to 18 2  Vimizim sales are expected in the range of  400  420 million  previously  400  430 million   Kuvan sales are projected in the range of  400  420 million  previously  380  410 million   Naglazyme sales are projected in the range of  310  330 million  previously  300  330 million  Expenses related to R D are expected within  600  620 million  down from  610  640 million while SG A expenses are projected in the range of  530  550 million  compared with  530  560 million previously The bottom line  on an adjusted basis  is expected to turn positive in 2017  The company raised its 2017 adjusted net income guidance from  30    70 million to  60    80 million  Meanwhile  management is committed to profitability improvements over the longer term At the call  BioMarin also said it expects its present marketed products plus pegvaliase to drive the top line at a 15  compounded rate through 2020 while costs will rise at a lower level BioMarin carries a Zacks Rank  3  Hold   A better ranked stock in the biotech sector is Amgen  Inc    NASDAQ AMGN   with a Zacks Rank  2  Buy   You can see  Amgen s earnings estimates have risen over 1  in 2017 and 0 7  in 2018 over the last 30 days  The company delivered an average four quarter positive surprise of 5 25   Shares have risen 20 7  so far this year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/biomarin-bmrn-q3-loss-narrows-profit-guidance-raised-200221519,200221519
125330,346845,SRPT,4 Biotech Stocks To Better Your Financial Health This Winter,opinion,Despite challenges like rising competition  pipeline setbacks  slowdown in growth of mature products and a generic competition for certain key drugs  the pharma and biotech industry has strengthened this year except for a small correction recently  A lot of factors were responsible for the recovery of the sector this year  These include ramp up of new product sales  R D success and innovation  strong clinical study results  regular FDA approvals and a continued solid performance of legacy products However  after rallying 15 4  in the first nine months of 2017  January September   the  industry has declined 12 3  so far in the fourth quarter  Oct 1 to date   The decline can be attributable to both macro and industry specific factors  A major macro economic factor that resulted in this downside is the uncertainty surrounding the passing of the tax reform  aimed at bringing down the corporate tax to stimulate economic as well as employment growth The proposed tax reforms  if approved  will leave more cash in the hands of the biotech companies  The cash can be invested for mergers acquisitions  relatively fewer this year  compared with the last  It goes without saying that a cloud of ambiguity over the timely sanctioning of the U S  tax reform has cast a shadow over the fate of the biotech sector  Meanwhile  the overall third quarter results of the biotech companies were tepid  thereby leading to the sector s decline post October  Although most big biotechs surpassed earnings and sales expectations in the quarter  a continued decline in the top line due to competitive and pricing pressure weighed heavily on the stocks  Moreover  some biotechs also lowered their guidance for the year However  we believe the biotech space to be back on track once there is more clarity regarding the timing of the tax reform s approval  This is because the fundamentals of the sector remain robust  Hence  it s needless to add that it is definitely discreet to select stocks from a sector that is intrinsically strong Our proprietary methodology makes the above decision fairly simple  We have taken the help of the  to pick the best bets  To shortlist the stocks from the vast biotech space  we have at first tapered down to the stocks with a bullish Zacks Rank  1  Strong Buy  or 2  Buy  We have also taken into consideration a few more criteria to streamline our choice  These include better returns than the industry this year  upward estimate revisions of more than 5  and an average daily volume of more than 20 000  Our research shows that stocks with these positives offer the best upside potential Here are four stocks that fulfilled the aforesaid criteria XOMA Corporation   NASDAQ XOMA   is a biotech company active in the field of antibody technologies  It sports a Zacks Rank of 1  Shares of the company have skyrocketed 615 6  year to date  substantially outperforming its industry s 1 3  increase  Also  the stock has seen the Zacks Consensus Estimate for current year earnings being revised 67 8  upward and for 2018  19 5  upward respectively  over the last 30 days Sarepta Therapeutics  Inc    NASDAQ SRPT   is a commercial stage biopharmaceutical company  focusing on the discovery and development of RNA based therapeutics  targeting rare and infectious diseases  It carries a Zacks Rank  2  Shares of the company have surged 102 9  year to date  outperforming the industry  Further  the Zacks Consensus Estimate for 2017  improved 7 9  and for 2018  moved 18 5  up over the last 30 days Sangamo Therapeutics  Inc    NASDAQ SGMO   is a biopharmaceutical company associated with developing technologies in gene therapy  It carries a Zacks Rank of 2  Shares of the company have soared a massive 431 1  year to date  significantly outperforming the industry  In addition  the stock has seen the Zacks Consensus Estimate for current year earnings being revised 11  upward and for 2018  8 8  upward over the last 30 days Emergent BioSolutions Inc    NYSE EBS   is a Zacks  1 Ranked clinical stage biopharmaceutical company  Shares of the company have rallied 33 8  year to date  outperforming the industry it belongs to  Moreover  the Zacks Consensus Estimate for both 2017 and 2018 has been raised 11 6  and 1   respectively  over the last 30 days You can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2017-12-01,Zacks Investment Research,https://www.investing.com/analysis/4-biotech-stocks-to-better-your-financial-health-this-winter-200269917,200269917
125348,346863,SRPT,Sarepta   BioMarin Settle Patent Litigation On Exon Skipping ,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   and BioMarin Pharmaceutical Inc    NASDAQ BMRN    have settled their ongoing global patent litigation regarding the exclusive license on a patent pertaining to exon skipping technology used in Duchenne muscular dystrophy  DMD  therapies  BioMarin has licensed the global exclusive rights to its DMD patent estate for Exondys 51 and all future exon skipping products to Sarepta Therapeutics 
Exondys 51 is a key drug for Sarepta and is marketed for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping A look at the company s share price movement shows that  Sarepta has outperformed the Zacks categorized  industry so far this year  While the stock has rallied 23 5   the broader industry witnessed a gain of 8 8  
Per the agreement  Sarepta will make a one time payment of  35 million to Biomarin plus unspecified regulatory and commercial milestone payments for exons 51  45  53  and on future exon skipping products  Additionally  the company will pay BioMarin royalties for compounds skipping exons 51  45  and 53  and possibly on future exon skipping products 
BioMarin is entitled to receive 5  royalty on U S  sales  through 2023  of Exondys 51 and both exons 45 and 53 skipping compounds  which use the exon skipping technology  and 8  royalty on European sales of the products  through Sep 2024  
BioMarin  however  has held back the right to convert the license to a co exclusive right in case it decides to proceed with an exon skipping therapy for DMD 
If Sarepta had not made the settlement with BioMarin  the latter could preclude Sarepta from commercializing Exondys 51 in several jurisdictions  Thus the settlement of patent litigation and the global license from Biomarin removes a major overhang for Sarepta Sarepta Therapeutics  Inc  Price and Consensus
 

   Zacks Rank   Stocks to Consider
Sarepta currently carries a Zacks Rank  3  Hold   Better ranked health care stocks in the same space include Enzo Biochem  Inc    NYSE ENZ   and Sanofi   NYSE SNY    While Enzo Biochem sports a Zacks Rank  1  Strong Buy   Sanofi holds a Zacks Rank  2  Buy   You can see  
Enzo Biochem s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018  over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 55 83   The share price of the company has increased 64 8  year to date 
Sanofi s earnings per share estimates increased from  3 08 to  3 18 for 2017 and from  3 26 to  3 30 for 2018  over last 60 days  The company pulled off positive earnings surprises in three of the trailing four quarters  with an average beat of 5 10   The share price of the company has increased 18  year to date 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-07-19,Zacks Investment Research,https://www.investing.com/analysis/sarepta---biomarin-settle-patent-litigation-on-exon-skipping-200202192,200202192
125352,346867,SRPT,Sarepta Therapeutics  SRPT  Stock Surged 24  Today  Here s Why,opinion,"On Thursday  shares of Sarepta Therapeutics   NASDAQ SRPT   are surging  up almost 24  to  42 14 per share in morning trading after the biotech company reported second quarter revenues that blew past expectations in its earnings report yesterday after the bell 
Sarepta reported quarterly revenue of  35 million  which was  13 million above what analysts at Thomson Reuters expected and reflected sequential growth of 115   This outperformance was mainly due to strong sales from Sarepta s Duchenne muscular dystrophy  DMD  drug  Exondys 51 
The company also incurred a narrower than expected loss in Q2  reporting earnings of a loss of 65 cents per share and beating the Zacks Consensus Estimate of a loss of 92 cents per share  Investors should note that loss per share excludes restructuring costs and gain from asset sale but includes the impact of share based compensation expenses 
Sarepta ended the second quarter with a strong balance sheet  boasting  301 7 million in total cash  And earlier this week  the company announced it has settled a global patent litigation with BioMarin Pharmaceutical   NASDAQ BMRN   regarding the exclusive license on a patent pertaining to exon skipping technology used in DMD therapies  If Sarepta hadn t settled with BioMarin  the latter could have prevented Sarepta from commercializing Exondys 51 in several new areas 
Looking ahead  Sarepta updated its guidance for Exondys 51  and now expects sales for the therapy to range from  125 million to  130 million in 2017  higher than its previous forecast of  95 million  The company raised its outlook primarily because of increasing market penetration  start forms from physicians  and additional new patients in the second quarter  Exondys 51 is also close to breaking into the European Union market  a positive next step for a controversial drug that costs  300 000 a year 
SRPT is currently a  5  Strong Sell  on the Zacks Rank  Shares of Sarepta have gained over 22  year to date  and are up almost 52  over the past 12 months 
3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   
Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-07-20,Zacks Investment Research,https://www.investing.com/analysis/sarepta-therapeutics-(srpt)-stock-surged-24-today:-here's-why-200202477,200202477
125353,346868,SRPT,Sarepta Therapeutics Shares Gain On Better Than Expected Q2 Earnings,opinion,"Sarepta Therapeutics Inc  NASDAQ SRPT 
Sarepta Therapeutics  Inc   SRPT   a biopharmaceutical company yesterday reported their second quarter 2017 financial results with earnings at a loss of  1 15 per share which fell short of analyst expectations of a loss of  0 92 per share 
Sarepta reported second quarter revenues of  35 million which beat analyst expectations of  21 8 million 
Sarepta Therapeutics  Inc  CEO s Comments

 We are pleased with the progress made in the second quarter and anticipate continued momentum for the remainder of the year  In an effort to become a global pharmaceutical company  we settled our patent dispute with BioMarin  which gave us the ability to launch our Managed Access Program and reach patients around the world   said Douglas Ingram  Sarepta s president and chief executive officer   We are particularly excited with the continued success of the EXONDYS 51   eteplirsen  launch  the progress with our internal pipeline and strategic partnerships  all toward the goal of maintaining our leadership position in DMD  We look forward to numerous catalysts between now and the end of the year  Specifically  announcing the results of our 4053 101 dystrophin data and potentially having up to seven experimental DMD therapies in the clinic   

SRPT Technical Analysis

SRPT opened trading yesterday at  34 05 which was up from the previous day s trading close of  33 89  SRPT closed trading yesterday at  34 08 and spiked up after market to  39 10  equivalent to a 15  increase from the closing price  Taking a look at the daily chart we can see the last time SRPT traded above these levels we have to go back to January 10th when it traded at highs of  39 36 
Taking a closer look at the daily chart we can see that before the spike up SRPT had already been in an overall upward trend dating back to May 30th when it traded at  29 12  SRPT has a of 51 08 million shares and traded 2 26 times the normal daily trading  on Wednesday 
For trading purposes  I would like to see SRPT open trading on Friday above  37 50 and if it does I would be looking to take a long position at the bell  My stop loss would be  0 30 from my entry position fearing anything more than that and the stock would start to fill in the gap up 
Company Profile
Sarepta Therapeutics  Inc   a biopharmaceutical company  focuses on the discovery and development of RNA based therapeutics for the treatment of rare neuromuscular diseases  The company offers EXONDYS 51  a disease modifying therapy for the treatment of duchenne muscular dystrophy  DMD   which is a rare genetic muscle wasting disease caused by the absence of dystrophin 
It also develops SRP 4045 and SRP 4053  which are exon skipping clinical product candidates for the treatment of DMD  The company has a strategic alliance with Nationwide Children s Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement  as well as Galgt2 gene therapy program under the license agreement  Catabasis Pharmaceuticals  Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement  and Charley s Fund  Inc  to support the development of product candidates using its proprietary exon skipping technologies under the research agreement 
It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons  collaboration and license agreement with Summit  Oxford  Ltd  for the development of ezutromid  an utrophin modulator which is in phase II clinical trials for the treatment of DMD  and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy 
The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States  Sarepta Therapeutics  Inc  was founded in 1980 and is headquartered in Cambridge  Massachusetts  ",2017-07-20,Ticker.tv News,https://www.investing.com/analysis/sarepta-therapeutics-$srpt-stock-shares-gain-on-better-than-expected-200202315,200202315
125354,346869,SRPT,4 Stocks To Watch  AXTI  CENX  LABU  MX,opinion,"AXT Inc  NASDAQ AXTI  is doing very well moving up the ranks  Over the course of the last couple weeks this stock has done very well  It s in a rising channel  and pulled back slightly  but  for me  Thursday was a breakout day  popping 35 cents  or 4 8   to 7 60  on 836 765 shares traded  There is some resistance where the snapback high and another high came in  That may be a difficult takeout at the 7 85  95 zone  That s my immediate target  If it gets through that  I m looking at 8 1 4 3 4 at the old high  More importantly  look at the long term chart  It s a beautiful chart and has been spinning  or consolidating all year so far  coming down  popping up  and coming down again  For me  once it reaches my target  it s free sailing to 10 and then 12  It has 3 8  
Century Aluminum Co   NASDAQ CENX  had a very nice recovery  I was really worried about the pullback  Look how it held around the 50  and near the bottom trendline  not far from the major trendline  Coming off that  bouncing and forming a flag  it broke out  On Thursday  it was up another 66 cents  or 3 7   to 18 34  on 2 7 million shares traded  with 5 8  short  As the next targets  I m looking at 20 and 24 
The Direxion Daily S P Biotech Bull 3X ETF  NYSE LABU  broke out  pulled back  formed a nice little flag  or wedge  it had a nice volume day  and then stalled right at resistance  For about two weeks it couldn t get through resistance  On Thursday  it did break out  and jumped 2 64  or 3 9   to 70 05  on 2 2 million shares traded  We ll be watching 73 00 73 07 on Friday  and if it gets through that  it s headed toward 80 00  Biotech s may be on the verge of a big move 
MagnaChip Semiconductor Corporation  NYSE MX  is one of our favorites  After holding near support  it popped on Thursday  advancing 35 cents  or 3   to 11 35  on 452 103 shares traded  It will probably need to get to 11 60  65  and run toward 13 00 and 15 00  which are my next targets 
On the long side  stocks included AbbVie Inc   NYSE ABBV   ADTRAN  Inc   NASDAQ ADTN   AXT Inc   AXTI   Century Aluminum Co   NASDAQ CENX   Datawatch Corporation  NASDAQ DWCH   Esperion Therapeutics  Inc   NASDAQ ESPR   Blackhawk Network Holdings  Inc   NASDAQ HAWK   Kite Pharma  Inc   NASDAQ KITE   Direxion Daily S P Biotech Bull 3X ETF  NYSE LABU   Seres Therapeutics  Inc   NASDAQ MCRB   Kopin Corporation  NASDAQ KOPN   Seres Therapeutics  Inc   NASDAQ MCRB   MagnaChip Semiconductor Corporation  NYSE MX   Nektar Therapeutics  NASDAQ NKTR   Impinj  Inc   NASDAQ PI   Sarepta Therapeutics  Inc   NASDAQ SRPT   and Zion Oil   Gas  Inc   NASDAQ ZN  ",2017-07-21,Harry Boxer,"https://www.investing.com/analysis/axti,-cenx,-labu,-mx-200202518",200202518
125361,346876,SRPT,Why Is Sarepta  SRPT  Down 9 9  Since The Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Sarepta Therapeutics  Inc    NASDAQ SRPT    Shares have lost about 9 9  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to the stock s next earnings release  or is it due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers Sarepta Q2 Loss Narrows  Ups Exondys 51 Sales ViewSarepta incurred a loss of  0 65 per share in the second quarter of 2017  narrower than the year ago loss of  1 35 as well as the Zacks Consensus Estimate of a loss of  0 92 Loss per share excludes restructuring costs and gain from asset sale but includes the impact of share based compensation expenses Quarterly DetailsIn the first quarter  Sarepta recorded revenues of  35 million  up 115  sequentially  primarily due to sales of Exondys 51  Revenues beat the Zacks Consensus Estimate  In the prior year quarter  Sarepta recognized no revenues Adjusted research and development  R D  expenses were  34 6 million in the second quarter  down 16 4  year over year  due to lower manufacturing expenses owing to the capitalization of inventory following the approval of Exondys 51 by the FDA  Adjusted selling  general   administrative  SG A  expenses were  25 4 million  up 92 1  year over year  due to increased legal fees and commercial initiatives  compensation and other personnel expenses Both R D and SG A expenses exclude the impact of restructuring costs and share based compensation expenses Sarepta received a one time payment of  22 million from Summit Therapeutics for completing enrolment in a phase II study evaluating utrophin modulator  ezutromidOutlookBased on sales trends witnessed in the second quarter  Sarepta updated its guidance for Exondys 51 sales to  125 million to  130 million in 2017  higher than its prior guidance of  95 million  The Zacks Consensus Estimate for 2017 sales is pegged at  103 51 million 
How Have Estimates Been Moving Since Then  
Following the release  investors have witnessed an upward trend in fresh estimates  There has been one revision higher for the current quarter Sarepta Therapeutics  Inc  Price and Consensus
    VGM Scores
At this time  Sarepta s stock has a poor Growth Score of F  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated also a grade of F on the value side  putting it in the fifth quintile for this investment strategy 
Overall  stocks has an aggregte VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate investors will probably be better served looking elsewhere 
Outlook
Estimates have been trending upward for the stock  The magnitude of these revisions also looks promising   Notably  the stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-08-22,Zacks Investment Research,https://www.investing.com/analysis/why-is-sarepta-srpt-down-99-since-the-last-earnings-report-200208758,200208758
125384,346899,SRPT,Sarepta Therapeutics  Stock Shares Fall On Poor Fourth Quarter Earnings,opinion,"Sarepta Therapeutics Inc  NASDAQ SRPT 
Sarepta Therapeutics  Inc   SRPT   a biopharmaceutical company yesterday reported their fourth quarter and full year 2016 financial results  Sarepta reported fourth quarter adjusted earnings of a loss of  1 58 per share which fell short of analyst expectations of a loss of  1 26 per share  Sarepta reported fourth quarter revenues of  5 4 million which beat analyst expectations of  5 million 
Sarepta Therapeutics  Inc  CEO s Comments

2016 was a transformative year  with the FDA accelerated approval of EXONDYS 51  In 2017  we are focused on our strategy to build shareholder value by executing a successful launch of EXONDYS 51 in the US  reaching more patients through global expansion  and rapidly advancing our pipeline through internal and external development efforts   said Edward Kaye  Sarepta s chief executive officer   We are pleased with the interest from the patient and physician community for EXONDYS 51  and with the progress we have made in discussions with payers  We believe this positions us well for potential growth and towards our goal at Sarepta Therapeutics to help all boys with Duchenne muscular dystrophy  

SRPT Technical Analysis


SRPT opened trading yesterday at  32 99 which was up from the previous day s trading close of  32 71  Shares closed trading yesterday at  31 11 and spiked down after market to  26 66  equivalent to a 14  decrease from the closing price  Taking a look at the daily chart we can see that the last time SRPT traded below these levels we have to go all the way back to September 13th  2016 when it traded at  25 60 
Taking a closer look at the daily chart we can see that before the spike down SRPT had already been in an overall downward trend dating back to October 5th  2016 when it traded at  62 35  SRPT has a float of 48 2 million shares and traded 1 19 times the normal daily trading volume on Tuesday 
For trading purposes  I would like to see SRPT open trading on Wednesday below  28 15 and if it does I would be looking to take a short position at the bell  My stop loss would be  0 30 from my entry position fearing anything more than that and the stock would start to fill in the gap down 
Company Profile
Sarepta Therapeutics  Inc   a biopharmaceutical company  focuses on the discovery and development of RNA based therapeutics for the treatment of rare  infectious  and other diseases 
The company s lead product candidate is Eteplirsen  an antisense phosphorodiamidate morpholino oligomer therapeutic  which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy  DMD   a genetic muscle wasting disease caused by the absence of dystrophin 
It is also developing exon skipping drugs for the treatment of DMD  and therapeutic candidates for the treatment of infectious diseases  such as influenza  Marburg  and Ebola 
The company has a strategic alliance with Charley s Fund  Inc  to support the development of product candidates using its proprietary exon skipping technologies  a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD  and a research collaboration agreement with Catabasis Pharmaceuticals  Inc to explore a combination drug treatment approach for DMD 
It also has a research and option agreement with Nationwide Children s Hospital for microdystrophin gene therapy program  Sarepta Therapeutics  Inc  was founded in 1980 and is headquartered in Cambridge  Massachusetts ",2017-03-01,Ticker.tv News,"https://www.investing.com/analysis/sarepta-therapeutics,-inc.-$srpt-stock-shares-fall-on-poor-fourth-qu-200177434",200177434
125385,346900,SRPT,Economic Calendar And Watch List March 1st 2017,opinion,"Economic Calendar   Watch List
Morning Notes
U S  Futures are trading at new record highs this morning while European stocks are trading higher by  1 5  on new signs of global economic strength and President Trump s speech to Congress yesterday evening  Asian stocks closed predominantly higher 
Technicals

The SPY  NYSE SPY  is gapping sharply higher this morning to new record highs and therefor no resistance  Near term support will lie at the high of Monday s range at  237 71  followed by yesterday s high at  236 95  then  236 01   235 41   235 09   233 95  and  233 85 
Small Cap Watch List
 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open 
  Others On Watch  
BBY  NYSE BBY 
SRPT  NASDAQ SRPT 
PANW  NYSE PANW 
WTW  NYSE WTW 
Economic Calendar
8 30 January personal spending expected  0 3 
9 45 Revised February Markit manufacturing PMI expected  0 2 to 54 5
10 00 February  ISM manufacturing index expected unch at 56
10 00 January construction spending expected  0 6 
10 30 EIA Weekly Petroleum Status Report
1 00 Dallas Fed President Robert Kaplan speaks
2 00 Beige Book
Notable Earnings Before Open
American Eagle Outfitters  NYSE AEO    EPS Est   0 38 Best Buy  BBY    EPS Est   1 67 Dollar Tree  NASDAQ DLTR    EPS Est   1 32
Lowe s Cos   NYSE LOW   LOW    EPS Est   0 79
Notable Earnings After Close
Juno Therapeutic  NASDAQ JUNO   JUNO    EPS Est    0 61 Shake Shack  NYSE SHAK    EPS Est   0 09",2017-03-02,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-list-3-1-2017-200177481,200177481
125386,346901,SRPT,SRPT  Expected Major Breakout With 50  Upside,opinion,After extensive research  I believe Sarepta Therapeutics Inc  NASDAQ SRPT  will likely breakout this week  The chart has consolidated for a long period  slowly falling from over  60 after the last fantastic bit of drug news  The breakout trend line seen in the chart below continues to be hammered and should give way on the next move up  I also believe there will be likely drug news in the next few weeks which will propel the stock to as high as  45  That is a 50  upside target  This company is on the cutting edge of multiple biotech drug treatments and at its current valuation  offers an amazing opportunity  I am looking to buy some this week  the second the stock crosses above the breakout trend line ,2017-04-03,Jenny Rebekka,https://www.investing.com/analysis/expected-major-breakout-with-50-upside...-200181087,200181087
125387,346902,SRPT,Sarepta  SRPT  Q1 Loss Narrows  Exondys 51 Sales Pick Up,opinion,Sarepta Therapeutics  Inc    NASDAQ SRPT   reported narrower than expected loss in the first quarter of 2017  Meanwhile  the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased in the first quarter  coupled with progress in the reimbursement programs Sarepta posted a loss of 70 cents per share in the first quarter of 2017  narrower than the year ago loss of  1 31 as well as the Zacks Consensus Estimate of a loss of 85 cents  Loss per share excludes restructuring costs and gain from asset sale but includes the impact of share based compensation expenses So far this year  Sarepta s shares are up 26 6   This compares favorably with 4 8  increase registered by the Zacks classified  industry during this period Quarterly DetailsSarepta gained accelerated approval for Exondys 51 in the U S  in Sep 2016 for the treatment of patients suffering from Duchenne muscular dystrophy  DMD  amenable to exon 51 skipping  Exondys 51 is the company s first product to receive marketing approval   In the U S   Sarepta commenced shipments of Exondys 51 at the end of the third quarter of 2016  The drug is under review in EU In the first quarter  Sarepta recorded revenues of  16 3 million  up 201  sequentially  primarily due to sales of Exondys 51  Revenues beat the Zacks Consensus Estimate  In the prior year quarter  Sarepta recognized no revenues Adjusted research and development expenses were  27 2 million for the first quarter  down 24 2  year over year  due to lower manufacturing expenses owing to the capitalization of inventory following the approval of Exondys 51 by the FDA  Adjusted selling  general   administrative  SG A  expenses were  22 2 million  up 33 7  due to increased legal fees and commercial initiatives  compensation and other personnel expenses Both R D and SG A expenses exclude the impact of restructuring costs and share based compensation expenses Sarepta earned proceeds of  125 million from the sale of its rare pediatric disease priority review voucher  PRV     gained at the time of Exondys 51 approval   to Gilead Sciences Inc    NASDAQ GILD    The sale increased funds  which should support its DMD pipeline development OutlookBased on sales trends witnessed in the first quarter  Sarepta said it expects Exondys 51 to generate  95 million in 2017  exceeding its prior guidance of  80 million  The Zacks Consensus Estimate for 2017 is pegged at  95 04 million Meanwhile Sarepta is looking to build its own DMD pipeline beyond Exondys 51 by developing other exon skipping treatments  Sarepta has about eight exon skipping candidates in its pipeline that could treat 75  80  of the DMD population Sarepta Therapeutics  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderSarepta Therapeutics carries a Zacks Rank  4  Sell  A couple of better ranked stocks in the health care sector include Heska Corporation   NASDAQ HSKA   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    While Heska sports a Zacks Rank 1  Strong Buy   Regeneron carries a Zacks Rank  2  Buy   You can see  Heska s earnings estimates increased from  1 53 to  1 65 for 2017 and from  1 80 to  2 01 for 2018 over the last 60 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 291 54   The company s shares are up 47 2  so far this year Regeneron s earnings estimates remained almost stable for 2017 and 2018  respectively  over the past 30 days  The company recorded positive earnings surprises in three of the last four quarters  the average being 8 08  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-04-27,Zacks Investment Research,"https://www.investing.com/analysis/sarepta-(srpt)-q1-loss-narrows,-exondys-51-sales-pick-up-200186040",200186040
125388,346903,SRPT,Here Are 3 Of Perceptive s Latest Filings And The Catalysts To Watch,opinion,"Biotechnology investors will often look to piggyback the positions of hedge funds in an attempt to take advantage of the latter s due diligence resources  A hedge fund doesn t take a position in a company without instigating a large and resource intensive due diligence program   a program that the vast majority of retail investors couldn t hope to replicate in their own time 
One of the most widely piggybacked fund in the sector is Perceptive Advisors  Perceptive has grown from launch back in 1999 to manage more than  1 billion in assets today  and along the way  it s founder and long time manager  Joseph Edelmen  has developed into something of a household name among retail biotechnology traders and investors 
Edelmen has taken positions in some of biotech s biggest names   Perceptive s three lead holdings by dollar amount are Neurocrine Biosciences Inc  NASDAQ NBIX   Sarepta Therapeutics Inc  NASDAQ SRPT  and TESARO Inc  NASDAQ TSRO   but he s not afraid to pick up an exposure to a smaller  development stage company in anticipation of it reaching commercialization with one or more of its development assets 
In fact  this approach is at the core of his allocation strategy 
With this in mind  here are three companies in which Edelmen has increased or taken a stake in the last few months  with a look at what we think he sees in each    VBI Vaccines Inc  NASDAQ VBIV  Ordinary Shares        Shares held at March 31  2017  8 602 824 Value at last close  May 9   28 85    35 35 million Portion of company represented by shares  20 50 
First up  VBI Vaccines  This company has developed a technology that allows it to create vaccines that are both able to target infectious diseases for which preventative and combative vaccinations are not yet available and to improve on the current standard of care vaccinations in the sector  The technology is called the Envelope Virus Like Particle  eVLP  platform  and it harnesses mammalian cells  as opposed to the plant cells used in the vast majority of available vaccines  and specifically  the ability of these cells to closely mimic the viruses they are targeting  to introduce rapid and strong immunogenicity 
The technology has spawned a number of assets  which are currently under investigation across a range of target indications  cytomegalovirus  CMV   glioblastoma multiforme  GBM  and Zika  to name just three 
The real value driver right now  however  and the one we think Edelmen had his eye on when he first picked up an exposure to VBI  is called Sci B Vac  It s a hepatitis B vaccine that differentiates itself from the current standard of care vaccine in the space  Engerix  through its expressing of a range of hepatitis B antigens  Antigens are the part of a virus  or in this instance  the vaccine that s trying to mimic a virus  that the immune system is trained to recognize  Once this recognition takes place  the signal goes out instructing the body to attack the virus in question 
The higher the degree of recognition  the quicker and stronger the response  By incorporating three separate hepatitis B associated antigens into its Sci B Vac asset  VBI seeks to take advantage of this improved response concept 
The drug is already approved in fifteen countries globally  but the real return for shareholders will come when it picks up approval in Europe  the US and Canada  VBI needs to conduct a phase III study  the data from which it can use to underpin registration applications in these three markets  and recent management communication has detailed a pretty clear path forward in both Europe and Canada  We expect similar progress in the US near term  before the end of the year  and  subsequently  for the phase III study to get underway 
Once the phase III study up and running  milestones and catalyst should stack up  contributing to value appreciation as and when they are hit    Global Blood Therapeutics Inc  NASDAQ GBT         Shares held at March 31  2017  3 128 978 Value at last close  May 9   28 85    90 20 million Portion of company represented by shares  8 38 
Next  Global Blood Therapeutics  This one is a California based biotechnology company that is working to develop treatments within two specific target indications   sickle cell disease  SCD  and idiopathic pulmonary fibrosis  IPF   The drug under investigation  in both instances  is an asset called GBT440   a so called anti sickling hemoglobin modifier 
The SCD indication is the lead right now  and Global Blood Therapeutics is currently putting the drug through its paces as part of a phase 3 program designed to investigate safety and efficacy of GBT440 in the SCD population  Data to date has been strong  and  as Edelemen will be well aware  this is a patient population that very much needs a fresh treatment option 
The current standard of care therapies in the space are symptom targeted and  in a large portion of the population  don t work particularly well  if at all  If Global Blood Therapeutics can get its asset through phase 3 with a successful topline readout  and beyond that  if it can pick up a green light for commercialization from the FDA  there s a peak sales target for the drug of  2 7 billion 
When taken against the company s current market capitalization of  1 3 billion  there s clear potential for upside revaluation on a GBT440 approval in SCD  even if the IPF program falls flat 
Buyout rumors have fueled speculative attention recently  with a  3 billion price tag the most widely acknowledged as representative of the company s value ahead of its phase III completion    Amicus Therapeutics Inc  NASDAQ FOLD         Shares held at March 31  2017  17 296 672 Value at last close  May 9   28 85    115 02 million Portion of company represented by shares  12 10 
This one is a biotechnology company that focuses on the development of rare diseases in the US  It is based out of New Jersey and its principal product is what s called migalastat HCl  or Galafold  The drug is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease and it is currently the center of a commercialization effort in Europe  The European Medicines Agency  EMA  approved the asset last year and the majority of the last 12 months have been spent preparing for  and more recently executing on  a sales push across major regions in Europe 
The UK  Italy and France just converted to full reimbursement  which is the target aim for a launch in the most of the various regions that comprise the European Union  and Germany looks set to follow suit near term  With these four regions in place  the lion s share of the European market will be accessible  and realistic from a revenues generation perspective  
Japanese approval should come next  with the company targeting the second quarter of this year  so  at some point within the next month or two at the outside  for New Drug Application  NDA  submission in the region  There s a big market for the drug in Japan and any feedback on the submission has the potential to inject some upside momentum into the company s market capitalization as and when it hits press  assuming it s positive 
Beyond Europe and Japan  Amicus is trying to push for approval in the US  although this is likely more of a long term catalyst  The drug is available as part of some expanded access programs right now  but the path to FDA approval is not yet 100  clear and near term value for Amicus is going to derive from the above mentioned regions primarily 
The company just put out some numbers  and has reported that over 300 patients are taking the drug right now  this is a relatively strong number given population size  based on sales of the drug during the first quarter of this year came in at  4 2 million   a sequential increase of close to 50  on the  2 8 million recorded during the final quarter of 2016 ",2017-05-11,Samuel Rae,https://www.investing.com/analysis/here-are-three-of-perceptive's-latest-filings-and-the-catalysts-to-watch-200188500,200188500
125389,346904,SRPT,Sarepta Looks To Focus On Exondys 51   DMD Pipeline In 2017,opinion,We issued an updated research report on Cambridge  MA based Sarepta Therapeutics  Inc    NASDAQ SRPT   on Jun 28 Sarepta is a commercial stage biopharmaceutical company that focuses on the discovery and development of RNA based therapeutics targeting rare and infectious diseases  especially Duchenne muscular dystrophy  DMD  So far this year  Sarepta s share price has outperformed the Zacks categorized  industry  The stock has surged 21 6  compared with an increase of 10 0  for the broader industry Sarepta received a boost with the FDA s accelerated approval for Exondys 51  eteplirsen  in the U S  in Sep 2016  Exondys 51 is the first approved disease modifying therapy for DMD in the U S  as well as the company s first product to receive marketing approval  The drug is under review in the EU The company is conducting a confirmatory phase III study   PROMOVI   evaluating the clinical benefits of the drug as part of the accelerated approval process  The study evaluates whether Exondys 51 improves motor function in DMD patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping In the first quarter  Sarepta recorded revenues of  16 3 million  up 201  sequentially  primarily due to sales of Exondys 51  Also  the company recognized a narrower per share loss of 70 cents from the year ago loss of  1 31  However  selling  general   administrative  SG A  expenses have increased due to higher legal fees and commercial initiatives  compensation and other personnel expenses related to commercialization of Exondys 51 Moreover  based on sales trends witnessed in the first quarter  the company expects Exondys 51 to generate  95 million in revenues in 2017  exceeding its prior guidance of  80 million Meanwhile  Sarepta is focused on building its DMD pipeline beyond Exondys 51  The company has eight exon skipping candidates in its pipeline that is estimated to treat 75  80  of the DMD population  The company is also evaluating candidates targeting exon 53  Study 4053 101 6 to15 years  ambulatory  data expected this year  and exon 45 53  Study 4045 301 7 to16 years  ambulatory   In addition  Sarepta is conducting Study 4045 101 in non ambulatory boys aged 7 to 21 years amenable to skipping exon 45 Meanwhile  after the approval of its DMD drug  Sarepta collaborated with Catabasis Pharmaceuticals in 2016 to conduct a joint research to explore a combination drug treatment approach for DMD Apart from DMD  the company develops treatments for infectious diseases including Marburg virus  Ebola virus and influenza  which is primarily funded and supported by the National Institutes of Health s National Institute of Allergy and Infectious Diseases  NIAID   Along with it  Sarepta has an exclusive license and collaboration agreement with Summit Therapeutics plc   NASDAQ SMMT   for the rights to the latter s utrophin modulator pipeline However  Pfizer Inc    NYSE PFE    BioMarin  PTC Therapeutics  Inc    NASDAQ PTCT   and many more are developing RNA based treatments for DMD  With small and major companies developing their own pipeline  the DMD market is set to become competitive in the future Sarepta Therapeutics  Inc  Price and Consensus   Zacks RankSarepta currently holds Zacks Rank  2  Buy   You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-06-29,Zacks Investment Research,https://www.investing.com/analysis/sarepta-looks-to-focus-on-exondys-51---dmd-pipeline-in-2017-200198581,200198581
125410,346925,SRPT,Sarepta Summit Ink Deal For Utrophin Modulator DMD Drugs,opinion,"Sarepta Therapeutics  Inc    NASDAQ SRPT   announced that it has entered into an exclusive license and collaboration agreement with Summit Therapeutics plc   NASDAQ SMMT   for the rights to the latter s utrophin modulator pipeline for the treatment of Duchenne muscular dystrophy  DMD  Although Sarepta s shares remained mostly stable  having gained a mere 0 9   Summit s stock price surged 65 9  on the news  With this spike  Summit s shares touched a new 52 week high of  19 75 on Oct 4  eventually closing a little lower at  14 35 Terms of the DealSummit received an upfront payment of  40 million from Sarepta  In addition  the company is eligible to receive  522 million in milestone payments  Moreover  Summit is eligible to receive development and regulatory milestones related to its next generation utrophin modulators  The company is also entitled to additional fees  milestones  and royalties if Sarepta exercises its option for Latin American rights Meanwhile  research and development costs will be shared between Sarepta and Summit on a 45 55 basis starting 2018 Benefits for SareptaSarepta acquired the rights to Summit s utrophin modulator pipeline  including its lead candidate  ezutromid  in Europe  in Turkey and the Commonwealth of Independent States Ezutromid is currently being evaluated in a phase II study   PhaseOut DMD   with 24 week biopsy data from the initial group of patients anticipated in the second quarter or third quarter of 2017 The candidate enjoys Orphan Drug status for DMD in both the U S and the EU  which will make it eligible for additional regulatory support and market exclusivity upon approval  In the U S   ezutromid also has Fast Track and Rare Pediatric Disease designation SAREPTA THERAP Price
    Benefits for SummitThrough this partnership  Summit will gain access to Sarepta s research and development capabilities in the development of disease modifying therapies for DMD Summit believes that the receipt of payments under the collaboration will be sufficient for the company s operating expenses and capital expenditure requirements through Dec 31  2018 SUMMIT THERAPTC Price
    Our TakeEver since Sarepta gained approval for its DMD drug  EXONDYS 51  the company has been pursuing strategic collaborations for the development of its disease modifying DMD pipeline We remind investors that last week  Sarepta entered into a joint research collaboration with Catabasis Pharmaceuticals  Inc    NASDAQ CATB   to explore a combination drug treatment approach for DMD Sarepta currently carries a Zacks Rank  3  Hold   while Summit is a Zacks Rank  2  Buy  stock A Stock to ConsiderAchillion Pharmaceuticals  Inc    NASDAQ ACHN   is a favorably placed stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  The company has posted a positive earnings surprise in each of the last four quarters  with an average beat of 364 79  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-04,Zacks Investment Research,https://www.investing.com/analysis/sarepta-summit-ink-deal-for-utrophin-modulator-dmd-drugs-200157216,200157216
125411,346926,SRPT,Catabasis Presents Data From DMD Study On Edasalonexent,opinion,"Catabasis Pharmaceuticals  Inc    NASDAQ CATB   announced that it has presented results from the part A of the MoveDMD study  phase I II  on edasalonexent at the congress of the World Muscle Society Edasalonexent  a molecule that inhibits a protein called NF kB is being developed for the treatment of patients with Duchenne muscular dystrophy  DMD  The part A results revealed that a pre selected NF kB gene set was significantly inhibited in whole blood mRNA in boys with DMD  who were dosed with edasalonexent  67 mg kg and 100 mg kg  for one week Currently  edasalonexent is being evaluated in the part B  phase II  of the study to assess the safety and efficacy of the candidate for 12 weeks  Top line data from the study are expected in the first half of 2017 The candidate is also being assessed in an open label extension  part C  of the phase II portion of the study  Patients completing part B is eligible to be enrolled in the extension study  They will receive edasalonexent for 36 weeks CATABASIS PHARM Price
    In the U S   edasalonexent enjoys Orphan drug  Fast Track and Rare Pediatric Disease designations for the treatment of DMD  Edasalonexent also enjoys Orphan Medicinal Product designation for this indication in the EU DMD  a devastating and debilitating disease  represents a market with significant unmet medical need We remind investors that last month the FDA has granted accelerated approval to Sarepta Therapeutics  Inc  s   NASDAQ SRPT   EXONDYS 51  the first DMD drug to be approved in the U S Meanwhile  earlier this year  BioMarin Pharmaceutical Inc    NASDAQ BMRN   had received a Complete Response Letter from the FDA for its DMD candidate  Kyndrisa Also  Mallinckrodt Public Limited Company   NYSE MNK   is developing Synacthen Depot for the treatment of DMD  In Aug 2016  the company received Fast Track designation in the U S  for its Investigational New Drug  IND  application for Synacthen Depot in this indication Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-10,Zacks Investment Research,https://www.investing.com/analysis/catabasis-presents-data-from-dmd-study-on-edasalonexent-200158206,200158206
125412,346927,SRPT,2 Biotech Beauties Poised To Breakout,opinion,"can be made not from investing in Big Pharma companies  but from smaller cap stocks in the biotech sector  We ve pinpointed two small biotech companies poised to break out  VBI Vaccines Inc  NASDAQ VBIV  and InMed Pharmaceuticals Inc  SNX IN  
VBI s vaccines are unique because they harness a proprietary technology created by the company  called an enveloped virus like particle  VLP   This allows efficient and effective delivery of the vaccine by mimicking the ways the viruses travel through the body s systems 
VBI is currently developing two vaccines for diseases that have high demand for prevention  hepatitis B and the cytomegalovirus  similar to Zika  
But VBI isn t just a shot in the dark  floating alone in the scary biotech space  There are some big names standing behind the small cap   111 million  company  Perceptive Advisors  biotech focused fun  the Perceptive Life Sciences Fund  which is led by CEO Joseph Edelman  has bought a sizeable stake  as has Arch Ventures  helmed by Robert Nelsen  and Opko Health Inc  NASDAQ OPK   with CEO Dr  Phillip Frost 
These are biotech investors with impressive track records   from Edelman s stunning 5 000  play on Sarepta Therapeutics Inc  NASDAQ SRPT  to Nelson s early bid on Juno Therapeutic  NASDAQ JUNO   to Frost s own IVAX  a vaccination company that he sold to Teva Pharmaceutical Industries  NYSE TEVA  for more than  7 billion 
VBI s CEO  Jeff Baxter  is also in a good place to lead his company to success  He has a long and impressive resume that includes stints at Glaxo  as well as at Unilever  LON ULVR  and British American Tobacco  LON BATS   
With its impressive roster of financial backers  as well as a seasoned exec  VBI is the best small cap play for investors  from the growing vaccine market 
InMed is a mere penny stock   currently priced around 15 cents per share   but it packs a wallop  The company has created its own proprietary biosynthesis drug development platform that derives cannabinoids from plants in an unprecedentedly cost effective and efficient manner  This process can help the company develop treatments at a faster pace than any other medical marijuana treatment maker 
InMed s chief medical officer  Dr  Ado Muhammed  formerly served as associate medical director at mid cap marijuana biotech GW Pharmaceuticals Plc  NASDAQ GWPH  and is one of the few scientists who has had clinical experience with a cannabinoid based drug that has already been approved by the FDA  Sativex  GM s blockbuster MS treatment  
InMed is developing therapies for conditions such as epidermolysis bullosa  EB  a serious pediatric skin disease   as well as glaucoma  There s the potential for as much as  1 billion for a successful EB drug   currently  there s no therapy on the market 
That would give InMed and its investors some incredible profits  as well as making the stock ripe for the picking by any Big Pharma player 
The most exciting biotech gains are currently   and will continue to be   made in from marijuana based treatments  As pot picks up in pharmaceutical popularity  prepare your portfolio for sky high profits ",2016-11-12,John Persinos,https://www.investing.com/analysis/two-biotech-beauties-poised-to-breakout-200164273,200164273
125413,346928,SRPT,3 Stocks To Add To Your Portfolio As Biotech M A Hopes Rise,opinion,"2016 has not been a great year for mergers and acquisitions  M As  in the pharma and biotech sector although some headline deals like the Pfizer   NYSE PFE   Medivation and the Teva Actavis Generics acquisitions were completed this year  While expectations were high that this year too  the pharma and biotech sector would see lots of M A activity that did not happen  with the focus being mostly on small bolt on acquisitions and licensing deals and agreements Will a Trump Presidency Trigger More M A Deals for Biotechs Although it may be too early to speculate  there is a lot of chatter about a possible increase in M As in the pharma and biotech sector now that Donald Trump is President elect   Basically  the Trump victory is being viewed as a positive for the biotech and pharma sector  There are several reasons for this  the foremost being the drug pricing issue  The general view is that a Hillary Clinton win would have been a negative for pharma and biotech stocks given her stand on rising drug prices and her plans to address the excessive price hikes of treatments that have been available for years and to lower drug prices for all Americans  With Clinton s frequent rhetoric regarding drug prices  biotech and pharma stocks have been under intense pressure for more than a year Trump  on the other hand  has not been so vocal about drug pricing though he did call for price transparency from all healthcare providers and drug re importation  Not just that  his pro business stand is also expected to benefit the sector  Major biotech and pharma companies should gain from Trump s proposed tax plan and proposal to repatriate corporate profits held offshore at a one time tax rate of 10  With focus on drug pricing expected to subside and given the possibility of repatriation of funds  hopes are up that M A activity will pick up with companies like Pfizer  Merck  NYSE MRK   Johnson   Johnson  NYSE JNJ  expected to take the lead  Big companies with deep pockets often look to replenish and boost their pipelines as well as portfolios by acquiring companies with innovative pipelines and technology  Stock PicksHere we highlight 3 companies that have often been considered attractive take over targets and have a Zacks Rank of  1  Strong Buy  or  2  Buy  ARIAD Pharmaceuticals Inc    NASDAQ ARIA    Cambridge  MA based ARIAD focuses on bringing innovative treatments for rare cancers to market  ARIAD  which already has a marketed product  Iclusig  in its portfolio  could well become a two product firm as early as 2017 if it gains FDA approval for brigatinib in April  Meanwhile  Iclusig s growth should be driven by new patient starts  extended treatment duration and label expansion  ARIAD s product portfolio  potential brigatinib approval and its next wave of discovery and development programs such as AP32788 and the immuno oncology program make it an attractive acquisition target  The Zacks Rank  2 stock has a solid earnings track record having surpassed expectations in each of the last three quarters 
ARIAD PHARMA Price and Consensus   Incyte Corporation   NASDAQ INCY    Wilmington  DE based Incyte has two marketed products in its portfolio and a strong pipeline  Flagship product  Jakafi   a JAK1 JAK2 inhibitor   looks well positioned for growth and is expected to bring in sales of  850    855 million in 2016  Moreover  with Gilead presenting mixed results on its experimental JAK inhibitor  momelotinib  the competitive threat for Jakafi seems to have gone down considerably  Incyte  a Zacks Rank  2 stock  has a robust pipeline as well with a focus on the highly sought after immuno oncology space  Jakafi s strong performance along with the company s pipeline makes Incyte an attractive acquisition target 
INCYTE CORP Price and Consensus   Exelixis  Inc    NASDAQ EXEL    South San Francisco  CA based Exelixis is also focused on bringing cancer treatments to market  Approved products include Cabometyx  advanced kidney cancer   Cometriq  certain forms of thyroid cancer  and Cotellic  advanced melanoma   Exelixis  earnings track record is good having surpassed expectations in three of the last four quarters  Cabometyx is experiencing rapid and broad uptake in the market with label expansion opportunities leaving room for upside  The Zacks Rank  2 stock has quite a few pipeline catalysts lined up for the coming quarters  You can see  
EXELIXIS INC Price and Consensus   The three companies discussed above are not the only ones with acquisition potential  Several other companies like Sarepta   NASDAQ SRPT    TESARO   NASDAQ TSRO    and AveXis   NASDAQ AVXS   are often viewed as acquisition targets  The bottom line is that companies with innovative technologies and pipelines are highly sought after with niche disease areas like nonalcoholic steatohepatitis  NASH   immuno oncology  multiple sclerosis and hepatitis C virus  HCV  in demand  Treatments for orphan diseases are also in demand Zacks  Best Investment Ideas for Long Term ProfitToday you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information ",2016-11-16,Zacks Investment Research,https://www.investing.com/analysis/3-stocks-to-add-to-your-portfolio-as-biotech-m-a-hopes-rise-200165227,200165227
125414,346929,SRPT,5 Medical Tech Stocks You Should Be Investing In,opinion,"The medical sector is growing rapidly and getting in on the ground floor with med tech can be highly profitable for smart investors  but how can you know which stocks to choose  In many cases  the best way to track leading med tech stocks is by looking at larger health trends  Weight loss  pharmaceutical development  and medical equipment manufacturers all stand out as top picks 
Weighing In On Weight Loss
At a time when about one third of the global population is overweight of obese  it s no surprise that   This is especially true since being significantly overweight increases many other health risks  including the likelihood of heart disease  diabetes  and many types of cancer 
In order to combat these risks  people are turning to solutions ranging from taking herbal supplements to  in an attempt to stave off future disease  and the medically informed companies behind these strategies are profiting 
MEDIFAST INC  NYSE MED   for example  has caught the attention of 11 hedge funds due to its weight loss oriented portfolio  the company has four major distribution channels and also produces the popular Owings Mills meal replacements  hydration products  and vitamins   The same is true of the more well known NutriSystem Inc  NASDAQ NTRI  brand  with 23 hedge funds taking long positions on the stock  Weight loss brands have undeniable profit potential 
Rare But Reliable
For many years  rare diseases got little to no medical attention   with few sufferers  these diseases simply didn t have the political or financial pull to push drug development forward  so companies often abandoned them  Such illnesses and their associated drugs even came to be known as  orphans  for this reason  Now  however  social media has helped sufferers band together  pushing companies to develop treatment regimens for rare conditions  which is how Sarepta Therapeutics gained the public eye 
Sarepta Therapeutics Inc  NASDAQ SRPT  recently received the first FDA approval in history for a Duchenne muscular dystrophy  DRD  drug  About 13 percent of DRD patients have the particular mutation this drug is meant to address  but although the market is narrow  investors are responding  Immediately following the FDA approval  Sarepta s stock price rose more than 80 percent  It s not too late to get in on this groundbreaking company s stock  either 
Biopharmaceuticals Go Big
Biologics and biopharmaceuticals are big business today  as the medical industry realizes that the best way to treat many diseases is by drawing on our own biological systems  In this category are blood products  proteins engineered from the human genome  and other similar products  One of the most powerful developments in the biopharmaceutical industry is immunotherapy  which can be used to treat cancers  as well as autoimmune diseases 
Kite Pharma  NASDAQ KITE  has been working on developing and launching a form of   but as their current products are still in phases 1 and 2 of clinical trials  the stock is trading fairly low  Keep an eye on this company as they approach an FDA approval  however  as this could lead to significant price jump  as seen with Sarepta 
Equipment Evolution
Finally  if you re looking for a highly diverse  innovative medical sector  consider investing in medical device development  Medical device companies include those developing traditional hospital monitors and surgical tools as well as those engineering nearly invisible data collection tools 
Among the former  NxStage Medical Inc  NASDAQ NXTM  is a standout stock  The company designs hemodialysis machines that can be used to prolong the lives of patients with renal disease  After beating third quarter expectations this year  investors are feeling confident about the company s 2017 potential  Invest now for strong payout potential 
On the other end of the med tech spectrum are companies like G Tech Medical that make tools for managing gastrointestinal diseases like Crohn s and ulcerative colitis  Though this company is not yet being traded publically  they recently raised  1 5 million in growth capital through the Propel x  platform  Keep an eye on this company  whether a larger biotech brand acquires them or they go public  they ve already built a powerful business 
The biomedical industry is expansive and offers a great way to diversify your portfolio  Whether your interests run towards the pharmaceutical or the mechanical  there s a hot stock  or five  out there for you ",2016-12-01,Modest Money,https://www.investing.com/analysis/5-medical-tech-stocks-you-should-be-investing-in-200167581,200167581
125415,346930,SRPT,Short Term Trades With High Returns  Evaluating A Real Life Example,opinion,"Covered call writing is a conservative strategy for cautious investors  We want the higher than risk free returns with the least amount of risk  One question that does come up in this regard is why not enter a short term trade that offers impressive returns  To get an understanding if this is a beneficial approach there is nothing like a real life example to dissect every aspect of such a trade  I will be using Sarepta Therapeutics Inc  NASDAQ SRPT  to highlight the key aspects of this article 
SRPT  3 day trade from June 6  2016   June 9  2016
6 6 2016  Buy SRPT at  15 40
6 6 2016  Sell  16 00 call at  1 90
6 9 2016  Plan to close trade prior to expiration
Ellman Calculator

The multiple tab of the Ellman Calculator shows a 3 day initial return of 12 3  with the possibility of an additional 3 9  if share price moves up to the  16 00 strike by expiration  This annualizes to between 1000    2000   I don t know about you but I m beginning to get nervous 
Here s what we know without even 1 second of research
1  We know that options returns of this magnitude and time frame are based on an underlying security with massive   This means that the market is anticipating huge price movement in either direction  Frequently  this will results in  ups or gap downs sudden and dramatic price movement  Is this what we want as conservative investors where capital preservation is a top priority   hint no   To confirm this  let s have a look at a 1 year price chart for SRPT showing two gap downs of over 50  each time 

Neither gap down was related to an earnings report but rather the nature of the underlying security 
2  We know that there is a likelihood of some event expected that could rock the share price in either direction  We have eliminated earnings reports as that event due to our standard screening process 

So what happened 

Clearly the trade had a happy ending with a 3 day return of 16 2   12 3    3 9   as share price moved from near 16 00 to near  21 00  brown field   Is our conclusion then that short term volatile trades should be a recurring aspect of our trading strategies  hint well you know  
For Whom and when should such trades be considered 
Trades which offer huge short term potential profits are highly risky trades which make a lot of money or result in extensive losses  They are for traders with high risk tolerance looking to hit it big  Covered call writing is on the other end of the spectrum  most appropriate for conservative investors who stress capital preservation  Should such a high risk reward trade be entered  a covered call will limit the upside but not the downside  In the highlighted trade   2 50   1 90    0 60  was generated but it could have been more than  5 00 per share had the call not been written  The major reason for not entering such a trade is the downside risk had the news been disappointing 
Discussion
Short term trades offering high returns are most appropriate for investors looking to hit a grand slam homerun with the understanding that substantial losses are possible  With that in mind  each investor must decide which strategy is most beneficial based on personal trading style 
Market tone 
US stocks continued its rise records this week   including 11 record daily closing highs in a row for the Dow Jones Industrial Average  Investors appear confident that President Donald Trump will cut taxes  reduce regulation and implement a sweeping infrastructure spending program  The S P 500 Index is up 5 3  year to date and has gained over 21  over the past 12 months  Market volatility increased slightly this week  but remains historically low  Oil prices remained relatively unchanged this week  This week s reports and international news of importance 
In minutes released this week  US Federal Reserve officials signaled the potential for a rate hike at its next policy meeting in March relating to potentially increased spending and reduced taxation under the Trump administration  the minutes suggest that the Fed may act more aggressively to keep a lid on inflation
The central bank increased the federal funds rate to between 0 5  and 0 75  in December and indicated then the potential for three quarter percentage point increases this year
President Trump said this week that he supports a form of the proposed  border adjustment tax   BAT   a tax on all imports  Trump suggested that such a tax would entice companies to relocate manufacturing operations to the United States  which would create more US jobs  Retail stocks have taken a huge hit in recent months over speculation that a border tax would be implemented  The retail industry imports most goods it sells in the US 
JC Penney  NYSE JCP  announced this week that it would close more than 100 stores  and rivals Kohl s  NYSE KSS  and Macy s  NYSE M  announced they would lease some of their retail space to other retailers in an effort to generate more revenue from real estate assets  Under the proposal  US export income would be tax free  which could benefit some energy companies  such as crude oil exporters
Greece agreed to legislate pension and other structural reforms this week  generating some optimism that negotiations on its bailout terms would resume after months of gridlock  Yields on Greek government debt fell to their lowest level in a month  although serious issues still remain
THE WEEK AHEAD
MONDAY  February 27th
Durable goods orders Jan 
Pending home sales Jan 
TUESDAY  February 28th
Gross domestic product Q4
Case Shiller home price index Dec 
Consumer confidence index Feb 
WEDNESDAY  March 1st
Personal income Jan 
Consumer spending Jan 
Core inflation Jan 
ISM manufacturing Feb 
Beige book
THURSDAY  March 2nd
Weekly jobless claims 2 24
FRIDAY  March 3rd
ISM non manufacturing Feb
For the week  the S P 500 was up by 0 69  for a year to date return of 5 74   
Summary 
IBD  Market in confirmed uptrend
  6 6  Buy signal since market close of November 10  2016
BCI  I am currently fully invested and have an equal number of in the money and out of the money strikes  How will nationalistic policies fare in a global economy 
WHAT THE BROAD MARKET INDICATORS  S P 500 AND VIX  ARE TELLING US
The 6 month charts point to a slightly bullish outlook  In the past six months  the S P 500 was up 10  while the VIX  11 47  declined by 15  ",2017-02-26,Dr. Alan Ellman,https://www.investing.com/analysis/short-term-trades-with-high-returns:-evaluating-a-real-life-example-200176849,200176849
125440,346955,SRPT,Catabasis  DMD Drug In Phase II Open Label Extension Study,opinion,Catabasis Pharmaceuticals  Inc    NASDAQ CATB   announced that it has initiated an open label extension  Part C  of the phase II portion of its MoveDMD study  phase I II  on edasalonexent  CAT 1004   Edasalonexent  a molecule that inhibits a protein called   NF kB   is being developed for the treatment of patients with Duchenne muscular dystrophy  DMD   Patients who complete the 12 week phase II portion  Part B  of the MoveDMD study will be eligible to enroll in the open label extension  They will be given edasalonexent for 36 weeks  The open label extension study will evaluate the longer term safety and efficacy of the candidate with the same clinical endpoints as Part B CATABASIS PHARM Price   We note that Part B was initiated in Apr 2016 to evaluate the safety and efficacy of oral edasalonexent  67 mg kg day and 100 mg kg day  for 12 weeks  with the primary endpoint being the change in magnetic resonance imaging  MRI   Top line results from Part B are expected in late 2016  In the U S   edasalonexent enjoys Orphan drug  Fast Track and Rare Pediatric Disease designations for the treatment of DMD  Edasalonexent also enjoys Orphan Medicinal Product designation for the DMD indication in the EU  DMD  a devastating and debilitating disease  represents a market where there is currently no approved drug  indicating significant unmet need for treatments  Note that Sarepta Therapeutics  Inc    NASDAQ SRPT   is looking for an approval of its DMD drug  eteplirsen  A New Drug Application is currently under review in the U S  BioMarin Pharmaceutical Inc    NASDAQ BMRN   was also developing its pipeline candidate  Kyndrisa  for the DMD indication  However  last month  the company announced that it has withdrawn a Marketing Authorisation Application  MAA  for the product from the EU  following discussions with the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP   which hinted at the issuance of a negative opinion  Kyndrisa has also received a Complete Response Letter from the FDA  Consequently  BioMarin had stopped developing Kyndrisa  Catabasis currently carries a Zacks Rank  2  Buy   Another favorably placed stock in the health care sector is GW Pharmaceuticals plc   NASDAQ GWPH    sporting a Zacks Rank  1  Strong Buy  ,2016-07-07,Zacks Investment Research,https://www.investing.com/analysis/catabasis'-dmd-drug-in-phase-ii-open-label-extension-study-200140743,200140743
125441,346956,SRPT,4 Stocks To Watch  ADXS  EXEL  NVAX  XNCR,opinion,"It was a nice rally back on Wall Street on Wednesday  We have a lot of stocks that are doing well  so let s take a look at them and see how they are doing 
Advaxis  Inc   NASDAQ ADXS  was the super star on Wednesday  up 2 61 to 13 69  or 23 1 2   on 5 7 million shares  and reaching as high as 14 24  That was a big day for this stock  With 12 9 days to cover  even though it s at resistance  there s a possibility that it could extend to the 16 17 18 range  I don t know if it will make it  but if it pulls back and consolidates nicely  it could get up to the next level  It has 12 9 days to cover 
Exelixis  Inc   NASDAQ EXEL  has a phenomenal trend  a really tight rising channel  On Wednesday  it was up 24 cents to 9 39  or 2 6   on 7 3 million shares  It reversed on Wednesday and then in afterhours it was trading low again  Even though there is resistance in this area  it wouldn t surprise me if it ran up to the 11 12 area  It has 7 days to cover 
Novavax  Inc   NASDAQ NVAX   a swing trade of ours  has been consolidating for a couple weeks  and on Wednesday it popped 42 cents to 7 61  or 5 84   on 4 3 million shares  It looks like it s ready to test the 8 8 1 4 range  and then 9 1 2  It has 12 2 days to cover 
Xencor  Inc   NASDAQ XNCR   one of our swing trades  did great on Wednesday  up 1 88 to 21 16  or 9 75   on 541 100 shares traded  It broke out of a wedge and took off running  actually tagging 21 81  which is my target  The secondary target is 24  We ll see if we get a follow through  and then consolidate  It has 5 35 days to cover 
Stocks on the long side included Advaxis  Inc   ADXS   Amkor Technology  Inc   NASDAQ AMKR   Cempra  Inc   NASDAQ CEMP   Cemtrex Inc   NASDAQ CETX   CaesarStone Sdot Yam Ltd   NASDAQ CSTE   3D Systems Corporation  NYSE DDD   Eleven Biotherapeutics  Inc   NASDAQ EBIO   Etsy  Inc   NASDAQ ETSY   Exact Sciences Corporation  NASDAQ EXAS   Exelixis  Inc   EXEL   Fitbit Inc   NYSE FIT   INSYS Therapeutics  Inc   NASDAQ INSY   Direxion Daily S P Biotech Bull 3X ETF  NYSE LABU   MeetMe Inc   NASDAQ MEET   NeoPhotonics Corporation  NYSE NPTN   Novavax  Inc   NVAX   Oclaro  Inc   NASDAQ OCLR   Ocean Power Technologies  Inc   NASDAQ OPTT   Aratana Therapeutics  Inc   NASDAQ PETX   Primo Water Corporation  NASDAQ PRMW   Shopify Inc   NYSE SHOP   U S  Silica Holdings  Inc   NYSE SLCA   Sarepta Therapeutics  Inc   NASDAQ SRPT   and Xencor  Inc   XNCR  ",2016-08-04,Harry Boxer,"https://www.investing.com/analysis/adxs,-exel,-nvax,-xncr-200146009",200146009
125442,346957,SRPT,Mallinckrodt DMD Drug Gets Fast Track Status In The U S ,opinion,"Mallinckrodt Public Limited Company   NYSE MNK   announced that it has received Fast Track designation in the U S  for its Investigational New Drug  IND  application for Synacthen Depot for the treatment of patients with Duchenne muscular dystrophy  DMD  We note that the FDA grants Fast Track status to facilitate the development and quicken the review process for the candidates that are being developed for the treatment of serious conditions that have an unmet medical need  Synacthen Depot is currently approved and commercialized in ex U S  markets for certain autoimmune and inflammatory conditions Mallinckrodt revealed that it has initiated a phase I study on the product for the DMD indication MALLINCKRODT PL Price
    DMD  a devastating and debilitating disease  represents a market where there is currently no approved drug  indicating significant unmet need for treatments We remind investors that Sarepta Therapeutics  Inc    NASDAQ SRPT   is looking for an approval of its DMD drug  eteplirsen  A New Drug Application  NDA  is currently under review in the U S Moreover  Catabasis Pharmaceuticals  Inc    NASDAQ CATB   is developing its DMD candidate  edasalonexent  CAT 1004   in a phase II  MoveDMD  study  Results from the study are anticipated later this year  Edasalonexent enjoys Orphan drug  Fast Track and Rare Pediatric Disease designation in the U S  for the treatment of DMD  The candidate also enjoys Orphan Medicinal Product designation for this indication in the EU Mallinckrodt currently carries a Zacks Rank  3  Hold   ANI Pharmaceuticals  Inc    NASDAQ ANIP   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-25,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-dmd-drug-gets-fast-track-status-in-the-u.s.-200150241,200150241
125443,346958,SRPT,Sarepta Shares Soar On News Of Key Drug Critic FDA Exit,opinion,"Shares of Sarepta Therapeutics  Inc    NASDAQ SRPT   rose around 27  on Wed  Sep 14 on news that a key critic  Farkas  of its lead pipeline candidate  eteplirsen  has left his job at the FDA  raising hopes of approval of the drug 
The biopharmaceutical company is looking to get eteplirsen approved for the treatment of patients suffering from Duchenne muscular dystrophy amenable to exon 51 skipping 
We remind investors that in Apr 2016  an FDA advisory committee voted against approving eteplirsen for the treatment of DMD  Dr  Ronald Farkas had led the panel and has reportedly been critical of the drug SAREPTA THERAP Price and Consensus
 

   One of the most common fatal genetic disorders affecting children around the world  DMD is a devastating and incurable muscle wasting disease and there is significant unmet need for its treatments 
Following the committee s decision  the FDA failed to provide a decision on the candidate by the extended Prescription Drug User Fee Act  PDUFA  date of May 26  2016  The agency informed the company that it was still reviewing the latter s New Drug Application  NDA  and will try to reach a decision as early as possible However  in June  the FDA requested the company to provide dystrophin data from biopsies obtained from the ongoing confirmatory study on eteplirsen  as part of the agency s ongoing evaluation of the NDA 
Given that Sarepta has no approved product in its portfolio at the moment and that eteplirsen is its lead pipeline candidate  the departure of Farkas definitely improves chances of approval of the drug  However  we cannot rule out the fact that Farkas was not the only member of the advisory committee who had concerns about eteplirsen 
Stocks to Consider
Currently  Sarepta Therapeutics carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Johnson   Johnson   NYSE JNJ    Geron Corp    NASDAQ GERN   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    While Geron and ANI Pharmaceuticals sport a Zacks Rank  1  Strong Buy   J J has a Zacks Rank  2 
You can see the  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-15,Zacks Investment Research,https://www.investing.com/analysis/sarepta-shares-soar-on-news-of-key-drug-critic-fda-exit-200153825,200153825
125444,346959,SRPT,Economic Calendar  Stocks And SPY,opinion,"Morning Notes
US Futures are pointing slightly higher this morning while European stocks also are higher as markets await the results of the 2 day Fed policy meeting and BOJ meeting  Asian stocks closed mostly mixed 
Technicals

The SPY  NYSE SPY  traded in a choppy  range bound fashion throughout the majority of yesterday s session  Support will lie at the low of yesterday s range at  213 03  followed by the double bottom formation at  212 50 and then the 100 day moving average at  212 33  Resistance will lie the high of yesterday s range at  214 88  followed by  215 73   216 81  and the 50 day moving average at  216 87 
Small Cap Watch List
  Others On Watch  
Sarepta Therapeutics Inc  NASDAQ SRPT 
Economic Calendar
8 30 August housing starts expected  1 7  to 1 190M
10 30 FOMC begins 2 day meeting
Notable Earnings Before Open
Lennar  NYSE LEN    EPS Est    88  Rev Est   2 66B
Notable Earnings After Close
Adobe Systems  NASDAQ ADBE    EPS Est    72  Rev Est   1 45B
KB Home  NYSE KBH   KB Home   EPS Est    39  Rev Est   954 12M",2016-09-20,Ticker.tv News,https://www.investing.com/analysis/economic-calendar---watch-list-9-20-2016-200154476,200154476
125466,346981,SRPT,Biotech Stock To Watch  Sarepta  Biomarin  Acadia,opinion,"Sarepta Therapeutics
On Monday April 25  2016 Sarepta Therapeutics  NASDAQ SRPT  had a FDA advisory panel shoot down its drug Eteplirsen  used to treat patients with Duchenne Muscular Dystrophy    DMD  The panel voted against Eteplirsen on all questions  Even the last question which asked if Eteplirsen should be approved for DMD patients was also voted down on  The panel vote was  3  yes  for approval  7  no  against approval  and 3 panelists abstained from even answering the question 
The main concern with Sarepta s drug was that it had only ran a clinical trial with a total of 12 patients  The panel noted many times during the hearing that proper efficacy can t be concluded from just a small patient population  That would have been enough to typically reject a drug compound  except for the fact that the way Sarepta designed its trial it gets much worse  The company ran the trial with no placebo arm  A placebo arm is important in a clinical trial  because it proves whether the new drug is better than the current standard  By not applying a placebo compound  Sarepta left the FDA panel to guess what the placebo would have been 
In addition  Sarepta tacked into their data historical controls  Historical controls  means that the company used placebo data from old trials done many years ago  It does make you wonder though  maybe the company didn t do placebo trials because they knew that the drug wouldn t perform any better than placebo  The FDA is set to decide upon whether it should approve Eteplirsen or not by May 27 of this year  If the FDA decides to accept the panel advisors  decision then it is likely that the drug will not be approved for DMD patients 
Putting aside the no use of placebo in the trial and running a small 12 patient trial something else can be pointed as solid evidence on why Eteplirsen won t be approved  That is the fact that Biomarin Pharmaceutical  NASDAQ BMRN   which ran a 290 patient trial and ran the trial with a placebo failed to receive approval of its drug Kyndrisa  The FDA panel was not happy with the efficacy of this drug either thus the rejection  Which brings me to the main point that if the FDA didn t approve Kyndrisa with such a large trial and good efficacy  why on earth would it approve Eteplirsen  After all  it only recruited 12 patients in a trial and no placebo arm  I don t expect the FDA to play favorites  and I predict that Sarepta will receive a Complete Response Letter    CRL 
Investors have to keep in mind that yes people tend to live off of emotions  but keep this one thing in mind  The FDA doesn t work based off of emotions  They approve or disapprove drugs based on clinical facts and findings  Therefore with the weak data  I don t expect the FDA to approve Eteplirsen for patients with DMD 
Acadia Pharmaceuticals
On Friday April 29  2016 ACADIA Pharmaceuticals  NASDAQ ACAD  announced that it had received FDA approval for its drug Nuplazid  It had received approval to treat a disease known as Parkinson s Disease Psychosis  Patients with Parkinson s Disease Psychosis    PDP    experience hallucinations and delusions  This is an extraordinary feat for Acadia  because it will be the first drug ever to be approved for PDP 
According to data from the National Parkinson Foundation there are approximately five million people globally that suffer from Parkinson s Disease  Out of all those people  around 40  have the psychosis component of the disease  The problem has been that there has been no FDA approved drugs to treat this portion of the disease until now  Acadia had received breakthrough designation back in 2014  The good part about Breakthrough therapy designation is that the company receives a faster review time 
Instead of the company having to wait 7 to 9 months for review they only need to wait typically 2 to 3 months  It saves a lot of time this way  and this is especially good if the drug treats a population that have no other treatment options  With this approval patients won t even have to wait that long of a time period  because Acadia expects to launch the drug in June  In just a few months patients will be able to relieve their symptoms of psychosis 
Acadia stands to make a lot of money with the drug  because analysts expect that Nuplazid could potentially produce  1 billion in sales  Such a huge amount of revenue with no competition  could be an attractive takeover target for big pharmaceutical companies  with a large pocket book  Big pharmaceutical companies are struggling with weak R D and they need to buy small cap biotechnology companies to keep their revenue stream flowing  Well  Acadia with a recently approved drug with limited competition should stir a bidding war battle among the big pharma players ",2016-05-03,Joshua Rodriguez,https://www.investing.com/analysis/biotech-stock-news-(srpt)-(bmrn)-(acad)-200127599,200127599
125467,346982,SRPT,Why Is Sarepta Therapeutics  SRPT  Stock Soaring 20  Today ,opinion,"On Wednesday  shares of Sarepta Therapeutics   NASDAQ SRPT   are soaring  up almost 20  in afternoon trading on news that the company announced that the Food   Drug Administration  FDA  has delayed ruling in its drug eteplirsen  which treats Duchenne muscular dystrophy  DMD  
The delay has raised hopes that eterplirsen may be approved 
The FDA let Sarpeta know that it would be unable to complete the review of its New Drug Application  NDA  by the scheduled Prescription Drug Uder Fee Act  PDUFA  deadline of May 26  the FDA added it will work past the deadline to complete the review as soon as possible 
DMD is a rare disease that usually emerges in young boys  causing weakness in the arms and legs and eventually the lungs and heart  There is currently no other treatment available  If the FDA rejects eterplirsen  it will be the third time it has turned down a DMD drug this year 
The FDA s decision is the deciding factor for Sarepta as a company  and it may be the last chance for it to debut a product to the market after 36 years 
Sarepta Therapeutics currently sits at a  3  Hold  on the Zacks Rank ",2016-05-25,Zacks Investment Research,https://www.investing.com/analysis/why-is-sarepta-therapeutics-(srpt)-stock-soaring-20-today-200132228,200132228
125468,346983,SRPT,Why Is Sarepta Therapeutics  SPRT  Stock Down 20  Today  ,opinion,"Shares of Sarepta Therapeutics   NASDAQ SRPT   fell nearly 20  in early morning trading Thursday after new reports suggested that the Food and Drug Administration may force the company to offer its Duchenne muscular dystrophy  DMD  drug to patients at cost 
The rumors are swirling based on an FDA  that detailed plans for the regulatory body to streamline its expanded access program  This process  often called  compassionate use   allows doctors to individually request access to investigational drugs for their patients 
 The FDA has a long history of supporting patient access to investigational treatments and we hope the information released today will help health care professionals  patients  and industry to more easily navigate the expanded access process and help patients who qualify to gain access to potentially life saving investigational treatments   the agency said 
While the new process could allow Sarepta to offer its eteplirsen drug to patients with DMD without first receiving FDA approval  another caveat of the compassionate use program is that drug makers must only charge patients enough to recoup manufacturing costs 
It is important to note that Sarepta and eteplirsen were not mentioned specifically in the FDA s statement  However  it appears that investors are connecting the dots between today s announcement and the agency s decision to  on eteplirsen last week 
Sarepta has been fighting an uphill battle against the FDA to get eteplirsen approved  The agency has already turned down the drug twice this year  but last week s delay caused some to regain hope that the FDA might still approve the DMD drug 
Duchenne muscular dystrophy  which currently has not approved treatments  is a rare degenerative disorder that causes weakness in the arms and legs and eventually death  DMD affects about one in 3 600 boys 
FDA approval is necessary for Sarepta  as the compassionate use program will probably not be economically feasible for the company in the long term ",2016-06-02,Zacks Investment Research,https://www.investing.com/analysis/why-is-sarepta-therapeutics-(sprt)-stock-down-20-today-200133707,200133707
125469,346984,SRPT,Sarepta Asked To Provide Dystrophin Data On Eteplirsen,opinion,Sarepta Therapeutics  Inc    NASDAQ SRPT   announced that it has been requested by the FDA to provide dystrophin data from biopsies obtained from the ongoing confirmatory study on eteplirsen  as part of the agency s ongoing evaluation of the New Drug Application  NDA  The company said that it plans to submit the data from 13 patient biopsy samples to the FDA over the next few weeks to facilitate the agency s decision on the NDA Sarepta is looking to get eteplirsen approved for the treatment of patients suffering from Duchenne muscular dystrophy  DMD   amenable to exon 51 skipping We note that last month  the company received a notice from the FDA  which stated that the agency will not be able to deliver a decision regarding the approval status of eteplirsen on the previously scheduled date of May 26 and has thus  extended the Prescription Drug User Fee Act  PDUFA  date  The agency informed the company that it continues to review the NDA and will try to reach a decision as early as possible We remind investors that DMD drugs have not witnessed much success on the regulatory front so far  Last week  BioMarin Pharmaceutical Inc    NASDAQ BMRN   announced that it does not intend to continue with the development of Kyndrisa  The company withdrew its marketing application in the EU following discussions with the Committee for Medicinal Products for Human Use  CHMP   which indicated that the drug would receive a negative opinion from the committee  Kyndrisa had also received a complete response letter  CRL  earlier this year DMD  a devastating and debilitating disease  is estimated to affect nearly 1 in every 3 500 5 000 boys born across the world  indicating significant unmet need for treatments in this space Investor focus is expected to remain on the outcome of the approval status of eteplirsen Sarepta currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include Bristol Myers Squibb Company   NYSE BMY   and Pfizer Inc    NYSE PFE    both sporting a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-06,Zacks Investment Research,https://www.investing.com/analysis/sarepta-asked-to-provide-dystrophin-data-on-eteplirsen-200134517,200134517
125470,346985,SRPT,Sarepta Therapeutics Skyrockets After FDA News,opinion,"Sarepta Therapeutics Inc  NASDAQ SRPT  shares have been  of late  and they soared by more than 23  to as high as  19 75 on Tuesday  The drug maker said it has reached an agreement with the Food and Drug Administration regarding dystrophin data from trials of its drug Promovi  Wedbush analysts upgraded Sarepta after the news  although analyst calls on the company are simply all over the place 
Wedbush upgrades Sarepta Therapeutics  SRPT 
Analyst Heather Behanna said in a report dated June 6 that she upgraded Sarepta Therapeutics Inc  NASDAQ SRPT  from Neutral to Outperform and more than doubled her price target from  14 to  36 per share  She believes the agreement between the company and the FDA will enable it to get onto the fast track to getting Promovi  a k a  eteplirsen  approved  The agency has agreed to review the dystrophin data that Sarepta already has on hand  This is good news because it means that the company won t have to spend more time and money collecting new biopsies because it can use those it already collected 
She believes the data will show that dystrophin production is within an acceptable range  so she thinks the drug maker s stock is a buy before the regulatory approval  However  she also noted that there is still a risk that dystrophin will be a problem in terms of getting Promovi approved because there are no clear guidelines of how much of an increase in dystrophin production is needed  She believes that an increase of two to three times may be all that s needed in order for approval  however 
Rough waters for Sarepta Therapeutics  SRPT 
Analysts are all over the map in terms of ratings on Sarepta Therapeutics Inc  NASDAQ SRPT   For example  Janney analysts have a Neutral rating but raised their price target from  18 to  25 per share following the FDA news  On the other hand  Jefferies analysts have an Underperform rating and  7 per share price target  as they don t see much chance of Promovi receiving FDA approval  Their take on the deal announced this week is that the agency is granting one more chance to Sarepta to demonstrate that its drug works 
JPMorgan has an Underperform rating and  10 price target  while Leerink has an Underperform rating and  5 price target  On the extreme bullish side  we have Oppenheimer with an Outperform rating and  60 per share price target  as the firm s analysts believe the FDA is already fairly certain that accelerated approval is warranted for Sarepta Therapeutics  drug 
Volatility in the stock has been exceptionally high of late  and  posits that the reason analyst ratings and price targets vary so much is become of this volatility as the stock has punished longs and shorts alike  Short interest in the company has skyrocketed over the last few months as about 22 6 million shares were out on loan as of May 13  compared to only 10 million shares at the beginning of the year 
Shares of Sarepta Therapeutics Inc  NASDAQ SRPT  skyrocketed 22 55  to close at  19 67 on Tuesday ",2016-06-08,ValueWalk,https://www.investing.com/analysis/sarepta-therapeutics-inc-(srpt)-stock-skyrockets-after-fda-news-200134617,200134617
125471,346986,SRPT,Biotech Stock Roundup  Biogen Slips On MS Results  ASCO Data In Focus,opinion,"Several biotech companies were present at the annual meeting of the American Society of Clinical Oncology  ASCO  to showcase data on their cancer treatments  While focus was mainly on ASCO data  companies like Biogen   NASDAQ BIIB   and Sarepta   NASDAQ SRPT   remained in the limelight on pipeline updates Recap of the Week s Most Important Stories1  Biogen s shares plunged 12 8  with the company s experimental multiple sclerosis  MS  treatment  opicinumab  anti LINGO 1  missing the primary endpoint in a mid stage study  The secondary efficacy endpoint was also missed  However  instead of writing off the drug  Biogen intends to analyze the results further to determine the design of the next study  The company said that despite the missed primary endpoint  it found evidence of a clinical effect with a complex  unexpected dose response  Read more    2  It s been quite a week for Sarepta with the company s shares on a rollercoaster ride  Shares first plunged 26 6  on speculation that new FDA guidelines regarding expanded access  compassionate use  were an indication that the agency would not grant approval to Sarepta s experimental Duchenne muscular dystrophy  DMD  treatment  eteplirsen  Read more    
However  Sarepta s shares recovered much of the lost ground earlier this week when the company announced that the FDA has asked it to provide dystrophin data  as measured by western blot  from biopsies already obtained from the ongoing confirmatory study of eteplirsen  PROMOVI   as part of its ongoing evaluation of the regulatory application  Shares shot up 22 6  on this update   Read more    3  Alexion   NASDAQ ALXN   also had some disappointing news with its blockbuster product Soliris failing to achieve the primary endpoint in a late stage study in patients with refractory generalized myasthenia gravis  Shares were down 10 9  on the study results  Read more    4  Regeneron   NASDAQ REGN   and partner Sanofi  PA SASY  announced positive data from a late stage study on their experimental skin disease drug   dupilumab  Dupilumab met the primary and key secondary endpoints in the study that was conducted in patients with moderate to severe atopic dermatitis  Read more     Plans are on to seek regulatory approval in the third quarter of the year  If approved  the drug could bring in blockbuster sales 5  And finally a look at some ASCO results   while companies like Kite  Read more     Exelixis  Read more    and Cyclacel  Read more    saw their shares soaring on data presentation  AbbVie s   NYSE ABBV   data on its recently acquired Rova T failed to inspire much enthusiasm from investors  Read more    on concerns that the company may have paid too much for the Stemcentrx acquisition  Amgen   NASDAQ AMGN   was also at ASCO with data on Kyprolis PerformanceAmong major biotech stocks  Celgene   NASDAQ CELG   gained 1 78  over the last five trading days while Biogen declined 12 73   Over the last six months  Amgen was up 1 74  while Regeneron lost 27 83  during this period 

The NASDAQ Biotechnology Index was down slightly  0 78   over the last five trading days  See the last biotech stock roundup here    What s Next in the Biotech World Watch out for the usual pipeline updates and data presentations from biotech companies Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-08,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-biogen-slips-on-ms-results,-asco-data-in-focus-200134835",200134835
125492,347007,SRPT,Sarepta Therapeutics  SRPT  Stock Is About To Soar,opinion,"Sarepta Therapeutics  NASDAQ SRPT  is an incredibly strong stock in the biotechnology space  However  it seems as though the stock is going to get stronger  and it s going to happen soon  I m not quite sure what s up their sleeve  but insider trading shows that something big is likely to happen as SRPT  Today  we ll talk about why it s important to watch insider trading  what we re seeing from SRPT  and what we can expect to see moving forward  So  let s get right to it   
Why It s Important To Watch Insider Trading
As investors  we really don t have very much information available to us  Sure  we can watch technical data and focus on the fundamental data we know  but the truth is  most fundamentals are outdated by the time we get to them  Nonetheless  there is one clue that often leads to big gains  or big declines  That clue is insider trading  The bottom line is that no one knows more about a publicly traded company than those on the inside  When they start to sell shares in the company for which they are insiders  we can expect to see declines  However  when they start to buy shares  we can expect that something big is just around the corner  and SRPT insiders are buying shares 
We re Seeing Quite A Bit Of Insider Activity In Sarepta Therapeutics
Over the past week or so  we ve seen quite a bit of positive insider activity at SRPT  In fact  over this short period of time  three directors at the company have made the decision to purchase shares  Between the three insiders  a total of 154 500 shares were purchased  The prices on these shares ranged from  14 54 per share to  16 54 per share  bringing the total cost to the insiders to approximately  2 5 million  When one insider purchases shares  we expect to see something good happen  However  in the case of SRPT  three insiders started loading up on shares at the same time  While I m not sure what they re seeing coming around the corner  there s got to be a reason these three insiders jumped in on  2 5 million in shares of the company 
What We Can Expect To See Moving Forward
As mentioned above  I m in the dark just like you when it comes to what s coming  The truth is that I have no crystal ball  nor do I have any other way to look into the future  However  I do know that when we start to see big insider buys  those insiders are buying for a reason  In the case of SRPT  I don t see this any different  The insiders made educated decisions to purchase shares  Why  I have no idea  but they did 
With that said  I m expecting to see something big from the company relatively soon  Maybe they ve reached a big time medical breakthrough  maybe they are expecting to move forward with a new clinical study  maybe they just have great financial data to report  Nonteheless  something is coming  so  we need to be watching closely  This could open the door to incredible trading opportunities ",2016-03-21,Joshua Rodriguez,https://www.investing.com/analysis/sarepta-therapeutics-(srpt)-stock-is-about-to-soar-200122363,200122363
125494,347009,SRPT,3 Stocks To Watch  INGN  LITE  NPTN,opinion,"It was yet another interesting trading day on Monday  The markets were mixed and the stocks we follow did well  Let s take a look at a few of those 
Inogen  Inc   NASDAQ INGN  had a swing put on it on Monday  because I love this pattern  First of all  it went 5 waves down  rallied back  formed a wedge and then broke out of the wedge  formed a breakaway gap  and then proceeded to go into a wedge pattern  On Monday  it broke out of the wedge  up 32 cents to 41 56  on 154 100 shares traded  I like the way it looks  Now  what to be looking for is whether it can get over key resistance at 42  If it can get over that  look for it to run up to 45  48  and above 
Lumentum Holdings Inc   NASDAQ LITE   one of our swing trades  made a post IPO  all time high on Monday  up 84 cents to 26 92  or 1 2   on 664 000 shares traded  Look for this stock to make it to the 30 32 zone 
NeoPhotonics Corporation  NYSE NPTN  is looking great and continues to impress  After the spike up  and then the 4 day pullback  it held support  trend line and moving averages  This stock popped  pulled back  and popped again on Monday  up 14 cents to 12 82  or 1 1   on over a million shares  It looks like it may be testing the spike high at 13 1 4 as early as Tuesday  and if it gets through that  the target is 15 3 4 
Stocks on the long side included Advaxis  Inc   NASDAQ ADXS   Celator Pharmaceuticals  Inc   NASDAQ CPXX   3D Systems Corporation  NYSE DDD   Energy Recovery  Inc   NASDAQ ERII   GW Pharmaceuticals plc  NASDAQ GWPH   Inogen  Inc   NASDAQ INGN   Direxion Daily S P Biotech Bull 3X ETF  NYSE LABU   Lumentum Holdings Inc   LITE   NeoPhotonics Corporation  NPTN   Oclaro  Inc   NASDAQ OCLR   OvaScience  Inc   NASDAQ OVAS   PayPal Holdings  Inc   NASDAQ PYPL   U S  Silica Holdings  Inc   NYSE SLCA   Sarepta Therapeutics  Inc   NASDAQ SRPT   Supernus Pharmaceuticals  Inc   NASDAQ SUPN   Swift Transportation Company  NYSE SWFT   USA Technologies Inc   NASDAQ USAT   and Intrexon Corporation  NYSE XON  ",2016-03-22,Harry Boxer,"https://www.investing.com/analysis/ingn,-lite,-nptn-200122378",200122378
125495,347010,SRPT,4 Top Stocks To Watch Today  CPXX  FEYE  FPRX  GWPH,opinion,"It was a spectacular day on Wall Street on Wednesday  The market opened firm and moved up all session  closing at the highs for the day going away  We had a lot of stocks that moved very nicely  It was a great day for trading at TheTechTrader com  Let s take a look at some of those stocks 
Celator Pharm  NASDAQ CPXX   one of our swing trades  is doing spectacular  up 65 cents to 13 08  or 5 2   on 3 4 million shares  It popped  pulled back for two days  popped  pulled back for three days  and now it s moving again  The top of the channel says this stock could be 17 18 short term  especially if it takes out the 12 70 75 range as early as Thursday 
Fireeye Inc  NASDAQ FEYE  has come down from the high 50 s to the low teens  reversed  and is now coiling above the moving averages  A swing was put on it in anticipation of this move  The first target is 19 1 2  and the secondary target is 22 1 2  We will see where this stock wants to go from there  On Wednesday it was up 75 cents to 38 71  or 4 3   on 4 million shares 
Five Prm Th  NASDAQ FPRX   one of our swing trades  tagged its target today  up 3 01 to 45 80  or 7   on 1 5 million shares  It s been acting great since the inverse head and shoulder breakout  Look for a target of 50 51 short term  It has 4 65 days to cover 
GW Pharmaceuticals Plc  NASDAQ GWPH  is doing great  up 4 82 to 79 25  or 6 5   on 680 700 shares traded  After the spectacular  explosive move it made recently  and then the pullback  pop  pullback that formed a double bottom  a swing was put on it on Wednesday  and it moved up a couple points  It looks like it will test the 91 92 zone  and if it breaks through  we could see upwards of 105 110 
Stocks on the long side included ACADIA Pharmaceuticals Inc  NASDAQ ACAD   Advaxis Inc  NASDAQ ADXS   Anacor Pharmaceuticals Inc  NASDAQ ANAC   ANI Pharmaceuticals Inc  NASDAQ ANIP   ProShares Ultra Nasdaq Biotechnology  NASDAQ BIB   Direxion Daily S P Biotech Bull 3X Shares  NYSE LABU   Lsb Industries Inc  NYSE LXU   Celator Pharm  NASDAQ CPXX   Fireeye Inc  NASDAQ FEYE   Five Prm Th  NASDAQ FPRX   GW Pharmaceuticals Plc  NASDAQ GWPH   Intercept Pharmaceuticals Inc  NASDAQ ICPT   Incyte Corporation  NASDAQ INCY   Inogen Inc  NASDAQ INGN   Inovio Pharmaceuticals Inc  NASDAQ INO   Intracellular Th  NASDAQ ITCI   Juno Therapeutic  NASDAQ JUNO   Ocular Therapeutix Inc  NASDAQ OCUL   Rackspace Hosting Inc  NYSE RAX   Sorrento Therape  NASDAQ SRNE   Sarepta Therapeutics Inc  NASDAQ SRPT   Transenterix Inc  NYSE TRXC   USA Technologies Inc  NASDAQ USAT   Valeant Pharmaceuticals  NYSE VRX  Valeant Pharmaceuticals International Inc  NYSE VRX   and Weibo Corp  NASDAQ WB  ",2016-04-07,Harry Boxer,"https://www.investing.com/analysis/cpxx,-feye,-fprx,-gwph-200124244",200124244
125496,347011,SRPT,Sarepta Therapeutics Stock  Here s Why It s Sinking,opinion,"Sarepta Therapeutics Inc  NASDAQ SRPT 
Sarepta Therapeutics is having an overwhelmingly rough day in the market today  and for good reason  The company recently received bad news from the FDA with regard to a treatment that it is working on getting approved  Today  we ll talk about the news  how the market is reacting  and what we can expect to see from SRPT moving forward  So  let s get right to it   
SRPT Receives Negative News From The FDA
Sarepta Therapeutics has been working hard to get eteplirsen approved by the FDA as a treatment for Duchenne muscular dystrophy  Unfortunately however  the FDA still seems to be looking at the treatment in a negative light  SRPT announced that the FDA is expected to conduct an outside advisory panel on April 25th to review eteplirsen data  Nonetheless  an internal assessment by the FDA s review team appears to cast doubt with regard to the drug s chances of becoming an approved treatment 
The New Drug application was postponed on January 21st by the panel as they pointed out what it believed was errors in the original FDA review of the treatment from SRPT  Unfortunately  it seems though this opinion has not yet changed  In a statement  the FDA had the following to offer   
  W e do not agree with the applicant s characterization of inaccuracies in the initial FDA briefing document    Although FDA is prepared to be flexible with respect to a devastating illness with no treatment options  we cannot approve drugs for which substantial evidence of effectiveness has not been established  
How The Market Reacted To The News
As investors  we know that the news moves the market  Any time there is positive news released with regard to a publicly traded company  we can expect to see gains in the value of the stock associated with that company  Adversely  negative news will generally lead to declines  Given the fact that the FDA is still doubtful with regard to the treatment from SRPT  the news that was released today was overwhelmingly negative  As a result  we re seeing big declines surrounding the stock at the moment  Currently  9 59   SRPT is trading at  11 95 per share after a loss of  7 76 per share or 39 37  thus far today 
What We Can Expect To See From SRPT Moving Forward
While I would love to see the stock gain  I have to say that my opinion of Sarepta Therapeutics is incredibly bearish at the moment  The reality is that the company has been working to get eteplirson approved for quite some time  However  the FDA seems to continue finding problems with regard to the drug that will likely stop it from being approved  With that said  short term sentiment following the negative news is likely to drag the stock quite a bit further down  On top of that  when it is announced that the drug is not being approved  as there is a high likelihood of this happening  chances are that SRPT is going to sink much  much further  In the long run  I m sure that the company will make it over this hurdle  However  as it is at the moment  there seems to be no end in sight for the declines we re seeing at the moment ",2016-04-21,Joshua Rodriguez,https://www.investing.com/analysis/sarepta-therapeutics-(srpt)-stock:-heres-why-its-sinking-200125910,200125910
125498,347013,SRPT,Here   s Why Sarepta Therapeutics  SRPT  Stock Is Surging Today,opinion,"On Monday  shares of Sarepta Therapeutics  Inc    NASDAQ SRPT    a company that focuses on the discovery and development of RNA based therapeutics  are surging  up over 12  after research firm Oppenheimer upgraded its stock after they cited several supporting factors for eterplirsen s accelerated approval 
Analyst Christopher Marai upgraded SRPT to  Outperform  from  Perform  while keeping the price target of  60 
Enterplirsen isdesigned for the treatment of some mutations that cause Duchenne muscular dystrophy  DMD   a genetic degenerative muscle disease  An FDA advisory committee believes patients suffering from the disease will likely see improvement with the use of eterplirsen 
Recent FDA decisions have created some flexibility to address unmet needs  while encouraging drug development  Oppenheimer also noted that  the FDA takes into consideration more than just science law  They gave an example of the approval of Addyi for the treatment of female patients with sexual dysfunction  and despite the drug having only marginal efficacy  it was approved because of unmet needs  patient advocacy  and desired incentivized drug development  ",2016-05-02,Zacks Investment Research,https://www.investing.com/analysis/heres-why-sarepta-therapeutics-(srpt)-stock-is-surging-today-200127346,200127346
125516,347031,SRPT,4 Stock To Watch Today  FATE  NLNK  GMCR  VRNS,opinion,"So far it s been an ugly start to the month and Wednesday was no exception  The indices are at a critical point  and oversold  but not extremely so  They are set up for a potential snapback any day now  In the meantime  we re going to take a look at the long side and short side here  Some of the stocks we follow on the long side still look pretty good
Fate Therap  NASDAQ FATE  had a big day on Wednesday  up 2 28 to 7 24  or 46   on 2 7 million shares  On Tuesday it closed at 4 96  and opened at 8 72  right near the high for the day on Wednesday  and then backed off for the rest of the session  Sometimes where there is a big thrust on volume  as there was for this stock  and then a pull back  the next day they follow through  So be watching for that to occur  In afterhours trading on Wednesday this stock was back up again from 6 00  back up to the 7 30  40 zone  We just need to see if there s an extension to this rally 
NewLink Genetics Corporation  NASDAQ NLNK   one of our favorites  moved up very nicely  and then backed off  as many of the biotech s did  and on Wednesday  it snapped back  Despite the late pullback it s actually doing quite well  even at the close  closing up 3 29 to 50 31  or 7   on 851 700 shares traded  and not far from the high for the day at 50 54  The volume was the best on an up day in 5 6 weeks  If it can get up to and through the 50 1 2 51 zone  it may test 53  and then 58 plus 
Stocks on the Short Side  
Keurig Green Mountain Inc  NASDAQ GMCR   which had been very toppy  rolled over the early part of this year  came down  the neckline was broken on Wednesday  and it was down 1 92 to 108 08  or 1 3 4   on 4 4 million shares  It was choppy in afterhours  dropping from 108 9  all the way down to 88  before bouncing and coiling near the 96 level  Still  it was down 11 1 2 12 points 
Varonis Systems  NASDAQ VRNS   which we ve highlighted several times the past couple weeks  was down another 77 cents to 26 68  After it broke out and bear flagged  it broke again  bear wedged  and on Wednesday  the bear wedge is rolling over  The target on this one is 23 1 2 
Other stocks on Harry s Charts of the Day included Carbo Ceramics Inc  NYSE CRR   Intercloud  NASDAQ ICLD   PowerSecure International Inc  NYSE POWR   PlasmaTech Biopharmaceuticals  NASDAQ PTBI   Sorrento Therape  NASDAQ SRNE   Sarepta Therapeutics Inc  NASDAQ SRPT   and TrovaGene Inc  NASDAQ TROV   
Stocks on the short side included 3D Systems Corporation  NYSE DDD  Fossil Group Inc  NASDAQ FOSL   Host Hotels   Resorts  Inc   NYSE HST   Open Text Corporation  NASDAQ OTEX   SanDisk Corp   NASDAQ SNDK   and Yelp Inc  NYSE YELP ",2015-05-07,Harry Boxer,"https://www.investing.com/analysis/fate,-nlnk,-gmcr,-vrns-250915",250915
125517,347032,SRPT,Wednesday s Pre Market Insights  YHOO  SRPT  TWC  ETSY,opinion,"Yahoo  Inc  NASDAQ YHOO  shares increased more than 2  to  41 85 per share in pre market trading on Wednesday after the company confirmed plans to spin off Alibaba  NYSE BABA  holdings despite IRS comments that might complicate the tax status of the move 
Sarepta Therapeutics Inc  NASDAQ SRPT  shares soared over 50  to  24 60 in pre market trading after the pharmaceutical company announced that it will begin the process of gaining regulatory approval for eteplirsen  a therapy for Duchenne muscular dystrophy 
Time Warner Cable Inc  NYSE TWC  shares increased 2 5  to  162 in pre market trading following news that the cable company has been approached with a takeover offer from French owned Altice SA  AMS ATCE   TWC is currently valued at  45 billion and recently called off a merger with Comcast  NASDAQ CMCSA   Neither TWC nor Altice provided a comment 
Etsy Inc  NASDAQ ETSY  shares fell more than 16  to  17 52 after the platform for craft goods reported huge quarterly losses  Etsy posted a loss seven times wider than the same quarter last year and missed Wall Street s revenue estimate  Etsy went public in April with an IPO price of  16 ",2015-05-20,Sarah Roden,"https://www.investing.com/analysis/wednesdays-pre-market-insights:-yahoo!-inc.-(yhoo),-sarepta-therapeutic-252420",252420
125518,347033,SRPT,Sarepta Therapeutics Inc Will File NDA  Analysts Have Mixed Ratings,opinion,"On May 19  Sarepta Therapeutics Inc  NASDAQ SRPT  announced plans to complete a New Drug Application  NDA  for eteplirsen  Sarepta s lead product candidate  SRPT shares surged 44  to  23 following the news  Eteplirsen is a treatment for Duchenne muscular dystrophy and Sarepta plans to complete the application by mid 2015 
Sarepta s interim CEO Edward Kaye  M D  noted   The initiation of our NDA submission for eteplirsen marks a significant milestone for the Duchenne community and we look forward to completing the submission by the middle of the year and to continuing to work with the  FDA  towards the goal of providing treatments to patients as quickly as possible  
Christopher Garabedian resigned suddenly as Sarepta s CEO last month  Garabedian s resignation served as a disruption in conversations with the FDA about eteplirsen 
Several analysts weighed in on the stock following the news  Due to the volatility of SRPT shares in the past two year  most analysts have not earned high success rates or average return recommending this pharmaceutical company 
On May 19   of Oppenheimer maintained an Outperform rating on Sarepta Therapeutics with a  45 price target  assuming accelerated approval of eteplirsen  Marai noted that the rolling NDA submission  bodes well for NDA filing  and for  chances for approval   The analyst also noted the  New CEO previously highlighted that if for any reason FDA signaled submission not ready at pre NDA meeting  SRPT would not submit   Marai expects NDA filing by the FDA for accelerated approval of the drug by the third quarter and estimates full approval by 2017 
Christopher Marai has a 77  overall success rate recommending stocks with a  31 8  average return per rating  He has rated SRPT 11 times since April 2013  he has earned a 64  success rate recommending the stock with a 1 7  average loss per SRPT rating 
However  not all analysts were as bullish on the stock   of Piper Jaffray reiterated a Neutral rating on Sarepta Therapetuics with a  20 price target  Tenthoff seemed cautious when noting that  It was not disclosed what  if any  changes to the NDA packet were agreed upon   He continued   Dosing has begun in the 48 week  open label Phase III confirmatory study of eteplirsen in ambulatory DMD boys as well as a 96 week study in 20 non ambulant DMD boys  
Edward Tenthoff has a 67  overall success rate recommending stocks with a  28 9  average return per rating  Tenthoff has rated SRPT 8 times since April 2013  earning a 50  success rate recommending the stock with a 26 6  average loss per rating 
Separately   of Canaccord Genuity upgraded SRPT from Neutral to Buy and raised his price target from  14 to  33  Walsh has a 78  overall success rate recommending stocks with a  32 5  average return per rating  Since he has only rated SRPT with a Neutral rating once before  he does not have a success rate or average return recommending the stock 
While analysts have not fared well recommending SRPT in particular  they have earned tremendous returns recommending other biotech stocks  Check out their performance history to see where they earned the greatest returns 
To see more SRPT ratings  visit  today ",2015-05-20,Sarah Roden,https://www.investing.com/analysis/sarepta-therapeutics-inc-(srpt)-will-file-nda;-analysts-have-mixed-ratin-252441,252441
125519,347034,SRPT,Sarepta Flying The Flag High And Tight,opinion,"Sarepta Therapeutics Inc  NASDAQ SRPT  is a biopharmaceutical company based in Cambridge Massachusetts  They are making drugs to fight some serious diseases  Some deep stuff  And after over a year of their stock price doing nothing  it seems to be coming back to life 
The chart below shows that long tight consolidation  But then after coming to an agreement with the FDA on submitting rolling NDA it jumped  I have no idea what rolling NDA is but I do know what the price action is saying  BUY 

The stock rose  10 on that news  Over 60   And since then it has consolidated  You might think that 60  move was enough  but the chart suggests you could see another  10 move very soon  The consolidation since the move up has put the stock back into the Bollinger Bands  and has been tightening against resistance at 26 85  The RSI has remained bullish and strong through this and then MACD pulled back only in a minor way  With the consolidation in a bull flag a break to the upside would look for a move up to 36  And with 45  short interest this is not a pipe dream  Are you ready for this 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2015-06-10,Gregory W. Harmon,https://www.investing.com/analysis/sarepta-flying-the-flag-high-and-tight-254529,254529
125520,347035,SRPT,4 Stocks To Watch  EXEL  GPRO  DDD  EMES,opinion,"It was a really nasty looking day for the stock market on Monday  Everything looked negative  Advance declines were negative on both exchanges and the up down volume was 2 to 1  negative on one and 3 to 1 negative on the other  Some of the large cap Nasdaq stocks did well  but it appears to mask a much bigger market  so everyone needs to be careful here  For now  let s take a look at both longs and shorts here 
Exelixis  Inc   NASDAQ EXEL   on drug news on Monday  exploded 1 97 to 5 88  or 50   on 74 6 million shares  It gapped up and closed at the high end of the range  Look for more upside on this one  The target is 7 7 1 4  however  there is potentially some resistance around the 6 1 4 area  If it can punch through that on Tuesday  the targets are 7 1 4 and 8 3 4 
GoPro  Inc   NASDAQ GPRO  had another good day  It popped 4 16 to 60 80  or 7 3 4   on 14 7 million shares  That s the biggest volume on an up day in several weeks  The level to watch is 61 19  Monday s high was 61 20  If it gets through here  look for it to run up towards 68 9  Let s see what happens with this stock over the next couple days 
Stocks on the Short Side  
3D Systems Corporation  NYSE DDD  has not done well for quite some time  down another 1 32 to 14 47  or 8   on 5 9 million shares on Monday  In 2014  DDD reached 97 00  and now it s all the way down to 14 00  When it was trading in the 50 s  the potential target was 17 00  Look at it now  There s no bottom in sight  The next potential support level is all the way down at high single digits  Something terrible is going on with this stock  or a takeover may ensue 
Emerge Energy Services LP  NYSE EMES  is another stock that is unbelievable  down 1 35 to 23 71  or 5 39   on 432 770 shares traded  It wedged several times on its way down  flagged and keeps going down  It went from 140  and change  to 23  and there s no bottom in sight  The target is 18 9 
Other stocks on Harry s Charts of the Day included Alarm com Holdings  Inc   NASDAQ ALRM   Anthera Pharmaceuticals  Inc   NASDAQ ANTH   Cempra  Inc   NASDAQ CEMP   Facebook  Inc   NASDAQ FB   Amicus Therapeutics  Inc   NASDAQ FOLD   Horizon Pharma plc  NASDAQ HZNP   Novavax  Inc   NASDAQ NVAX   Sorrento Therapeutics  Inc   NASDAQ SRNE   Sarepta Therapeutics  Inc   NASDAQ SRPT   and Intrexon Corporation  NYSE XON  
Stocks on the short side included American Airlines Group Inc   NASDAQ AAL   Fossil Group  Inc   NASDAQ FOSL   Hi Crush Partners LP  NYSE HCLP   Kate Spade   Company  NYSE KATE   Michael Kors Holdings Limited  NYSE KORS   Qualys  Inc   NASDAQ QLYS   TAL International Group  Inc   NYSE TAL   TriNet Group  Inc   NYSE TNET   Universal Electronics Inc   NASDAQ UEIC   United Rentals  Inc   NYSE URI   Varonis Systems  Inc   NASDAQ VRNS   Yelp Inc   NYSE YELP  ",2015-07-21,Harry Boxer,"https://www.investing.com/analysis/exel,-gpro,-ddd,-emes-258918",258918
125531,347046,SRPT,Opexa Therapeutics A Significant Growth Opportunity For Both Short Term,opinion,As regenerative medicine continues to slowly bridge the gap between its future promise and the scientific reality of today  companies in the space are positioning themselves to benefit from the world s technological advances  Today  regenerative medicine is becoming a reality while companies  researchers  patients  and investors alike also face ethical and religious questions to be answered  Important steps along those lines figure to be taken next month  as the Vatican prepares for its Second International Vatican Adult Stem Cell Conference  Regenerative Medicine   A Fundamental Shift in Science   Culture  taking place from within The Vatican  April 11 13   is part of a five year collaboration between The Stem for Life Foundation  NeoStem  NBS   and The Vatican s Pontifical Council for Culture  The goals of conference are to  Foster an open dialogue amongst researchers  physicians  philanthropists  faith leaders and policy makers in order to help identify clear  unmet medical needs throughout the world that can be addressed through the development of cellular therapies that will reduce human suffering Expand global awareness of the here and now opportunities of adult stem cell therapies  reducing misperceptions surrounding the field of cellular research Lay the groundwork for a collaborative network of scientists  educators and patrons Companies present for the conference include a number of well known names in regenerative treatment  such as Celgene  CELG   Osiris  OSIR   NeoStem   and Athersys  ATHX   Also to be featured at the conference is Opexa Therapeutics  OPXA   and their T cell immunotherapy  Tcelna  which is in development for secondary progressive multiple sclerosis  SPMS   Shares of Opexa look poised to breakout higher for several reasons including a new partnership agreement with Merck Serono  a recent large institutional share purchase  and other new developments  Let s delve into Opexa s short and long term prospects  Opexa is focused on the development of patient specific cellular therapies for the treatment of autoimmune diseases  Currently  the company s leading product candidate  Tcelna  is in phase 2b of a clinical trial focused on addressing the large multiple sclerosis  MS  patient population  According to the Tcelna is a personalized therapy that is specifically tailored to each patient s disease profile  Tcelna is manufactured using ImmPath  Opexa s proprietary method for the production of a patient specific T cell immunotherapy  which encompasses the collection of blood from the MS patient  isolation of peripheral blood mononuclear cells  generation of an autologous pool of myelin reactive T cells  MRTCs  raised against selected peptides from myelin basic protein  MBP   myelin oligodendrocyte glycoprotein  MOG  and proteolipid protein  PLP   and the return of these expanded  irradiated T cells back to the patient  Opexa believes the potential combination of efficacy  superior safety  excellent tolerability and administration may position Tcelna as the MS treatment of choice as compared to existing therapeutics  In MS patients  the faulty immune system is not able to prevent the attack of a small sub population of myelin reactive T cells  MRTCs    is to identify which specific antigens within each individual patient may be targeted by the immune response  and to inject a large therapeutic bolus of attenuated MRTCs back into the patient  The Tcelna consists of attenuated antigen specific Myelin Reactive T cells  and the injection is meant to educate the body s immune system to recognize the similar MRTCs as  foreign  and destroy them  T cell therapy is certainly getting a lot of attention lately  The potential impact is not lost on big pharma  In February   the execution of an agreement with Merck Serono  a division of Merck  for the development and commercialization of Tcelna    Opexa will receive an upfront payment of  5 million for granting an option to Merck Serono for the exclusive license of the Tcelna  imilecleucel T  program for the treatment of MS  The option may be exercised prior to or upon completion of Opexa s ongoing Phase IIb clinical trial in patients with SPMS  Upon exercising this licensing option  Merck Serono would pay an upfront license fee of either  25 million or  15 million  depending upon whether certain conditions are met   and in return receive worldwide development and commercial rights to Tcelna  imilecleucel T  in MS  excluding Japan  After exercising the option Merck Serono would be wholly responsible for funding clinical development  subject to Opexa s co funding option  as well as regulatory and commercialization activities for the MS program  Additional financial considerations of the agreement include development and commercial milestone payments to Opexa of up to  195 million and a tiered royalty rate from the high single digits to the mid teens based on net sales payable to Opexa  The potential payments to Opexa could  therefore  total  225 million excluding royalty payments  The terms of the agreement are encouraging to investors on a number of fronts  Of particular note is that Merck Serono would not only pay Opexa a licensing fee of  15m  25m along with potentially  225 million plus royalties  but would also fund all additional clinical development  regulatory  and commercialization costs  I also find it interesting that the rights to Japan were withheld from the terms of the otherwise worldwide agreement  It is possible that a separate agreement for Japan will be announced in the near future and act as a catalyst  Cash Position and Institutional OwnershipA Feb 11  2011 filing reveals a very interesting new 9 6  stake in Opexa taken by  LLC  Sabby is a very savvy healthcare related investment group  Their position combined with the Merck Serono agreement  represents a couple of confidently placed large investments in a company with Opexa s small market capitalization of only 17M  Cash on hand is always a concern with small developmental biotech companies  but the recent  private placement and the upfront fee of  5 0M received from Merck Serono has helped temper that concern for Opexa  With a current monthly burn rate of only  885K  the cash position has been shored up considerably  The potential of a  15M to  25M fee from Merck Serono coming at the conclusion of the current phase 2b trial along with Merck Serono shouldering the burden of additional clinical development of Tcelna for MS  goes a long way in clearing up the cash worry for current Opexa shareholders  Conclusion Trading shares of small float biotech companies is certainly not a risk averse endeavor  and the proper risk reward allocation is a crucial component to any successful portfolio  Having said that  the developmental biotech space is where investors can find returns similar to Sarepta Therapeutics  SRPT   Sarepta traded under  3 00 a year ago as it worked through a phase II trial for eteplirsen  indicated for the treatment of Duchenne Muscular Dystrophy  DMD   It now trades now at over  32 a share while the company expects to hear from the FDA on accelerated approval for eteplirsen soon  It is my opinion that Opexa Therapeutics presents both a high probability swing trade as well as considerable upside potential for the long term investor  The company is due to release its quarterly 10K Wednesday morning at 7 30  With only 8 5M shares outstanding  and an undervalued market cap of only 17 3M  a positive news announcement could send shares of Opexa surging quite a bit higher ,2013-03-27,Scott Matusow,https://www.investing.com/analysis/opexa-therapeutics-a-significant-growth-opportunity-for-both-short-term-160668,160668
125533,347048,SRPT,Muscular Dystrophy Drug Succeeds  Sarepta Buyers Flood In,opinion,Yesterday we saw erratic  bullish action in shares of Sarepta Therapeutics  SRPT  after key data was released early on  from a study on GlaxoSmithKline  GSK  and Prosena s drug known as drisapersen  which is also being developed for the treatment of Duchenne Muscular Dystrophy  DMD   Although this is a drug that could compete with Sarepta s DMD drug eteplirsen later on  buyers pushed SRPT over 11  higher on the notion that the drisapersen trial provided more data establishing the efficacy of DMD treatments that induce skipping of exon 51 during transcription of the dystrophin gene  The Disease   Mechanism of Action DMD is the most common form of muscular dystrophy in children  and affects roughly one out of every 3 500 boys worldwide according to Sarepta s own estimates  which equates to roughly 600 male births per year   Because the gene that causes muscular dystrophy is located on the X chromosome it s virtually impossible for a female to be affected due to the existence of a functional copy on their second X chromosome  although they have a 50  chance to pass the disease onto their offspring  Muscular dystrophy  which gradually kills muscle cells throughout patients  lifespans  is caused by mutations of the gene that code for the production of a vital protein known as dystrophin  The dystrophin protein itself is absolutely vital for connecting the structural components of individual muscle cells to one another through the extracelluar matrix  Scientists will not be able to develop a true cure for muscular dystrophy in the near future  but there are many angles through which we can slow the overall progression of the disease  Some have proven more successful than others  but nothing compares to the likes of eteplirsen and drisapersen  After research performed in previous decades  scientists have mapped out and located the exact mutations of the dystrophin gene that cause the various types of muscular dystrophy  Duchenne Muscular Dystrophy has been linked to exon 51  Successful Manipulation of RNA   Dystrophin Using cutting edge technology  Sarepta and Prosena designed compounds that induce skipping of exon 51 during the transcription process  when DNA is written into RNA   This allows muscular dystrophy patients to produce functional dystrophin proteins that don t contain the exact amino acids coded for in exon 51 without replacing their actual DNA  a very difficult task   This mechanism of action is proving to be quite viable  as more and more data suggests that these altered dystrophin proteins seem to be highly functional  Drisapersen s Phase III efficacy data was based on something known as the 6MWD  6 minute walk distance   which is a crude but simple to understand method of measuring slowdown in muscular dystrophy progression  Statistically significant improvements in the  continuous  drisapersen arm versus placebo were seen after 24 and 48 weeks  although the  intermittent  arm was only able to outperform placebo at the 48 week mark  This suggests that exon 51 skipping drugs need to be taken quite consistently to produce optimal therapeutic results  In agreement with Feuerstein  who provided the results yesterday  I m interested to see whether these top line results were stellar because of the outperformance of patients that took drisapersen or because of more rapid deterioration in the placebo arms  We d also be able to say that exon 51 skipping works with much more conviction had they included dystrophin protein levels as a secondary endpoint  although Sarepta investors should realize that this data takes care of an issue that many had with the Phase II results that they first announced in early October 2012   the tiny patient population  The Takeaway Sarepta s Phase II trial enrolled only 12 children  while GSK s trial enrolled 53  Although this is still small for a Phase III trial  duchenne muscular dystrophy is an extremely rare genetic disorder that has a very limited patient population  Given the situation  the FDA would be hard pressed to reject these drugs based on the small number of patients that they were tested on  Sarepta recently held a meeting with the FDA to discuss the potential approval of eteplirsen based on existing clinical trial data  although the results of this meeting are not yet public and will be released  some time before the end of April   The top line drisapersen Phase III results were not available at the time  although it would make the most sense if the FDA linked the success of the drisapersen trial to the early approval of eteplirsen  Depending on the actual results of that meeting  we should see significant movement in SRPT in either direction before the end of April  A fresh  buy  rating on SRPT from Ritu Baral of Canaccord Genuity put out in reaction the drisapersen data suggests that the efficacy link between drisapersen and eteplirsen is also established by Wall Street analysts  Another positive brought about by the drisapersen Phase III trial is its potential impact on RNA based therapeutics as a whole  As mentioned in my note from early March 2013  I have a lot of confidence in the RNA sector due to the flexibility and power of RNA manipulation in the treatment of various diseases  Muscular dystrophy seems to be one of the first indications that RNA will thrive in  but more indications will come as technology improves  Sarepta is now one of the major players in the field  which is one of the reasons it has received so much attention this year  Although valuable by itself  eteplirsen is also a financial stepping stone that Sarepta will use to leverage its RNA technology in other indications ,2013-04-11,Myriad Equity,"https://www.investing.com/analysis/muscular-dystrophy-drug-succeeds,-sarepta-buyers-flood-in-162619",162619
125534,347049,SRPT,May 15th  11  Gains For Pandora Trade,opinion,Active Trading Partners alerted our subscribers to buy Pandora Media  P  on May 9th at 14 75 or lower  We are closing out the trade this morning with 11  gains in under 5 trading days  Some of our recent closed out trades include InfoBlox  BLOX  up 9 8   Boyd Gaming  BYD  up 30  in only 3 days  Pandora up 11  in only 4 trading days  and Sarepta Therapeutics  SRPT  currently up 17  in 3 weeks and holding ,2013-05-17,David Banister,https://www.investing.com/analysis/may-15th--11-gains-for-pandora-trade-167287,167287
125538,347053,SRPT,May 15th  A Review Of Our SRPT Trade  Up 17 ,opinion,Sarepta  SRPT  is a Biotech that we alerted readers about after a  13 pullback from  43 to  30 per share ranges  At ATP we like to look for certain set ups that have Fibonacci relationships and chart patterns  coupled with fundamentals and catalysts   Here is our April 24th commentary while we Alerted to go long SRPT near  30   SRPT  Sarepta  29 90 time of alert A biotech with an advanced stage drug candidate for a form of Muscular Dystrophy  mostly that attacks children  The stock has had a huge run in the past year or so  but now a  13 almost pullback in 7 10 days allows a strong entry for aggressive partners only   We sold 1 2 on May 9th up 9 8  and held 1 2 with a  29 stop on close  As of May 14th we are up 17  on that remainder 1 2 ,2013-05-17,David Banister,https://www.investing.com/analysis/may-15th--a-review-of-our-srpt-trade--up-17-167288,167288
125542,347057,SRPT,Sarepta Investors See GSK s Drisapersen Receiving Breakthrough Status,opinion,Sarepta Therapeutics  SRPT  is a company that focuses on RNA therapeutics  and is currently focusing on the use of their platform to develop drugs that induce exon skipping  which alters the RNA transcription in muscular dystrophy patients and produces functional versions of a protein known as dystrophin   SRPT continues to see elevated levels of bearish speculation ahead of another post Phase II meeting with the FDA  which will determine whether or not the company s Duchenne Muscular Dystrophy  DMD  drug eteplirsen will be eligible for accelerated approval based on the data that was produced from the 12 patient Phase II trial that initially sent Sarepta stock soaring to new highs in October 2012   If eteplirsen receives accelerated approval  eteplirsen could realistically be on the market in Q4 2014 with incomplete data from Phase III trials  Without it  investors generally expect a 1 1 5 year delay that could discourage investment in the company until Phase III data  The accelerated approval application would probably be submitted in early 2014   Although the stock itself is on a steady uptrend  total short interest has remained close to 10 M shares  or about 33  of float  Options activity also implies heavy speculation  especially on the bearish  or put side  ahead of the next meeting with the FDA  Note that this meeting is scheduled to occur near the end of July 2013   This bearish sentiment grew yesterday after the only other competing DMD drug  GSK s Prosensa  drisapersen  received breakthrough drug status from the FDA  Investors seemed nervous that Prosensa might take market share away from eteplirsen due to a virtually identical mechanism of action  although these fears are overblown  Note that both drugs induce exon 51 skipping to create semi functional dystrophin proteins  although drisapersen s toxicity profile is far less favorable   The initial bearish reaction in SRPT stock to the drisapersen update has been reversed  as Sarepta investors make the argument that this may actually bode well for eteplirsen s chances at being eligible for accelerated approval   Although Sarepta has become expensive at this point  the short interest  as mentioned  is extremely high and presents some downside protection in the event that eteplirsen cannot receive accelerated approval ,2013-06-30,Frank Kollar,https://www.investing.com/analysis/sarepta-investors-see-gsks-drisapersen-receiving-breakthrough-status-173378,173378
125561,347076,SRPT,Sarepta Therapeutics  Impressive Date Released ,opinion,Investment summary  Orphan prospectsSarepta Therapeutics  formerly AVI BioPharma  has reported impressive initial data from a Phase IIb study with its lead product eteplirsen  AVI 4658  in Duchenne muscular dystrophy  DMD   triggering a share price rise of 190   A Phase III trial will probably be started in 2013  Despite the major re rating of the shares  there remains further upside  There are currently limited treatments for patients with DMD  and this data also provides validation of Sarepta s RNA based product platform Eteplirsen demonstrates significant efficacy in Phase IIb trialPatients receiving eteplirsen  a RNA based product  showed a decline of only 8 7m distance walked during the six minute walk test  6MWT  baseline mean 396m  n 4   compared to 78 0m  baseline mean 394 5m  n 4  over 36 weeks  Despite the small numbers  this difference is statistically significant  p 0 019   Full data from the trial  including results from 6MWT at 48 weeks and muscle biopsies to detect dystrophin expression  will probably be presented at the World Muscle Society meeting in October Phase III trial expected to start next yearSarepta will conduct an end of Phase II meeting with the FDA once it has 48 week data to discuss regulatory requirements for a Phase III programme  However  it believes a single pivotal study in c 60 patients will be required for eteplirsen to be approved with the 6MWT as the primary endpoint  This trial will probably start in 2013 and could be conducted alone  dependant on capital raise  or with a partner Platform validation and prospect of follow on productsThe data validates Sarepta s exon skipping approach with RNA based products to treat genetic diseases  Eteplirsen will target at c 13  of the DMD market  c 2 000 people in US   variations on this product could treat up to c 85  of DMD patients Valuation  Current EV is c  197mSarepta s share price increased by 190  after the announcement of the Phase II data  We still believe there is significant upside  as eteplirsen could generate sales of c  400m in the US if priced in line with Shire s Vpriv for Gaucher disease  another orphan drug   with further sales from the rest of the world and follow on products To Read the Entire Report Please Click on the pdf File Below ,2012-07-31,Edison,https://www.investing.com/analysis/sarepta-therapeutics:-impressive-date-released-131492,131492
125562,347077,SRPT,Stock Up 300  In Six Weeks    But There s More    Right  ,opinion,Sarepta Therapeutics Inc    SRPT  formerly AVI BioPharma  Inc   is a biopharmaceutical company focused on the discovery and development of ribonucleic acid based  RNA  therapeutics for the treatment of both rare and infectious diseases  This is a vol and stock note on a bio tech with some very interesting news  I ll summarize what s the happs below  then we ll move onto the options and vol  I ll be taking a chunk of this content from a Seeking Alpha article  cited below Sarepta Therapeutics  SRPT   formerly known as AVI BioPharma  is closing in on a significant medical breakthrough for the largest segment of Duchenne Muscular Dystrophy sufferers  Duchenne Muscular Dystrophy is an affliction that results in muscle degeneration and certain early death  It affects mostly boys with most sufferers wheelchair dependent by age 12 and a life expectancy of 25 years  There is no known cure for Duchenne Muscular Dystrophy  Sarepta s stock has been on a tear the last five weeks going from around  4 per share on July 23rd and closing at  15 82 August 31  The catalyst for this move was Sarepta s release of 36 week data of their current phase IIb extension study that  according to Sarepta s CEO Chris Garabedian  showed  statistically significant clinical benefit  in the 6 minute walk test   which is a  clinical meaningful outcome measure  for Duchenne Muscular Dystrophy        that the lead investigator for the trial is Dr  Jerry Mendell  who is the director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children s Hospital in Columbus  OH  Dr  Mendell stated Sarepta s drug had  an unprecedented treatment effect  on participants in its latest trial  Sarepta plans to release the full 48 week trial results for the above referenced study in October  If the results are positive as expected  Sarepta will go for accelerated FDA approval      Source  Seeking Alpha via Yahoo  Finance    written by R S  Analytics  So that was a pretty awesome article  though I haven t verified essentially any of it  Buyer beware  Let s start with the Charts Tab  six months   below  The top portion is the stock price  the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  We can see the incredible run of late    SRPT was trading at  3 46 on 7 23 2012 and is now nearly  15 in less than two months  The first gap up came on 7 24 2012  when the stock moved from  3 46 to  8 52  close to close   Here s the news from that day CAMBRIDGE  Mass   AP     Sarepta Therapeutics Inc  said Tuesday that its experimental muscular dystrophy drug eteplirsen met its goal in an extension study  and shares of the company more than doubled in value     Source  AP via Yahoo  Finance    The stock found a bit of a quiet period following the gap up  but has recently risen again  The stock closed at  10 78 on 8 24 2012 and is now nearly 40  higher in about two weeks  On the vol side we have a bit murkier of a picture since the stock changed symbols recently  Having said that  we can see that the implied is now at an annual high pushing over 140   But the news is due out in Oct  probably   and the Skew Tab shows us that  Let s turn to the Skew Tab to examine the line by line and month to month vols  We can see high the vol in the Oct options is well above the vol in Sep and Nov  This reflects the likelihood of an event  announcement  in Oct  I do note that the skew is flat to the upside  which is not necessarily what I would have expected given the interim good news  Having said that  with the stock up 400   or whatever  in the last 6 weeks  the option market may be reflecting lower risk  potential  from the current levels than when this was a single digit stock price Finally  let s turn to the Options Tab  for completeness Across the top we can see the monthly vols are priced to 113 66   176 40  and 154 32   respectively for Sep  Oct and Nov  I do note a few things  1  Sep is still elevated which reflects the risk that  something  comes out before the expected Oct date  That something may just be more anecdotal results from extremely happy parents  that s been happening apparently   2  Oct vol will likely rise if no new news slips out  As the event date approaches  the weighted average of vols in Oct will lead to a rise in the overall level  200   vol is not impossible here and may be too low  But  of course  surprise news can change all of that  3  Nov is quite elevated  While that expiry does include all of the days in Oct  it feels like there is risk of the news coming out after Oct expo  maybe    In any case  all options and stock prices aside  I hope this drug is an absolute revelation as it seems to be in early stages  I can honestly say  I am rooting for this company  Disclosure  This is trade analysis  not a recommendation ,2012-09-05,Ophir Gottlieb,https://www.investing.com/analysis/stock-up-300-in-six-weeks----but-there's-more...-right-135206,135206
